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Abstract 
Liver cancer is the second most common cause of cancer-related mortality. 
Traditionally, liver cancer is considered a fatal disease with an overall survival of less 
than 6 months. Doxorubicin combined with trans-arterial chemoembolization (TACE) 
is the standard treatment for intermediate stage liver cancer patients, which can 
increase mean survival by 5.8 months in patients compared with those underwent 
systemic chemotherapy. Liver cancer has displayed substantial heterogeneity within 
one tumor, which may occur due to either clonal evolution or cancer cells being 
hierarchically organized with a subset of cells, termed cancer stem cells or tumor 
initiating cells.  Such cells play critical roles in the initiation, maintenance and 
metastasis of the disease. While doxorubicin is effective in killing proliferating and 
differentiated liver cancer cells, the drug remains inefficient in eliminating liver cancer 
stem cells, thereby resulting in treatment failure. Among chemoresistance mechanisms 
present in cancer stem cells, the overexpression ATP-binding cassette (ABC) 
transporters and activation of autophagy are two of the major causes underlying the 
resistance of liver cancer stem cells to doxorubicin treatment. 
The multidrug resistance protein 1 (MDR1), also named ABCB1 or P-glycoprotein, is 
present in over 80% of liver cancer tissues. It is responsible for extruding doxorubicin 
out of the cancer cells leading to the failure of chemotherapy. Using CD133 and 
epithelial cell adhesion molecule (EpCAM) as liver cancer stem cell markers, MDR1 
was shown to be over-expressed in the cells with both EpCAM and CD133 expression 
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(EpCAM+CD133+). The addition of MDR1 inhibition with either pharmacological 
inhibitor valspodar or RNA interference significantly increased cellular doxorubicin 
accumulation compared with doxorubicin alone in both bulk population and 
EpCAM+CD133+ cancer stem cell population of liver cancer cells. In addition, 
following MDR1 inhibition, the apoptosis induced by doxorubicin was significantly 
increased in both the bulk tumor population and the EpCAM+CD133+ cancer stem cell 
population. Finally, the combined doxorubicin and MDR1 inhibition treatment led to 
enhanced efficacy in suppressing self-renewal of liver cancer stem cells compared with 
doxorubicin alone (Chapter 3). 
The ABCG2 is one of the most studies drug efflux pumps among the ABC transporters. 
Although its expression is scanty in liver cancer tissues in comparison with that of 
MDR1, the ABCG2-expressing (ABCG2+) liver cancer cells were considered to harbor 
cancer stem cell properties. In Chapter 4, we aimed at eliminating liver cancer stem 
cells by targeting ABCG2 protein. The expression ABCG2 was found to be 
significantly increased in the EpCAM+CD133+ liver cancer stem cell population than 
the bulk liver cancer cells. The addition of ABCG2 inhibition with either 
pharmacological inhibitor ko143 or RNA interference significantly facilitated the 
internalization of doxorubicin into the bulk population and cancer stem cell population 
of liver cancer cells. Additionally, after inhibition of ABCG2, doxorubicin induced 
elevated apoptosis in both the bulk tumor population and the EpCAM+CD133+ cancer 
stem cell population. Finally, the combinational treatment of ABCG2 inhibition 
resulted in enhanced efficacy in inhibiting self-renewal of liver cancer stem cells from 
PLC/PRF/5 cells but not so much in Huh7 cells compared with that treated with 
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doxorubicin alone. Since the expression of ABCG2 is high in PLC/PRF/5 cells but low 
in Huh7 cells, the results indicated that inhibition of ABCG2 alone may not be 
sufficient to sensitize liver cancer stem cells to doxorubicin, and other ABC 
transporters may play a role (Chapter 4). 
Besides direct inhibition of these ABC transporter, we have used the aptamer-guided 
targeted-therapy for the delivery of doxorubicin into liver cancer stem cells via 
endocytosis thus bypassing the ABC transporters on the plasma membrane. 
Doxorubicin was loaded into two engineered RNA aptamers against CD133 or 
EpCAM. The CD133 aptamer-doxorubicin conjugate was shown to be stable at pH 7.4, 
however, quick release of doxorubicin from the aptamer-doxorubicin conjugate at pH 
5.0 was observed. This suggests that CD133 aptamer-doxorubicin conjugate can 
remain stable in the circulation, but doxorubicin can be release quickly in the acidic 
environment of lysosomes after endocytosis. The CD133 aptamer showed specific 
binding to CD133-expressing cells. Compared with free doxorubicin, the CD133 or 
EpCAM aptamer-guided delivery of doxorubicin resulted in increased doxorubicin 
uptake and retention in the liver cancer cells. The aptamer-doxorubicin conjugates 
showed greater potency in impairing the self-renewal of liver cancer stem cells than 
free doxorubicin, whereas the inhibition of autophagy by 3-MA enhanced the capacity 
of either free doxorubicin or aptamer-doxorubicin conjugates to eliminate liver cancer 
stem cells. Treatment of doxorubicin induced autophagic activity, which may act as a 
protect mechanism against apoptosis. The addition of autophagy inhibitor 3-MA 
reversed doxorubicin-induced autophagy activation. Treatment CD133 aptamer-
doxorubicin conjugate led to apoptosis in both the bulk and cancer stem cell population 
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of liver cancer compared with free doxorubicin. The addition of autophagy inhibition 
either with 3-MA or RNA interference significantly potentiated apoptosis led by the 
treatment of CD133 aptamer-doxorubicin conjugate or free doxorubicin (Chapter 5).  
The results from this thesis highlights three novel approaches to target liver cancer 
stem cells: 1) inhibition of MDR1 or ABCG2 to sensitize liver cancer stem cells to 
doxorubicin treatment; 2) aptamer-guided targeted delivery of doxorubicin into liver 
cancer stem cells; 3) inhibition of autophagy to augment the capacity of aptamer-
doxorubicin conjugate or free doxorubicin to eliminate liver cancer stem cells. 
Therefore, without the costly development of novel drugs aptamer-guided and ABC 
transporter-targeted therapy and/or the inhibition of autophagy can provide clinical 
benefit to liver cancer patients.
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Chapter 1 
Introduction and literature review 
1.1 Hepatocellular carcinoma 
Liver cancer, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, 
is the second most common cause of cancer-related mortality after lung cancer1. 
Hepatocellular carcinoma, which accounts for 70% - 85% of primary liver cancer2, is 
a major health problem worldwide as it is one of the cancers with an increasing 
incidence rate, affecting around 700 000 patients every year3. Traditionally, 
hepatocellular carcinoma is considered a fatal disease with 5-year survival rates of only 
18%4 and an overall survival of less than 6 months5.  
An estimated 75% of hepatocellular carcinoma cases are associated with chronic 
infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)6. HBV infection is 
responsible for approximately 50% of all the cases of hepatocellular carcinoma and 
almost all childhood hepatocellular carcinoma cases7. It is also the dominant risk factor 
of hepatocellular carcinoma in eastern Asia and Sub-Saharan Africa together with 
exposure to aflatoxin B13. A study of hospital-based cohort showed that the 
hepatocellular carcinoma risk started to increase when HBV DNA level was higher 
than 2,000 IU/ml and serum HBV DNA level higher than 10,000 IU/ml is strongly 
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correlated with hepatocellular carcinoma 8, 9. By contrast, HCV infection is the major 
risk factor in North America, Europe and Japan together with the heavy use of alcohol10. 
Other risk factors include non-alcoholic fatty liver disease (NAFLD), heavy coffee 
consumption, diabetes, obesity and tobacco11-13. It is noteworthy that approximately 
90% of hepatocellular carcinoma is associated with cirrhosis which is characterized by 
the replacement of normal liver tissue by fibrosis, leading to the loss of liver function14. 
The choice of treatment depends on both the extent of hepatocellular carcinoma and 
the degree of hepatic dysfunction15. Thirty percent of patients were diagnosed at the 
early stage of hepatocellular carcinoma, in which surgical management including 
hepatic resection and liver transplantation achieve the best outcomes in well selected 
patients with a 5-year survival of 60–80%3, 16. However, the cancer recurred in 70% of 
patients who received resection or complete ablation17. 
For patients who are in intermediate stage of hepatocellular carcinoma and diagnosed 
with multifocal intrahepatic tumors, trans-arterial chemoembolization (TACE) is the 
standard and first-line treatment18, 19. TACE involves intra-arterial administration of 
chemotherapeutic agents combined with arterial embolization which provides an 
extension of mean survival for 6.1 months20.  However, a proportion of patients who 
are treated with surgical resection and TACE successfully still experience treatment 
relapse21. In addition, sorafenib, a multikinase inhibitor, which is standard treatment 
for advanced stage hepatocellular carcinoma showed efficacy to patients with 
intermediate-stage hepatocellular carcinoma in whom TACE is not appropriate or 
failed22. Radioembolization with Y90 has shown promising outcomes in intermediate 
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hepatocellular carcinoma23-25. About 40% of patients will present with advanced 
hepatocellular carcinoma, and systemic therapy is indicated for such patients. 
Chemotherapeutic agents have been studied extensively in hepatocellular carcinoma 
in the last few decades but have not demonstrated an improvement in overall survival 
benefits compared with best supportive care that is not involved in drug treatment26. 
Doxorubicin is the most extensively studied agent in the treatment of advanced 
hepatocellular carcinoma. Although an initial trial achieved a 79% response rate of 
hepatocellular carcinoma to doxorubicin27, subsequent studies denoted less efficacy of 
doxorubicin as an single agent treatment with response rates around 10-20%28, 29. Other 
chemotherapy agents, including gemcitabine30, 31, capecitabine32, docetaxel33, 
paclitaxel34 and irinotecan35, failed to demonstrate any survival advantage. A variety 
of combination chemotherapy regimens have been studied. However, the results were 
disappointing as no survival benefit was discovered36-38. The lack of benefit by 
pharmacological intervention makes hepatocellular carcinoma somewhat unique in 
cancer as there is no standard chemotherapy for hepatocellular carcinoma39. The only 
drug approved for the treatment of advanced hepatocellular carcinoma is sorafenib, 
which provides a 3-month improvement in survival rate40. Therefore, hepatocellular 
carcinoma is still a refractory disease due to the highly chemoresistant nature of the 
tumor and the toxicity of chemotherapeutic agents. 
1.2 Doxorubicin in the treatment of hepatocellular carcinoma 
1.2.1 Pharmacology 
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Doxorubicin, isolated from a soil bacterium Streptomyces peucetius in the 1960s, is a 
member of anthracycline family of anti-cancer agents and has been widely used in 
cancer chemotherapy41. Being approved by the US Food and Drug Administration 
(FDA) in 1974, doxorubicin has being regarded as one of the most potent 
chemotherapeutic agents ever developed42.  It has a wide spectrum of anti-cancer 
activity and is used in the treatment of both solid and liquid cancers, including prostate, 
uterus, ovary, stomach, liver and breast cancer, sarcoma, acute myeloblastic and 
lymphoblastic leukemia43-51. 
Doxorubicin is a planar molecule that could intercalate between neighboring DNA 
base pairs and bind covalently to proteins that were involved in DNA replication and 
transcription52. The synthesis of DNA, RNA and proteins is inhibited by doxorubicin 
resulting in programmed cell death53, 54. Doxorubicin is also a topoisomerase II poison. 
The topoisomerase modifies the topology of DNA and catalyzes the unwinding of 
DNA for replication and transcription via the cleavage of one strand of DNA duplex. 
Doxorubicin interferes with this process leading to a failure to repair DNA and the 
induction of an apoptotic response55. 
Doxorubicin enters tumor cells by simple diffusion with high affinity to bind to the 
proteasome in cytoplasm. The doxorubicin-proteasome complex trans-locates into the 
nucleus. It has a higher affinity to nuclear DNA over proteasome therefore it 
dissociates from the proteasome and bind to the DNA56. 
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Although doxorubicin is a powerful agent in cancer chemotherapy, its effective dose 
in the clinic is limited by toxicity to normal tissues, especially the heart. The sub-lethal 
dose that can be administered led to the development of resistance in tumor cells42. 
1.2.2 Toxicity and metabolism 
The major dose-limiting side effect of doxorubicin is cardiotoxicity. First, doxorubicin 
could direct target mitochondria and disrupt its functions57, 58. It has high affinity to 
cardiolipin, a phospholipid on the inner site of the mitochondrial membrane. The 
interaction between doxorubicin and cardiolipin decreases the activity of critical 
mitochondrial enzymes and inhibits the respiratory chain59.  Cardiomyocytes have 
higher density of mitochondria per unit volume, making it more sensitive to 
doxorubicin than other tissues60. Second, doxorubicin could be metabolized into 
semiquinone within mitochondria. The semiquinone derivative doxorubicin is a toxic 
short half-life metabolite which reacts with O2 to produce reactive oxygen species 
(ROS)61. The fact that the heart possesses lower levels of antioxidants makes it more 
sensitive to ROS than other tissues62. The third possibility is that doxorubicin inhibits 
topoisomerase-IIβ (Top2β). It has been shown that mice lacking Top2β in their heart 
suffer less myocardial injuries after doxorubicin treatment63. 
Besides the cardiotoxicity induced by doxorubicin per se, it gains further cardiotoxicity 
after transforming to its metabolites. Approximately 50% of doxorubicin is eliminated 
from the body unchanged64. 
In terms of drug metabolism, there are three major metabolic routes identified for 
doxorubicin. 1) Deglycosidation accounts for approximately 1-2% of doxorubicin 
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metabolism. 2) Two-electron reduction of doxorubicin to the secondary alcohol 
Doxrorubicinol is the major metabolic route64. This reaction is carried out by several 
enzymes in different cell types. Aldo-keto Reductase 1A (AKR1A) is the most 
important enzyme in heart tissue while carbonyl reductase 1 (CBR1) is the major one 
in liver64, 65. 3) One-electron reduction of doxorubicin is catalyzed by several 
oxidoreductases to produce the semiquinone of doxorubicin. Semiquinone is cytotoxic 
in hypoxic environments though modification of cellular macromolecules. Re-
oxidation of the semiquinone back to doxorubicin leads to the formation of reactive 
oxygen species (ROS) and hydrogen peroxide. Rather than semiqinone of doxorubicin, 
ROS released by this route is considered more responsible for drug effect and 
cadiotoxicity66. One main enzyme is cytochrome P450 NADPH (reduced form of 
nicotinamide adenine dinucleotide phosphate) reductase (P450R). Researchers have 
found that doxorubicin may function as an inactivator of P450 and/or P450R67. 
1.2.3 Drug delivery systems of doxorubicin 
1.2.3.1 Liposome and nanoparticle   
Due to the the size and stability of nanoparticles are the two critical factors that 
determine their performance because they affect the circulation time and 
biodistribution in vivo. Uptake of the nanoparticles may be facilitated by passive 
diffusion and active mechanisms. Matsumura and Maeda found that most solid tumors 
exhibit enhanced vascular permeability68. Macromolecules larger than 40 kDa but less 
than 200 nm in size could selectively leak out from tumors vessels and accumulate in 
tumor tissues but not in normal tissues. This phenomenon is known as enhanced 
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permeation and retention (EPR) effect which is considered a landmark principle in 
tumor targeted chemotherapy69. Nanoparticles can also be conjugated with targeting 
ligands or antibodies, which recognize specific tumor targets thus facilitating drug 
accumulation into tumor tissues70. 
Macromolecular materials such as dextran and polyethyleneimine (PEI) were 
successfully used as drug delivery systems in chemotherapy71. One example is dextran-
graft-PEI nanoparticles loaded with doxorubicin which is applied to the treatment of 
osteosarcoma72. 
Liposomal drug delivery is another nanotechnology delivering therapeutic agents 
selectively into tumor tissues via the EPR effect. Liposomes are particularly successful 
among the many types of nanoparticles used in drug delivery and several liposome 
formulations are in clinical use73. Liposomal doxorubicin (Doxil®) is the first liposome 
approved by the US FDA for the treatment of cancers. It exhibits better tumor targeting 
capacity and reduced toxicity compared with free doxorubicin74. Doxil® is different 
from free doxorubicin by the two properties: 1) prolonged drug circulation time due to 
the PEGylated liposome structure; 2) high remote loading allowing the release of 
doxorubicin in tumor tissue. 
1.2.3.2 Local administration of doxorubicin 
The clinical use of doxorubicin is severely limited by the development of a progressive 
dose-dependent cardiomyopathy that irreversibly evolves toward congestive heart 
failure, usually refractory to conventional therapy. 
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Systemic administration of Doxil® shows little improvement of survival benefit 
compared with free doxorubicin75. Since liver is the main organ responsible for drug 
metabolism and patients with hepatocellular carcinoma usually have hepatic 
dysfunction, higher dosage of chemotherapy becomes difficult. With the development 
of medicine and material science, local administration of chemotherapeutic drugs in 
hepatocellular carcinoma treatment has been developed and is used widely in the clinic. 
Trans-arterial chemoembolization (TACE) is used for unresectable liver cancer or a 
temporary treatment while patients are waiting for liver transplant. It is a standard 
treatment for intermediate stage hepatocellular carcinoma. Figure 1 shows a schematic 
diagram of TACE. TACE is performed by injecting chemotherapeutic drugs mixed 
with a lipiodol and an embolic agent into the hepatic artery which feeds the liver tumors. 
The goal of TACE is to expose malignant cancer cells to high concentration of 
chemotherapeutic agents such as doxorubicin, cisplatin, and mitomycin to reduce 
systemic side effects76. Administration of intra-arterial chemotherapy alone is not 
superior to systemic treatment because of the short contact time between tumor cells 
and drugs77. In order to prolong the contact time, chemotherapeutic drugs are mixed 
with lipiodol which is a radiocontrast selectively retained in hepatocellular carcinoma 
for weeks to months78. The drug-lipiodol emulsion shows a slow release of drugs 
lasting hours to days in vitro79. By TACE, the concentration of chemotherapeutic 
agents within tumors can be 10 to 100 times higher than after systemic administration80. 
Randomized trials have suggested increased mean survival of 5.8 months in patients 
treated with TACE compared with those underwent systemic chemotherapy20. 
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Figure 1.1. Trans-arterial chemoembolization (TACE) is an invasive procedure in 
which chemotherapeutic drugs with embolic agents are injected through a catheter into 
hepatic artery directly supplying a tumor. (Adapted from Wang et al.81). 
 
Recently, a novel drug delivery system called drug-eluting beads was introduced by 
TACE. Drug-eluting beads are embolic microspheres loaded with chemotherapeutic 
agents (usually doxorubicin) and will gradually release the drugs into tumor tissues. 
Doxorubicin-eluting beads (DEB) is based on a hydrogel that is modified with 
sulphonate group with diameters ranging from 40-1,200 µm to prolong the contact time 
between tumor cells and doxorubicin and to avoid hepatic microcirculation damage82, 
83. Compared with conventional lipiodol-based TACE, DEB-TACE showed even 
lower systemic doxorubicin concentration and higher tumor concentration84. A recent 
meta-analysis shows that DEB-TACE provides significantly better tumor response and 
survival benefit compared with conventional TACE85. 
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Despite the all the improvements in treatment, hepatocellular carcinoma is still the 
most aggressive cancer with 5-year survival rates of only 18% - often less than 1 year 
survival4, 86. Therefore, novel and more effective treatments are urgently needed. 
1.3 Cancer stem cell hypothesis 
The majority of malignancies including hepatocellular carcinoma display substantial 
degree of molecular and cellular heterogeneity within one tumor due to intrinsic factors 
such as genetic instability, mutational rate and epigenetic status as well as extrinsic 
factors such as microenvironmental factors and therapy87-89. The tumor heterogeneity 
may occur as a consequence of either clonal evolution driven by genetic and/or 
epigenetic change90 or cancer cells being hierarchically organized with a subset of cells, 
termed cancer stem cells or tumor initiating cells which are responsible for the 
initiation and maintenance of  tumor and play critical roles in tumorigenesis91. In 1994, 
researchers for the first time demonstrated that a subset of leukemia cells was 
responsible for propagating the disease while the bulk of these cells did not92. Several 
years later, researchers revealed that this phenomenon also exists in human breast 
cancer93. These findings were followed by publications revealing that only a small 
subset of cancer cells harbor the potential to propagate cancer of the colon94, 
pancreatic95, melanoma96, hepatic97, lung98, prostate99, ovarian100 and brain101 cancers. 
Together, the new findings argued against the conventional cancer stochastic model 
that all cells have equal potential to propagate the disease. Generally, cancer stem cells 
are defined by their abilities to: 1) generate descendant cells possessing unlimited self-
renewal potential but uncommitted differentiation options; 2) generate large 
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populations of differentiated progenies that exit the stem cell state, and 3) form new 
tumors with high efficiency that resembles the original tumors after being 
xenotransplanted into immunodeficient mice102.  
The cancer stem cell theory is promising and has emerged as the mainstream idea due 
to it fits well with the clinical observations, which explains the poor outcome of current 
therapy against cancer as well as the mechanism of tumor relapse and metastasis103.  
1.3.1 Origin of liver cancer stem cells 
There are several hypotheses regarding the origin of cancer stem cells (Figure 2). One 
theory suggests that cancer stem cells are derived from normal stem cells. These cells 
obtain the ability to generate tumors when a special gene mutation(s) occurs. Some 
cancer stem cells possess similar properties to normal stem cells in phenotype, function 
and cell surface markers. For example, mammary gland stem cells have the surface 
marker CD44+/CD24- which also exist in cancer stem cells from breast cancer 
patients104.  Another theory proposes that cancer stem cells arise from normal somatic 
cells. These cells acquire stem-like properties and malignant actions through genetic 
alterations. For example, tumor cells acquire stem-like properties through epithelial-
mesenchymal transition (EMT), in which epithelial cells undergo transition to a 
mesenchymal phenotype, during which they lose their polarized organization and 
tight cell–cell junctions to develop a fibroblast-like morphology which is 
associated with enhanced self-renewal characteristics and invasive capacity105. Several 
studies show that cancer cells with an epithelial phenotype could survive in circulation 
and form metastasis106. It was revealed that liver cancer stem cells can originate from 
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three liver lineages: hepatic progenitor cells, lineage-committed hepatoblasts and 
differentiated adult hepatocytes in which hepatic progenitor cells are thought to have 
the highest potential of becoming liver cancer stem cells107. 
 
Figure 1.2. The hypothesis of hepatocellular carcinoma (HCC) origin based on the 
cancer stem cell (CSC) model. Liver cancer stem cells can originate from hepatic stem 
cells by mutations to acquire tumorigenic capacity. On the other hand, mutations on 
the differentiated liver cells will covert these cells that already have tumorigenic 
potentials into liver cancer stem cells. Ultimately, the liver cancer stem cells give rise 
to hepatocellular carcinoma. 
1.3.2 The frequency of liver cancer stem cells 
According to the hierarchical cancer stem cell model, only cancer stem cells can 
generate non-cancer stem cells, and the frequency of cancer stem cells is maintained at 
a low level. Some studies suggested that the frequency of cancer stem cells is less than 
1 in every 1000 tumor cells108, 109 and eradicating cancer stem cells is thought to be 
sufficient for cancer therapies. However, recent evidence suggests that the number of 
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cells that possess intrinsic tumorigenic potential might be higher. In breast cancer, non- 
cancer stem cells can de-differentiate to generate cancer stem cells110, 111. Hepatocytes 
may have the ability of self-renewal, biliary differentiation and unlimited proliferation 
under certain conditions112, 113. In colorectal cancer, it is shown that not all colorectal 
cancers follow the same hierarchical organization as the frequency of cancer stem cells 
might vary114. More importantly, prediction of the number of cancer stem cells in a 
particular tumor type depends on the experimental procedure, the choice of cell surface 
marker chosen and the types of immunodeficient mice into which the cancer stem cells 
are xenografted. Chiba and colleagues used side population (SP) analysis to detect cell 
subpopulations that act as cancer stem cells and found that SP cells that have high 
proliferative potential and anti-apoptotic properties exist in Huh7 (0.25%) and 
PLC/PRF/5 cells (0.8%)115. Kimura and colleagues analyzed the percentages of cancer 
stem cell surface marker in hepatocellular carcinoma cell lines and found that the 
percentage of CD133+ cells was 2.7% in Huh7 and 23.5% in PLC/PRF/5, and the 
percentage of EpCAM+ cell was 89.1% in Huh7 and 40.7% in PLC/PRF/5116. Using 
sphere-forming assays, Cao and colleagues found the cancer stem cells frequency was 
8.8% for PLC/PRF/5 cell line117. Since hepatocellular carcinoma is a complex disease 
with multiple pathogenic mechanisms, it is not feasible to identify liver cancer stem 
cells with a single marker. Therefore, a combination of cancer stem cells biomarkers 
might be more valuable for diagnosis and treatment of hepatocellular carcinoma118. 
1.3.3 Cancer stem cell identification and isolation 
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A few methodologies have been used to identify and isolate liver cancer stem cells 
including: 1) flow cytometric isolation according to cancer stem cell-specific cell 
surface markers119; 2) assessment of aldehyde dehydrogenase (ALDH) activity by 
Aldefluor method120; 3) detection of side population (SP) cells by their ability to 
extrude Hoechst 33342115; 4) determination of the ability to form non-adherent spheres 
in stem cell conditioned medium117; 5) enrichment of liver cancer stem cell via density 
gradient centrifugation-centered method121; 6) Intracellular autofluorescence122.  
1.3.3.1 Cell surface marker-based cancer stem cell isolation 
It has been shown that liver cancer stem cells can be identified on the basis of cell 
surface proteins including epithelial cell adhesion molecule (EpCAM), CD133, CD90, 
CD13, CD44, CD24, OV6, Sal-like4 (SALL4), delta-like 1 homolog (DLK1), ABCG2, 
glypican-3 (GPC3), ABCB5, granulin-epithelin precursor (GEP), and as shown in 
Table 1. The markers between liver cancer stem cells and normal stem cells might 
overlap making it significantly important to distinguish liver cancer stem cells from 
normal stem cells. In addition, it should be emphasized that there are no universal 
markers which identify a common liver cancer stem cell population, and the liver 
cancer stem cell phenotype are not necessarily universal in all liver cancer subtypes 
but may be subtype specific. For example, Yamashita et al. revealed the discrete nature 
of EpCAM+ and CD90+ subpopulations in which EpCAM+ cell showed rapid growth 
and CD90+ cells harbor highly metastatic capacity in the lung indicating distinct liver 
cancer stem cells may determine the clinical outcome of liver cancer123. Chan et al. 
showed that the prognostic role of CD133 was significant in early stage of 
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hepatocellular carcinoma while EpCAM was more important in advanced 
hepatocellular carcinoma as a prognostic factor124. Therefore, it would be important to 
clarify how the different liver cancer stem cell markers relate to one another. Increasing 
evidence suggests that the combination of multiple markers more effectively and 
specifically label liver cancer stem cell population than using single marker125-131. 
Table 1.1. Markers of putative liver cancer stem cells 
Marker Cancer cell line or tissue Characteristics References 
EpCAM+ 
Huh1, Huh7, Hep3B, Li-7, 
PLC⁄PRF⁄5, tumor tissue 
Chemoresistance and 
tumorigenicity, advanced 
stage marker 
116, 123, 
124, 132 
CD133+ 
Huh7, SMMC-7721, 
PLC/PRF/5, PLC8024, 
tumor tissue 
Radio- and 
chemoresistance, 
angiogenesis and 
tumorigenicity 
124, 133-138 
EpCAM+CD133+ Huh7 
Chemoresistance and 
tumorigenicity 
125 
CD133+ 
CD44+ 
SMMC-7721, tumor tissue 
Metastasis, 
Chemoresistance, and 
tumorigenicity 
126 
CD13+ 
CD133+ 
Huh7 
Metastasis, 
Chemoresistance, and 
tumorigenicity 
128 
CD13+ 
Huh7, PLC/PRF/5, tumor 
tissue 
Radio- and 
chemoresistance, 
tumorigenicity and 
metastasis 
139, 140 
CD90+ PLC, HepG2, tumor tissue 
Tumorigenicity and 
metastasis 
97, 123, 141 
CD133+ALDH+ PLC8024 tumorigenicity 120 
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Table 1.1. (Continued) 
Marker Cancer cell line or tissue Characteristics References 
OV6+ SMMC7721, tumor tissue 
chemoresistance, 
tumorigenicity and 
metastasis 
142, 143 
CD24+ 
Huh7, PLC/PRF/5, tumor 
tissue 
chemoresistance, 
tumorigenicity and 
metastasis 
144 
SALL4+ 
Huh7, PLC/PRF/5, tumor 
tissue 
Chemoresistance and 
tumorigenicity 
145, 146 
ABCG2+ SMMC7721, tumor tissue 
tumorigenicity, 
chemoresistance and 
metastasis 
147 
Oct4+ Huh7, PLC/PRF/5 
Tumorigenicity and 
chemoresistance 
148 
K19+ Huh7, tumor tissue 
tumorigenicity, 
chemoresistance and 
invasion 
149, 150 
ANXA3+ 
Huh7, HepG2, SMMC-
7721, tumor tissue 
Tumorigenicity, 
chemoresistance and 
metastasis 
151, 152 
TLR4+ 
Huh7, SMMC7721, tumor 
tissue 
Invasion and migration 153 
GPC3+ 
PLC/PRF/5, SNU-398, 
tumor tissue 
Self-renewal, cell cycle 
progression, and 
tumorigenicity 
154 
DLK1+ Huh7, Hep3B 
Chemoresistance and 
tumorigenicity 
155, 156 
GEP+ Tumor tissue Tumorigenicity 157 
GEP+ 
ABCB5+ 
Hep3B, tumor tissue 
Tumorigenicity and 
chemoresistance 
158, 159 
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1.3.3.2 ALDH 
Aldehyde dehydrogenases (ALDHs) belong to the oxidoreductase family of NAD(P)+-
dependent enzymes which catalyze the conversion of aldehydes to their corresponding 
weak carboxylic acids160. ALDH can be found in the cytosol, nucleus, endoplasmic 
reticulum and mitochondria161. Nineteen human ALDH gene encode the human ALDH 
protein which were oganized into 11 families and 4 subfamilies with distinct 
chromosomal locations162. 
Evidence suggests that increased activity of ALDH is obseved in cancer stem cells of 
several cancer type163. The functionality of ALDHs in live cells can be accurately 
assessed using the commercial reagent Alderfluor (StemCell Technologies Inc, 
Canada). The Alderfluor assay is based on the conversion of non-fluorescent substrate 
of ALDH to the fluoresent reaction product. The ALDH substrate BODIPY® 
aminoacetaldehyde (BAAA) is taken up via passive diffusion in live cells, whereupon 
BAAA is converted by ALDH to a negative charged, fluorescent product BAA- which 
is retained inside cells164, 165. The ALDH+ subset in cancer cells can be isolated by flow 
sorting. Using this assay, Cheung et al. reported for the first time that leukemic stem 
cells can be isolated on the basis of elevated ALDH activity166. The ALDH+ cells were 
also found in other malignant tissues including cancer of the liver, breast, colon, 
pancreas, lung, overian, pancreas, prostate and cervix167, 168. In hepatocellular 
carcinoma, Ma et al. reported that ALDH is expressed in CD133+ liver cancer cells. 
The ALDH+CD133+ liver cancer cells exhbit greater tumorigenic potential compared 
with the corresponding ALDH-CD133+ or ALDH+CD133- subset, indicating a more 
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accurate defination of cancer stem cells using the combination of ALDH and CD133 
as liver cancer stem cell marker120. ALDH1A1 belongs to the three isoforms of ALDH 
family (ALDH1A1, ALDH1A2 and ALDH1A3). ALDH1A1 serves as a cancer stem 
cell marker in several human cancer types169-183. Tanaka et al. investigated the 
correlation of ALDH1A1 expression and liver cancer stem cells. However, the results 
showed that ALDH1A1 was not co-expressed with liver cancer stem cell markers 
including BMI1, EpCAM, CD133, CD90, CD13 and CD24 indicating ALDH1A1+ is 
not a universal cancer stem cell184. Since ALDH is only associated with cancer stem 
cells, caution must be exercised when using ALDH assay as a sole criteria for the 
identification of cancer stem cells.   
1.3.3.3 SP cells 
Side population (SP) refers to a sub population of cells which are distinct from the 
main population due to their capacity to extrude the fluorescent DNA binding dye 
Hoechst 33342 dye which emits differential spectra when binds to chromatin using 
flow cytometry185. While Hoechst 33342 passes through the intact cell membrane of 
living cells by passive diffusion, its efflux is driven via an energy-dependent process186. 
Evidence suggests that only cells expressing high-level of ATP-binding cassette (ABC) 
transporter proteins can extrude Hoechst. In humans, 48 genes encode for ABC 
transporters, among which ABCB1 (p-glycoprotein/multidrug resistance protein 1, 
MDR1)187, ABCG2 (breast cancer protein resistance protein BRCP)188, 189, ABCC1-5 
(multidrug resistance proteins, MRP1-5)190, 191 and ABCA3192 are the utmost studied 
transporters that function to establish the SP phenotype.  
  
 
19 
 
Since its introduction as hematopoietic stem cell phenotype 20 years ago, the SP assay 
has emerged as a method for the isolating stem cells in normal tissues, including 
liver193, kidney194, skeletal muscle195, mammary glands196, brain197, skin198 and lung199. 
Besides its application in normal cells, SP cells have been identified in various 
malignant cells with their presence ranging from 0% to 20% of the total population200. 
The SP cells have displayed stem-like properties and increased tumorigenicity when 
transplanted into immunocompromised mice, e.g., hepatocellular carcinoma115, 
nasopharyngeal carcinoma201, glioma202, astrocytoma203, gastric cancer204, lung 
cancer205, pancreatic cancer206, mesenchymal neoplasm207 and bone sarcoma208.  
ABC transporter activity defined the SP phenotype, and it was shown that the 
contribution of a specific ABC transporter to the SP may be different in various 
malignancies. For example, in liver cancer Huh7 cells, both the ABCB1 and ABCG2 
define the SP cells204. In neuroblastoma, ABCA3 is more highly expressed in SP cells 
than in the non-SP209.  The SP cells in bone sarcomas have increased expression of 
ABCG2208.  
It should be noted that the SP does not exist in every type of cancer, and they do not 
necessarily represent cancer stem cells with enhanced tumorigenicity. For example, 
glioma SP cells which express higher level of stem cell markers such as Sox2, Oct4, 
do not have increased radiation resistance or tumorigenicity in vivo210. SP cells from 
human cervical cancer cell line Hela have higher expression of stem cell markers 
(Oct3/4, CD133, ABCG2) and show poorer differentiation than non-SP cells but no 
significant differences were observed between SP and non-SP cells in terms of 
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tumorigenicity in vivo211. SP cells in human glioblastoma and gastric cancer cell line 
BGC-823 is non-tumorigenic212, 213. 
Although most of the authors believed that SP cells form hepatocellular carcinoma 
have stem-like properties with increased tumorigenicity and metastatic potentials214-
219, Nakayama et al.220 revealed that SP cells from hepatocellular carcinoma cell lines 
HAK-1A and HAK-1B do not have the complete features of cancer stem cells 
indicating SP cells may not be used as a universal marker for liver cancer stem cells. 
It is worth noting that as Hoechst 33342 can be cytotoxic, making it is difficult to 
compare the biological characteristics of the SP and non-SP cells. For example, 
Hoechst 33342 depletes mobilized human peripheral blood of short term repopulating 
cells with myeloid potential221. Moreover, the SP phenotype should be considered as a 
kinetic parameter which leads to variable results due to the heterogeneity of ABC 
transporters within a population as well as culture growth phase222. 
To summarize, the SP assay is one of the well-documented methods for the 
identification and isolation of stem cells, especially when accepted universal markers 
of the cells are not available. Full characterization of cancer stem cell features should 
be performed for the SP cells in terms of self-renewal, differentiation and 
tumorigenicity. 
1.3.3.4 Gradient centrifugation 
Liu et al developed a density gradient centrifugation method to isolate liver cancer 
stem cells from primary rat liver cancer cells121. Other than using cell surface markers 
  
 
21 
 
or fluorescent dyes such as Hoechst 33342, this method is based on differential 
physical properties of liver cancer stem cells. The researchers showed that the stem-
like liver cancer cells reside within the moderate-density interface which express 
higher level of cancer stem cell markers such as EpCAM and CD133 and have a greater 
capacity for self-renewal and differentiation in vitro.  
1.3.3.5 Intracellular autofluorescence 
Miranda-Lorenzo et al. used intracellular autofluorescent vesicles to identify and 
isolate cancer stem cells from several epithelial cancers including pancreatic ductal 
adenocarcinoma, colorectal carcinoma, hepatocellular carcinoma and non-small-cell 
lung carcinoma122. The intrinsic autofluorescent phenotype was enriched in sphere 
culture, expressed pluripotency-associated genes and harbor metastatic capacity and 
long-term tumorigenicity. The overexpression of ABCG2 transporter, but not other 
ATP transporters, in membrane-bound cytoplasmic structures may confer the 
autofluorescent property to cells. Interestingly, the autofluorescent phenotype did not 
overlap with the side-population (SP) cells which is defined by overexpression of 
ABCG2 transporter on the cell membrane.  Thus, this method has limited value in 
identification of cancer stem cells. 
1.3.3.6 Tumorsphere formation assay and limiting dilution analysis 
Although cell surface proteins as markers have been used to identify and isolation liver 
cancer stem cells, they showed different expression patterns in different subset of liver 
cancer stem cells, indicating the heterogeneity of liver cancer stem cells and a lack of 
definitive markers for liver cancer stem cell selection. Moreover, this method is based 
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on magnetic-activated cell sorting (MACS) or fluorescent-activated cell sorting 
(FACS), in which MACS only allows monoparameter separation while the cost of 
FACS is high and the viability of recovered cells is usually low223. 
Reynold and Weiss reported the method to isolate neural stem cells by sphere-forming 
culture for the first time in 1992224. The cells which were dissociated from mouse brain 
were plated in non-adherent conditions in serum-free medium in the presence of 
epidermal grow factor (EGF). Cells with stem-like properties can proliferate though 
cell-cell interaction and form spheres while other cells cannot grow in suspension and 
die through anoikis225, 226. This concept was adopted by Dontu et al. who demonstrated 
primary mammary tumor stem/progenitor cells can be enriched in non-adherent 
mammospheres227. Besides mammary cancer stem cells, this non-adherent sphere 
culture technique is used for enrichment of cancer stem cells from a number of other 
tissues, including brain101, skin228, prostate229, ovarian230, lung231, kidney231, 
pancreas232, liver117 and colon233. It was shown that tumorspheres derived from liver 
cancer cell lines and clinical samples possess cancer stem cell properties and are highly 
resistant to doxorubicin, fluorouracil, gemcitabine, mitomycin and sorafenib 
respectively117, 234-236. The expression of putative liver cancer stem cell markers from 
sphere-forming cells is higher than their parental cells. For example, the expression of 
Oct3/4, OV6, EpCAM, CD133, CD44 is higher in PLC/PRF/5 sphere-forming cells 
than its parental cells117, the expression of CXCR4, Oct3/4, CD133 and CD90 in 
clinical samples is higher in sphere-forming cells than the parental cells236. It was 
shown that the tumorigenicity of sphere-forming liver cancer cells in mouse 
xenotransplantation models, which is considered the gold standard to evaluate 
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tumorigenicity of tumor cells, were enhanced compared with their parental cells237, 117, 
238. 
Although tumorsphere formation capability is widely used for identification and 
isolation of cancer stem cells, reports showed that in some cases, strong expression of 
cancer stem cell surface markers is not predictive of sphere formation and the 
formation of tumorspheres does not always predict enrichment of cancer stem cell, as 
some progenitor cells can form spheres as well. Therefore, tumorsphere formation 
assay cannot be considered as a universal way to enrich cancer stem cells. For example, 
sphere-forming cells from melanoma cell line B16-F10 did not show increased 
expression of cancer stem cell surface markers (CD133, CD1344 and CD24) compared 
with the B16-F10 adherent cells. Furthermore, B16-F10 sphere-forming cells were less 
tumorigenic than adherent cells when injected in mice, which indicated that additional 
characterizations should be performed to ensure that the tumorspheres are enriched in 
cancer stem cells239. 
Limiting dilution analysis (LDA) combined with xenotransplantation is the gold 
standard method in defining cancer stem cells. This was originally developed by 
microbiologists  to define the  frequency of a specific cell type in a population in cell 
biology240. The specific type of cells can be identified by their observable functional 
activities. The purpose of LDA is to obtain highly precise data at the macro level. LDA 
is a dose-response method that allows the detection of an all-or-none response in each 
individual culture. The frequency of a specific cell type is evaluated by determining 
the functional outcomes of a serially diluted dose of cells in the experiment. Different 
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cell doses are used in LDA, and the more replicates used in each cell density, the more 
precise the estimate will be. The fraction of negative cultures versus cell densities is 
plotted to give a straight line which could be fitted by regression analysis or the least 
square method241, 242. 
Ideally, several conditions need to be fulfilled to obtain precise data by LDA243. Firstly, 
the cells should be Poisson distributed. Secondly, the assay should be quantal - the 
individual cell culture should be either positive or negative. Thirdly, the cell dilutions 
should be designed to give rise to both positive and negative outcomes. Fourthly, the 
detection of the response of a single limiting cell is ideal, however, this is seldom 
achieved in solid cancers due to the limitation of current methodologies employed. If 
the conditions above are optimized, the LDA should be linear and follow a single-hit 
kinetic244. 
1.4 Chemoresistance of liver cancer stem cells 
Resistance to chemotherapy and targeted therapies is one of the major causes that leads 
to cancer treatment failure245. Since cancer stem cells have the capacity for self-
renewal and to initiate tumor progression, they are believed to be the most promising 
candidates in overcoming chemoresistance and tumor recurrence. 
The mechanisms of resistance to chemotherapy in tumor cells are complex, including 
mutation of the drug target, alteration in drug metabolism and increased rates of drug 
efflux. In the conventional view of chemoresistance, genetic changes occur in one or 
several cells in the tumor population. These cells are drug resistant and can survive 
after cancer chemotherapy. Cancer stem cells are naturally resistant to conventional 
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chemotherapies due to their “stem-like” features, including the microenvironmental 
stimuli, tumor dormancy, enhanced expression of ATP-binding cassette (ABC) 
transporters, activation of DNA damage repair and autophagy246. In liver cancer, the 
infection of HBV and HCV also plays critical roles in the resistance to chemotherapy247. 
1.4.1 ABC transporters 
One of the relevant mechanisms of chemoresistance is over-expression of ATP-binding 
cassette (ABC) transporters which function as pumps that extrude drugs, such as 
doxorubicin, out of the cells. In humans, 49 genes encode for ABC transporters among 
which three have been most extensively studied and represent the major mediators of 
the efflux of chemotherapeutic agents248. They are the multidrug resistance protein 1 
(MDR1/ABCB1/p-glycoprotein), multidrug resistance-associated protein 1 
(MRP1/ABCC1), and breast cancer resistance protein (BCRP/ABCG2)249.  
1.4.1.1 ABCB1 (MDR1/ p-glycoprotein) 
ABCB1 is the first identified ABC transporter and its increased expression in drug 
resistance has been studies for over 20 years250. ABCB1 transports a wide variety of 
drugs including doxorubicin which is the most commonly used chemotherapeutic 
agent in the treatment of hepatocellular carcinoma251. The response to doxorubicin 
chemotherapy was shown to be inversely related to the level of ABCB1 expression in 
patients with hepatocellular carcinoma252. ABCB1 is expressed in over 50% of all drug 
resistant tumors253, and over 80% of hepatocellular carcinoma showed positive 
ABCB1 expression from 101 surgical resection specimens from patients with primary 
hepatocellular carcinoma254. Ng et al. revealed that ABCB1 was expressed in most of 
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the hepatocellular carcinoma tissues but less extensively so than in the adjacent 
nontumorous livers255. The expression of ABCB1 has been correlated with clinical 
prognosis of cancer patients. Over-expression of ABCB1 in hepatocellular carcinoma 
was associated with reduction of overall survival and its expression might be a 
prognostic factor after surgical resection in patients256. Besides the studies which 
focused on expression of ABCB1 in hepatocellular carcinoma cell lines and primary 
hepatocellular carcinoma tissues, other studies investigated the association between 
single nucleotide polymorphisms (SNPs) in ABCB1 gene and hepatocellular carcinoma 
susceptibility which indicate that the presence of ABCB1 alleles might be a risk factor 
for hepatocellular carcinoma and the generic variants of ABCB1 gene might be a 
marker for hepatocellular carcinoma257, 258. 
ABCB1 plays a role in protecting cancer stem cells from chemotherapy. ABCB1 
expressing melanoma cells represent melanoma stem cells which are more resistant to 
dacarbazine treatment259. ABCB1 is up-regulated in human lung cancer SP cells and 
glioblastoma sphere-forming cells205, 260. Sugano et al. showed the association between 
ABCB1 overexpression and epithelial mesenchymal transformation (EMT) in lung 
cancer stem cells. Their study showed that inhibition of ABCB1 could reverse the 
resistance to MET inhibitors261. Oshikata262 and Zhou263 studied the association 
between ABCB1 and the properties of liver cancer stem cells, demonstrating that 
expression of ABCB1 confers spheroid culture of liver cancer cells with enhanced drug 
efflux activity262. By reducing ABCB1 expression, liver cancer SP cells acquired 
sensitivity to the cytotoxicity of doxorubicin263. 
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Interestingly, besides its role in extruding chemotherapeutic agents in cancer (stem) 
cells, the ABCB1 protein plays a drug-efflux-independent role in promoting cell 
survival in acute myeloblastic leukemia264, 265. However, whether it augments the 
survival of liver cancer stem cells still needs to be determined. In addition, it was also 
noted that knockdown of ABCB1 by siRNA reduced the migration capacity of breast 
cancer cells, indicating that the role of ABCB1 in cancer is more than just drug efflux 
pump266. 
1.4.1.2 ABCC1 (MRP1) 
Early studies have revealed that drug-selected lung cancer cell lines exhibited reduced 
cellular drug accumulation without detecable expression of ABCB1, which suggested 
the involvement of other ABC transporters267. As the second distantly related ABC 
protein, the ABCC1was identified and cloned in 1992, which showed low homology 
to ABCB1 and was highly expressed in several non-ABCB1-expression lung cancer 
cell lines268, 269. ABCC1 is expressed at moderate levels in most tissues including 
kidneys, lung, skeletal muscle, testis and peripheral blood mononuclear cells, but its 
expression is relatively low in the liver268, 270, 271. ABCC1 has been linked to the 
development of clinical multidrug resistance in a variety types of cancer including 
chronic lymphocytic leukemia, esophagus squamous cell carcinoma, non-small cell 
lung cancer, acute myelocytic leukemia, soft tissue sarcomas, melanoma, 
neuroblastoma, and cancer of the breast, kidney, prostate, ovary and colon272-274. With 
a significant overlap with the substrate specificity of ABCB1, ABCC1 was found to 
mediate the resistance of cancer cells against a broad range of chemotherapeutic agents, 
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including methotrexate, doxorubicin, etoposide, vinscritine, vinblastine, paclitaxel, 
ironotecan and flutamide275. 
ABCC1 is highly expressed in hepatic progenitor cells (HPC), protecting the cells from 
damage caued by cytotoxic drugs276, 277. It should be noted that not only hepatocytes 
but HPCs can give rise to hepatocellular carcinoma as well278-280. ABCC1 is not 
expressed in mature hepatocytes, in this sense it is of interest to characterize the 
expression and function of ABCC1 in hepatocellular carcinoma. Borght et al. have 
shown that the mRNA level of ABCC1 is significantly higher compared with the 
surrounding tissues281. In addition, the study has revealed that mRNA levels of ABCC1 
are higher in hepatocellular carcinomas with poor survival and the hepatoblast type of 
hepatocellular carcinoma, indicating the expression of ABCC1 is associated with  the 
HPC origin of hepatocellular carcinoma and an aggressive tumor phenotype.  
1.4.1.3 ABCG2 (BCRP)  
ABCG2 was identified by three separate groups in 1998 and 1999282-284. Besides its 
expression in many nomal tissues such as brain, placenta, liver, prostate and small 
instestine285, ABCG2 is expressed in 40%  solid tumors286. Although this transporter 
is also referred as breast cancer resistant protein (BCRP), no evidence so far indicated 
that ABCG2 is preferentially expressed in normal or malignant breast tissues266.  
The expression of ABCG2 is higher in hepatocellular carcinoma than in adjacent 
normal tissue of patients, but it was found only in a minor group of cells in 
hepatocellular carcinoma cell lines and patient tissues147, 287. Studies have shown a 
correlation between ABCG2 expression and differentiation status, age and hepatitis B 
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surface antigen287, 288. Up-regulation of ABCG2 ehhanced the capacity of 
hepatocellular carcinoma cells to proliferate, migrate, and get resistant to 
doxorubicin147. The overexpression of ABCG2 has confered poor outcome in 
hepatocellular carcinoma elderly patients288.  
A variety of anticancer drugs can be transported by ABCG2 including mitoxantrone, 
methotrexate, topotecan, flavopiridol and doxorubicin289, 290. More importantly, the 
expression of ABCG2 is shown to be correlated with the chemoresistance of cancer 
stem cells291. Zhou et al. have shown that ABCG2,  which was widely expressed in 
stem cells, served as a determinant of the SP cells, and stem cells from ABCG2-
deficient mice were more sensitive to mitoxantrone which is an ABCG2 substrate292, 
293. Since the SP phenotype is mediated mainly by ABCG2, it is reasonable that 
ABCG2 may serve as a cancer stem cell biomarker. Increased expression of ABCG2 
has been found in numerous putative cancer stem cells from cancer of the liver294, 
lung205, pancreas295 and ovarian296. Zen et al. demonstrated that liver cancer stem cell 
marker cytokeratin 19 and alpha-fetoprotein were expressed in the ABCG2+ liver 
cancer cells which indicated that hepatocellular carcinoma cells with expression of 
ABCG2 may play a critical role in the carcinogenesis and the maintainance of cancer 
cell hierachy of human hepatocellular carcinoma.   
1.4.1.4 ABCB5 
ABCB5 (human ATP-binding cassette, subfamily B, member 5), is a plasma 
membrane protein and belongs to the ABCB1 family member. Being  highly expressed 
by the cancer stem cells of malignant malanoma96, 297, 298, hepatocellular carcinoma159, 
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colorectal cancer299 and Merkel cell carcinoma300, the expression of ABCB5 is 
associated with tumor progression, chemoresistance and recurence in patients with 
these types of cancer. 
Cheung and colleagues have shown that granulin-epithelin precursor (GEP), a novel 
growth factor, regulated chemoresistance of liver cancer cell via modulation of the 
expression of the ABCB5 protein, which is associated with the reccurence of 
hepatocellular carcinoma after partial hepatectomy159. Furthermore, GEPhigh/ABCB5+ 
subpopulation accurately designated the liver cancer stem cells with enhanced 
tumorigeric ability in immunocompromised mice, while suppresion of ABCB5 
sensitized liver cancer cells to doxorubicin treatment158, 159. Interestingly, liver cancer 
cells which expressed GEP and ABCB5 also co-expressed liver cancer stem cell 
marker CD133 and EpCAM159. The gene expression of ABCB5 in liver cancer and the 
correlation of genetic polymorphisms and clinical features have been studied, which 
indicated the association between genetic polymorphisms of ABCB5 and advanced 
liver cancer301. 
1.4.2 Cell quiescence 
Cell quiescence is difined as a non-proliferating state. Instead of becoming quiescent 
by default as researchers believed previously, cells, particularly stem cells, actively 
stay in the quiescent phase of the cell cycle to preserve their genomic intergrity302. The 
tumor cells can maintain in non-deviding state for long time, while awakening of these 
cells can lead to tumor relapse which may occur after a long period303. It has been 
shown that in most of the times both normal stem cells and cancer stem cells stay in 
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the quiescent phase of the cell cycle304, 305. As chemotherapy, as well as radiotherapy, 
targets fast proliferating cells, the quiescent cancer stem cells are protected  from cell 
death induced by anti-proliferating drugs.  
The cell surface marker CD13 was identified as a cancer stem cell marker of liver 
cancer. The CD13+ liver cancer cells exhibited high tumorigenic potential and 
resistance to 5 fluorouacil (5-FU) treatment. It was obverved that CD13+ cells 
predominated exist in the G0 phase of the cell cycle
306. Using another cancer stem cell 
marker, Ymashita et al. reported that the EpCAM+ liver cancer stem cells remain 
quiescent in their celll cycle, and oncostatin M (OSM) is able to active cell division of 
these dormant liver cancer stem cells307. The combination of OSM and 5-FU efficiently 
eliminate both cancer stem cells and non-cancer stem cells307. The slow-cycling glioma 
cancer stem cells survived the treatment of chemotherapeutic agent temozolomide 
leading to tumor relapes308. After removing the slow-cycling cells, survival of tumor-
bearing mice was substantially prolonged308. In melanoma, targeting the slow-cycling 
melanoma cells via knockdown of the H3K4 demethylase JARID1B lead to reduction 
of tumor growh and metastatic progression in animal models309. In pancreas 
adenocarcinoma, the slowly cycling tumor cells can retain the lippphilic labeling dye 
DiI, while the bulk tumor cells did not. The DiI+ cells showed increased tumorigenic 
potential310. Imatinib and 5-FU successfully eliminate fast proliferating leukemia cells 
but fail to diminish the number of their quiescent counterparts311-313. In another study, 
the quiescent leukemia stem cells contributed to chemoresistance314. While 
doxorubicin reduced the overall cancer burden in breast cancer, it failed to kill the 
dormant cancer cells in mice315. Taken tegether, The quiescent cancer stem cells avoid 
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attacks from chemotherapy and radiotherapy thus contributing to the cancer stem cell-
related resistance.  
1.4.3 DNA damage response repair 
DNA damage has been recognized as a causal factor for cancer development. 
Erroneous DNA repair results in chromosomal aberrations as well as mutations, which 
affects tumor suppressor genes and oncogenes, resulting in malignant transformation 
of the cells. In fact, all cancers show defects in DNA repair316. Radiation and the 
majority of chemotherapeutic agents, such as topoisomerase II inhibitors (doxorubicin, 
daunorubicin), alkylating agents (cisplatin, carboplatin, oxaliplatin) and antimetabolite 
(methotrexate, 5-fluorouracil, gemcitabine, hydroxycarbamide), kill cells by inducing 
DNA damage317. Chemotherapy is most effective on cells that are actively dividing, 
because the fast proliferating cells give the drugs more chances to damage their DNA. 
However, increasing evidence has suggested cancer stem cells avoid DNA damaging 
treatment through multiple mechanisms including enhanced DNA repair capacity and 
the ability to scavenge reactive oxygen species (ROS)246. It should be noted that 
although the quiescent state of cancer stem cells prevents themselves from being 
attacked by chemotherapeutic drugs, DNA damage is inevitable once the DNA of cells 
has exposed to the drug318.   
In general, the DNA repair mechanisms can be categorized into two classes: those that 
repair single-strand damages, including base excision repair (BER), nucleotide 
excision repair (NER) and mismatch repair (MMR); and those that repair double-strand 
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breaks (DSBs) including homologous recombination (HR) and non-homologous end 
joining (NHEJ)319, 320. 
1.4.3.1 Base excision repair (BER) 
BER is considered as the “workhorse” repair mechanism of the cell, which corrects 
damages to the bases or sugar phosphate backbone causes by oxidative and alkylative 
agents, ionizing radiation, as well as everyday endogenous or exogenous adducts321. It 
is responsible for correcting small, non-helix-distorting base damages from the 
genome.   
DNA bases damages are most commonly caused by alkylation, oxidation and 
deamination, leading to incorrect base-pairing and DNA mutations. For example, most 
alkylating drugs are methyl donors, e.g., dacarbazine and temozolomide, which form 
adduct at the N- and O- atoms in DNA322. N7-methylguanine (7meG) is the most 
predominant methylation adduct and the most stable N-methylation adduct which 
accounts for ~75% of the total methylation damages in DNA bases323. 7meG is prone 
to depurination leading to the formation of an abasic site which is potentially 
mutagenic and cytotoxic324. Oxidation is another potentially harmful reaction. There 
are over 100 types of oxidative base modifications that may arise in DNA, among 
which 8-oxo-dG is one of the most predominant and well studied325. 8-oxo-dG may 
potentially cause mutagenic lesion due to its capacity to pair with adenine and cytosine 
during DNA replication thus leading to G:C to T:A transition mutations326, 327. 
Deamination is the process of removing amino groups from the molecule. In DNA, 
spontaneous deamination from cytosine, 5-methycytosine, guanine and adenine results 
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in the formation of uracil, thymine, xanthine and hypoxanthine respectively320. 
Deamination can lead to A:T to G:C and C:G to T:A transition mutations328. It has been 
reported that polymorphisms of BER genes increase liver cancer risk329.  
The BER involves five key enzymatic steps: 1) recognition of the lesion and excision 
of the inappropriate base, 2) incision of the phosphatediester group at the resulting 
abasic site, 3) replacement of the inappropriate nucleotide, 4) adding a hydroxyl on 
the 3' end and a phosphate on the 5' end of the DNA, 5) sealing of the final DNA nick330. 
1.4.3.2 Nucleotide excision repair (NER) 
The DNA sugar phosphate backbone often remains intact after the damage of chemical 
modification, the overall changes in DNA are relatively small compared with those 
lead to detrimental damages such as double-strand breaks. The NER system can deal 
with a broad spectrum of DNA lesions, including bulky base adducts and particularly 
base damages that distort the normal conformation of the duplex DNA such as 
cyclobutene-pyrimidine dimers (CPDs) and 6-4 pyrimidine-pyrimidone photoproducts 
(6–4PPs), which are the major lesions caused by ultraviolet (UV) radiation331. NER 
can occur either through global genome NER (GG-NER) or transcription-coupled NER 
(TC-NER). These two NER pathways are considered to differ only at the recognition 
step, but share the same other machinery for repair response. GG-NER functions 
throughout the whole genome by removing helix-distorting lesions. The NER protein 
XPC-RAD23B recognizes structural changes induced by damages in DNA and 
initiates the repair response332-334. The repair proteins are subsequently recruited to the 
damaged site to excise the damaged DNA and carry out gap-filing repair synthesis. 
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Finally, the nick is sealed320. The difference between GG-NER and TC-NER is that 
TC-NER initiates when RNA polymerase II stalls at the lesion in DNA. The RNA 
polymerase II can recognize the damage which replaces the need for XPC-RAD23B335. 
In liver cancer, it was found that hepatitis B virus X protein can inhibit NER and may 
contribute to the development of the disease336. 
1.4.3.3 Mismatch repair (MMR) 
MMR recognizes and corrects DNA mismatches including deletion, erroneous 
insertion, and mis-incorporation during DNA replication and recombination337-339. 
Defects in MMR increases the rate of mutation which is associated with human 
cancers337, 339, 340. The MMR system can eliminate damaged cells and prevent 
tumorigenesis.  
MMR is a high conserved process with great similarity between human MMR and E. 
coli MMR338, 339. Several human proteins are involved in MMR including MutS, MutL, 
EXO1, DNA polymerase δ, single-strand DNA-binding protein RPA, proliferating 
cellular nuclear antigen (PCNA), and DNA ligase I, within which the MutS and MutL 
homologs (hMutS/hMutL) are the fundamental components of MMR341, 342. In humans, 
the hMutSα protein recognizes DNA mismatches and small nucleotide 
insertion/deletion mispairs, while the hMutSβ protein recognizes large 
insertion/deletion mispairs343-345. The MutLα regulates the termination of mismatch-
provoked excision and MutLγ plays a role in meiosis respectively, but the specific role 
of MutLβ is still not clear338, 346. EXOI is a 5’-3’ exonuclease, which catalyzes both 5’ 
and 3’-directed mismatch excision346-349. In addition, researchers have shown the 
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possible 3’-5’ exonuclease activity of EXOI349, 350. The role of PCNA involves the 
initiation and DNA re-synthesis of MMR351, 352. PCNA is required for 3’-directed 
MMR, but it is not crucial for 5’-directed MMR353.  
It has been revealed that defects in human MMR lead to cancer development. 
Researchers have identified the germ-line mutations in hHSH2 in human colorectal 
cancer354. In addition, mutations in hMLH1 accounts for the majority of hereditary non-
polyposis colorectal cancer355, 356. Kitajima and colleagues have demonstrated that the 
reduce expression of hMLH1 and hHSH2 may play a critical role in gastric cancer 
progression357. Furthermore, the deficiency of PMS2, a MMR gene, was find in 88% 
of 49 cancers358. These findings suggest that defects of MMR are a potential cause of 
cancers.  
1.4.3.4 Homologous recombination (HR) 
Among a series of DNA damage, DSBs are considered as the most serious form. DSBs 
can be repaired by two major pathways: Homologous recombination (HR) and non-
homologous end joining (NHEJ). HR includes a series of pathways which repairs 
DSBs as well as inter-strand crosslinks (ICLs). HR is found in all forms of life, which 
provides high-fidelity repair, guarantees faithfully DNA duplication and telomere 
maintenance359. The fundamental difference between HR and NHEJ is the repair 
accuracy and their dependence on DNA homology360, 361. HR leads to accurate repair 
via using homologous chromosome as a template, while NHEJ is intrinsically 
mutagenic362, 363. Compared with NHEJ which can occur throughout the entire cell 
cycle, the repair function of HR is restricted to S and G2 phase. Therefore, NHEJ is 
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generally considered the predominant mechanism for DSB repair. Highly proliferating 
cells, such as cancer cells, are more committed to HR repair while NHEJ can repair the 
DNA lesions in non-proliferating cells such as stem cells and cancer stem cells364-366.   
The classic model of HR-mediated DSB repair in mammalian cells can be divided into 
three stages367. In the pre-synapsis stage, the 5’ ends of the break are resected while 
the 3’ ends are processed to 3’-OH ending tail. During synapsis, the homologous 
sequence search occurs followed by the pairing with a homologous DNA sequence to 
form a D-loop structure. The DNA synthesis is guided by polymerases using the intact 
homologous strands as a template. The D-loop can be processed into a full replication 
fork, which copies the distal portion of the chromosome. During DSB repair, both the 
3’ and 5’ ends are engaged in the process, resulting in the formation of double Holliday 
junctions which can be processed by endonucleolytic incisions, leading to the 
formation of genetic crossovers. 
1.4.3.5 Non-homologous end joining (NHEJ) 
As mentioned above, NHEJ-mediated DNA repair does not rely on homologous 
templates, therefore NHEJ is not restricted to a certain cell cycle. Compared with HR 
which is an accurate DNA damage repair pathway, NHEJ is considered an inherently 
error-prone process363. Three reasons account for the inaccuracy of NHEJ363: 1) the 
existence of alternative end-joining pathways besides the canonical NHEJ; 2) the 
versatility of canonical NHEJ to imperfect ends; 3) the DNA ends cannot be ligated 
directly. In addition, the quality of the end-joining is dictated by the structure of the 
DNA ends rather than by the NHEJ machinery.  
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The NHEJ is a conservative but adaptable process which can be divided into three steps: 
1) DNA end recognition and stabilization of NHEJ complex at the DSB site; 2) 
Bridging and processing of the DNA ends; 3) ligation of the broken ends and release 
of the NHEJ complex. For simple DSBs which do not have complicated configurations, 
the DNA ends can be identified and ligated by normal procedure. For complex DSB 
ends which are covalently modified and significantly mismatched, additional 
processing factors such as polynucleotide kinasephosphatase (PNKP), aprataxin 
(APTX), APTX–polynucleotide kinase/phosphatase-like factor 1 (APLF or PALF), 
Artemis and DNA polymerases are required for the modification of DNA ends prior to 
DNA ends ligation368. 
NHEJ plays a major role in DSB repairs, whereas HR is involved in 15-20% of DSB 
repair events369, 370. The factors that control the DNA end resection are crucial for the 
choice between HR and NHEJ in S and G2 phase of the cell cycle371, 372. It should be 
noted that the two repair mechanisms are tightly coordinated although the competition 
between HR and NHEJ in the choice of DNA repair pathway was studied in recent 
years373, 374. The choice of repair pathway is not simply a result of competition but it is 
flexible to respond to a variety of physiological and pathological situations.  
Growing evidence has shown that DNA damage repair proteins and checkpoint 
proteins such as BRCAs, XRCC5, p53, ATM are overexpressed in cancer stem cells 
but not in non-cancer stem cells375, indicating inhibition of DNA repair might sensitize 
cancer stem cells to the treatment of chemotherapy and radiotherapy. For example, it 
has been shown that BMI1, which is the key factor in the assembling of DNA repair 
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machinery, was overexpressed in cancer stem cells and irradiation can enhance its 
expression in cancer stem cells376-378. The deletion of BMI1 in cancer stem cells 
promotes DSBs and radio-sensitivity whereas increased expression of BMI1 reduced 
radio-sensitivity379, 380. Venkatesha and coleagues have revealed that inhibtion of ATM 
or CHK1, which are key factors that drive DNA damange response, can sensitive 
pancreatic and breast cancer stem cells to gemcitabine381. Treatment of colon cancer 
cell with DNA interstrands crosslinking agent lead to pronounced increase in the 
phosphorylation of CHK1 in CD133+ colon cancer stem cells382. It wa reported that 
CHD4 is involved in  UV-mediated DNA damage repair383, 384. Nio et al. have 
demonstrated that CHD4 is highly expressed in EpCAM+ liver cancer stem cells, and 
plays ctirical roles in the chemoresistance of liver cancer stem cells385. In addtion, 
targeting CHD4 significantly suppressed hepatocellular carcinoma growth385. The 
TP53 mutations following the expotsure of aflatoxin B1, which is a genotoxic 
hepatocarcinogen, resulted in defective DNA damage response in liver cells386. Ju et 
al. have demonstrated that aflatoxin B1 can mediate the mutation which induces the 
conversion of hepatic cancer cells to liver cancer stem cells387. These studies supported 
that targeting DNA repair pathway in cancer stem cells may overcome the resistance 
of cancer stem cell to chemotherapy.  
1.4.4 Autophagy 
Macroautophagy, hereafter refer to as autophagy, is an evolutionarily conserved 
cellular progress by which proteins and organelles are degraded and recycled in 
lysosomes to sustain metabolism and survival246, 388-391. Autophagy was first described 
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over 40 years ago, but its clear connections to human health and disease were only 
revealed recently including infection of bacterial392 and virus393, heart disease394, 
adaptive immune response395, inflammation396, aging397, neurodegeneration398 and 
cancer399. Aberrant autophagic activity serves as a critical function in the survival and 
chemoresistance of various cancers. Autophagy is involved in protection against 
malignant transformation of healthy cells, and being a critical survival factor for 
tumors cells under stressful situations, such as starvation, hypoxia, absence of growth 
factors, and chemotherapeutic treatments400-404. The function of autophagy in cancer 
can be neutral, tumor-suppressive, or tumor-promating405. In one instance, autophagy 
can play a critical role in the survival of cancer cells by providing energy and nutrients 
from the degradation of proteins and organelles400, 406. In contrast, induced autophagy 
can also promote cancer cell death though apoptosis, autophagic cell death or non-
lysosomal vasiculate cell death407. The effect of autophagy in cancer cells appear to be 
context-driven, which largely depends on the type of cancer cells and treatment408-412. 
Autophagy is a highly dynamic, multi-step process which can be modulated at several 
steps, both positively and negatively. The initiation of autophagy involves the 
formation of phagophores which expands into autophagosomes. Under physiological 
conditions, the autophagosomes are fused with lysosomes thus forming autolysosomes 
in which th encpsulated contents are degraded. The number of autophagosome 
formation can reflect autophagic activity. In some circumstances, the fusion of 
autophagosomes with lysomes can be blocked, or the formation of lysosomes can be 
disrupted, which results in an increased number of autophagosomes. The 
autophagosomes can also fuse with endosomes thus forming amphisomes, prior to 
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fusion with lysosomes, in which lysosomal enzymes digest the content and inner 
membrane413.  This process is regulated by a series of autophagy-related genes (Atgs),  
among which 33 Atgs have been identified so far414.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. The formation of autolysosome. The fusion of a double-membrane 
autophagosome (AP) with a lysosome generates an autolysosome (AL). The 
convergence of autophagy and endocytosis produces a single-membrane amphisome 
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(AM) that also form an autolysosome upon fusion with a lysosome. PG, phagophore 
(adapted from Klionsky et. al.415). 
 
1.4.4.1 The dual role of autophagy in hepatocellular carcinoma 
The role of autophagy in hepatocellular carcinoma has been relatively well studied. It 
can serve as either anti-cancer or pro-cancer mechanism. 
1.4.4.1.1 Autophagy as pro-cancer mechanisms 
In hepatocellular carcinoma, autophagy is activated in various stress conditions 
including starvation, hypoxia, growth factor deprivation and chemorethepeutic agents, 
which serves as a critical pro-survival mechanim in response to stress410, 416. Increased 
autophagy response has been found in advanced hepatocellular carcinoma and to 
correlate with malignant progression and poor progosis417-419. Liver-specific atg5-
knockout mice developed only benign hepatic adenoma but not cancer, indicating that 
autophagy is required to promote tumor development420. In addition, distinct from 
normal tissue microenvironment, tumor niche is hypoxic, acidic, low in energy and 
inflammatory, which induce autophagy though various pathways399, 421.  
1.4.4.1.2 Autophagy as tumor suppressor mechanims 
Autophagy plays a role in tumor suppression, and autophagy deficiency may result in 
hepatocellular carcinoma. 
1.4.4.1.2.1 Beclin 1 (Atg6) 
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The first link between autophagy and tumorigenesis was established by Liang et. al. 
who find that Beclin 1 inhibits tumorigenesis422. Abnormal expression of Beclin 1 has 
been associated with the development of various cancer, including cancer of the lung, 
liver, prostate, colon, ovarian, breast and brain422-427. Further study has showed that 
heterozygous deletion of Beclin 1 increases the frequency of spontaneous malignancies 
and accelerates the hepatitis B virus (HBV) – related premalignant injury428. These 
findings support Beclin 1 as a  tumor-sppressor gene and autophagy as a mechanism in 
tumor suppresion. In addtion, recent studies have shown the important role of Beclin 1 
in endocytosis, which seems to have explained the fact that Beclin 1 knockout mice 
died during embryoic period while atg5 and atg7 knockout mice can survive until birth 
due to the more complicated function of Beclin 1 other than autophagy in mice429-431. 
1.4.4.1.2.2 Atg5 and Atg7 
Studies have shown that mouse models with long-term mosaic deletion of atg5 and 
liver-specific deletion of atg7 led to development of spotaneous benign liver adenomas, 
suggesting that autophagy is necessary to suppress tumor progression beyong the 
benign state432. Meanwhile, enlarged mitochondria, oxidative stress, numerous 
perixosomes and increased genomic damage response were obseved in hepatocellular 
carcinoma cells432. 
1.4.4.1.2.3 The autophagy flux protein p62 
In the beginning of autophagosome formation, LC3, an autophagic receptor is 
incorporated into the phagophore and designated as LC3-II, which serves as a docking 
site for adapter proteins bound to ubiquitinated substances, such as organelles. The p62 
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protein, also known as sequestosome 1 (SQSTM1), is one of the linking adapters. The 
p62 protein binds to ubiquitinated substrates and delivers them into phagophore, in 
which it binds to LC3-II and is degraded along with its substrate433. Lack of autophagy 
leads to p62 accumulation which induces oxidative stress that results in desease such 
as hepatocellular adenoma432 while the low level of p62 which is caused by autophagy 
degradation may benefit the liver434. Cui and colleagues showed that p62 expression 
was found in hepatocellular carcinoma samples but not in the surrounding hepatocytes 
using paraffin-embedded samples435. Multiple signaling pathways have contributed to 
p62-induced carcinogenesis including Wnt/β-catenin, the mechanistic target of 
rapamycin (mTOR), nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κb), 5′ AMP-activated protein kinase (AMPK) and the nuclear factor erythroid 2 
(NFE2)-related factor 2 (Nrf2)430, 436-440. Taken together, understanding the role of p62 
protein may provide a new insight into the development and treatment of hepatocellular 
carcinoma. 
1.4.4.2 Autophagy and cancer stem cells 
Autophagy has been shown to be involved in the maintennance of stem cells. 
Autophagic activity is highly activated in normal stem cells, but relatively low in other 
cells441. Mortensen and colleagues revealed that the autophagy is essential for 
hematopoietic stem cell maintenance442, 443. Recently, it was revealed that the 
autophagy protein ATG5 and ATG7 play crutial roles in maintaining hematopoietic 
stem/progenitor cells by deducing cellular stress and promoting survival444. Ho and 
colleagues have demonstrated the autophagy becomes increasingly necessary with age 
  
 
45 
 
to maintain the regenerative function of old hematopoietic stem cells445. In muscle stem 
cells, autophagy is a key factor in maintaining their regenerative capacity by promoting 
quiescence and preventing senenscence while dysfunctional autophagy leads to 
declined function of muscle stem cells with aging446-448. Given the analogy between 
stem cells and cancer stem cells, one could expect autophagy may play a protective in 
the maintenance of cancer stem cells.  
Several studies revealed the important role of autophagy in liver cancer stem cells. 
Song et al. have reported the involvement of autophagy in the maintenance of CD133+ 
liver cancer stem cells in the hypoxic and nutrient-deprived conditions and the 
autophagic inhibitor chloroquine (CQ) increased cell apoptosis and decreased 
clonogenic capacity of CD133+ liver cancer stem cells449. Another study by Li et al. 
showed that interferon-gamma (IFN-γ) inhibited the proliferation of liver cancer cell 
lines with low percentage of CD133+ cells, but did not affect cell lines with high 
percentage of CD133+ population indicating CD133+ liver cancer stem cells resist IFN-
γ-induced autophagy which might explain the mechanism through which liver cancer 
stem cells escape immune surveilance450. Xue et al. demonstrated that autophagy-
deficiency in liver cancer stem cells leads to defects of stemness and enhances 
susceptibility to neoplastic trasnformation in hepatic progenitor cells451. Novel liver 
cancer stem cells marker glypican-3 mediates self-renewal and tumor formation partly 
by induction of autophagy suggesting that inhibition of autophagy might be a general 
approach to interven the function of liver cancer stem cells regardless of cell surface 
marker expression154. The novel first in class autophagy inhibitor GNS561 has been 
reported to be able to eliminate liver cancer stem cells. In this study, GNS561 exhibited 
  
 
46 
 
autophagy inhibition and apoptosis induction activities against ALDH+CD133+ liver 
cancer stem cells and hepatocellular carcinoma tumors from patients harboring 
sorafenib resistance, which offers great potential for hepatocellular carcinoma 
treatment452. Ginsenoside Rh2, a well-characterized compound which has been shown 
of therapeutic effects on several caner types453-458, was reported to eliminate liver 
cancer stem cells via activation of autophagy and inhibition of β-catenin signaling, 
indicating context-dependent role of autophagy in killing liver cancer stem cells459.  
Besides liver cancer stem cells, the involvement of autophagy was reported in cancer 
stem cells of other types of cancers, including cancer of the breast, pancreas, brain, 
urinary bladder, esophagus, colon, lung and leukimia460-464. Most of these stuides 
elucidated the positive regulatory role of autophagy on the cancer stem cells, leading 
to promoting the survival, maintenance, resistance and tumorigenicity of cancer stem 
cells. However, a few studies showed that autophagy may have a negative impact. For 
example, Kumar et al. revealed that rottlerin induced autophagy in breast cancer stem 
cells leading  to cell apoptosis465. Autophagy was shown to compromises self-renewal 
potency of breast and larynx cancer stem cells466. However, Yan and colleagues 
reported that enhanced basal level of autophagy in colorectal cancer stem cells does 
not contribute to radioresistance463. To summarize, the real role of autophagy in cancer 
stem cells may depend on the type and stage of the tumor in question, as well as genetic 
and epigenetic context.  
1.4.5 The cancer stem cell niche 
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In normal organs, the adult stem cells are located in a “stem cell niche”, an area within 
the specific anatomic location in which stem cells are present in an undifferentiated 
and self-renewable state, which plays a critical role in maintaining the self-renewal and 
multi-lineage differentiation capacity through cell-cell communication and by 
secreting several paracrine factors467. The stem cell niche is usually less exposed to 
external or immune attacks. For example, the intestinal stem cells hide at the bottom 
of the crypt away from the intestinal lumen468. The mammary stem cells locate under 
the luminal epithelium which is away from the acinar lumen469. The regulatory T cells 
provides a sanctuary for the hematopoietic stem cells from immune attack470.  
Similar in concept to normal adult stem cells, the cancer stem cells are located in a 
cancer stem cell niche which is essential to maintain a balance between the self-renewal 
and differentiation, and regulate resistance of cancer stem cells by cell-cell or secreted 
protein-cell interaction471. There are two types of cancer stem cell niche, the hypoxic 
niche and the perivascular niche318.  
1.4.5.1 Hypoxic niche 
Hypoxia has been recognized as the hallmark of cancer. It plays crucial roles in the 
survival, proliferation, angiogenesis, invasion and metastasis of cancer cells. The 
hypoxic niche is led by the rapid growth of cancer cells which exceeds its blood 
supply472. In response to hypoxia, the hypoxia-inducible factor (HIF) subunits HIF-1α 
and HIF-2α were activated473, 474, which are capable of promoting the stemness of 
cancer cells475. Zhang et al. have reported the capacity of HIFs promote the expression 
of stem cell markers in breast cancer476. In leukemia, deletion of hif1α results in 
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impaired clonogenicity of leukemic cancer stem cells477. In brain and pancreatic 
cancers, hypoxia promotes the expansion of cancer stem cells478-482. In prostate cancer, 
hypoxia elevates the expression of cancer stem cell marker SOX2483.  
In hepatocellular carcinoma, it has been shown that hypoxia activates β-Catenin which 
contributes to enhanced metastasis and poor prognosis484. The Wnt/β-catenin signaling 
enhances hypoxia-induced epithelial–mesenchymal transition (EMT) in hepatocellular 
carcinoma through interaction with HIF-1α484. Ye et al. have revealed that EMT in 
hepatocellular carcinoma cell which promotes metastasis485. Xu et al. have shown that 
hypoxia activates Wnt/β-catenin signaling by promoting the expression of BCL9 in 
hepatocellular carcinoma486. Lai et al. have shown that the hypoxia environment 
promotes the enrichment of liver cancer stem cells487. Mao et al. have demonstrated 
hypoxia induces the expression of caveolin-1, which enhances the invasiveness and 
metastasis of hepatocellular carcinoma cells488. The hypoxia niche in hepatocellular 
carcinoma up-regulates the expression of stem cell factor, which promotes the 
angiogenesis and metastasis of hepatocellular carcinoma489. The expression of 
stemness marker K19 and EpCAM and hypoxia marker CAIX are correlated with each 
other, and their expression confers hepatocellular carcinoma cells resistance to trans-
arterial chemoembolization and poor treatment outcome490. Chiu et al. have 
demonstrated that hypoxia can induce the recruitment of myeloid-derived suppressor 
cells (MDSCs), which support tumor growth, differentiation and metastasis491, via 
chemokine ligand 26 in hepatocellular carcinoma providing a novel mechanism by 
which hypoxia promotes the tumorigenicity of liver cancer cells492. Cui et al. have 
reported the positive feedback loop between HIF-1α and Specific small ubiquitin-like 
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modifier proteases 1 (SENP1) in contributing to the stemness and carcinogenesis in 
hepatocellular carcinoma under hypoxia493.  
Hypoxia can induce autophagy and promotes chemoresistance of hepatocellular 
carcinoma cells494, 495. A recent study has suggested that hepatocellular carcinoma 
patients with overexpression of NDUFA4L2,  a subunit in complex 1 of the electron 
transport chain, may benefit from HIF inhibitor treatment496.  
1.4.5.2 Perivascular niche 
The perivascular niche is the microenvironment close to vascular vessel in which the 
tumor cells can bind to the blood vessels497. In some types of tumors such as 
glioblastoma and head and neck squamous cell carcinoma, the cancer stem cell 
populations locate in the perivascular niche at the invasive tumor edge close to the 
blood vessels498, 499. The glioblastoma cancer stem cells produce a high level of 
endothelial growth factor (VEGF) which induces angiogenesis. Anti-VEGF receptor 2 
(VEGFR2) treatment depletes cancer stem cells leading to inhibition of tumor growth, 
indicating the importance of VEGF signaling in the maintenance of cancer stem cells500. 
The anti-angiogenesis drugs can inhibit tumor growth effectively in mouse tumor 
model. However, they fail to reduce tumor growth clinically with a few exceptions501, 
502. This might be due to the fact the dependence of blood vessels on VEGF is different 
in mouse and human tumors.  
Vascular normalization may inhibit cancer stem cell function because it reverses tumor 
hypoxia. In addition, vascular normalization may change the immune response in the 
cancer stem cell niche. For example, inhibition of VEGF suppresses expression of 
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programmed cell death-1 protein (PD1) in T cells so that the programmed death-ligand 
1 (PD-L1) expressed on cancer cells fails to mediate immunotolerance leading to tumor 
growth inhibition503.  
1.4.6 Infection of HBV and HCV and other factors 
1.4.6.1 HBV  
Chronic HBV infection is a major risk factor in the pathogenesis of hepatocellular 
carcinoma, especially in Southeast Asia where ~90% of hepatocellular carcinoma is 
due to the infection of HBV504. It has been shown that the risk of hepatocellular 
carcinoma in HBV carriers is 10-folds higher than in the non-carriers505. The hepatitis 
B virus X protein (HBx) was found to heavily contribute to the tumorigenesis of non-
tumor hepatocytes506. Yue et al. have shown that HBx induces DNA damage, disrupts 
nucleic acid metabolism, and block DNA repair leading to the occurrence of 
hepatocellular carcinoma507. Furthermore, HBx plays a role in the metastasis508 and 
resistance to targeted therapies in hepatocellular carcinoma509. HBx can promote the 
stemness of hepatocellular carcinoma though activating of β-catenin and upregulation 
of miR-181510.  
It was reported recently that HBx can promote the stem-like properties of OV6+ liver 
cancer stem cells via regulating the MDM2/CXCL12/CXCR4/β-catenin signaling 
axis511. Wang et al. have revealed that HBx can induce tumorigenicity of hepatic 
progenitor cells in a HBx transgenic mouse model512. Ng et al. have shown that c-
terminal-truncated HBx promotes carcinogenesis of hepatocellular carcinoma via 
induction of CD133+ liver cancer stem cells513. Researchers have revealed the 
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relationship between HBx and alpha fetoprotein (AFP), which is well known as a 
clinical hepatocellular carcinoma marker. They have shown that AFP can mediate 
HBx-induced hepatocarcinogenesis whereas HBx can promote the initiation of liver 
cancer stem cells by enhancing the expression of AFP via activating PI3K/AKT 
signaling pathway514-516. Mani et al. investigated the role of EpCAM-regulated 
intramembrane proteolysis (RIP) in HBV replicating cells. The results showed that 
EpCAM RIP induced the expression of liver cancer stem cell genes in HBV replicating 
cells, indicating the potential use of γ-secretase inhibitors to suppress EpCAM RIP517. 
1.4.6.2 HCV 
HCV infection often causes liver fibrosis and contributes to hepatocellular carcinoma 
by directly promoting the malignant transformation of hepatocytes or by indirect 
mechanisms including leading to the loss of virus-bearing hepatocytes518-520. 
Compared with other risk factors, such as intake of alcohol, HCV infection increases 
the risk of hepatocellular carcinoma to ~18-folds10.  
HCV is a positive-strand RNA virus which replicates outside the nucleus so that it 
cannot integrate its genetic information into the host’s genome. The HCV proteins are 
involved in a variety of activities such as cell signaling, proliferation, apoptosis and 
translational regulation521. HCV proteins can interact with cellular proteins which 
control cell proliferation. For example, the nonstructural protein 3 (NS3) and 
nonstructural protein 5A (NS5A) proteins disrupt the tumor suppressor p53. The non-
structural protein NS5B binds to the retinoblastoma protein, which plays a key role in 
overcoming infection-induced blocks to cell proliferation522, 523. The protein NS4B 
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mediates multiple signaling pathways, including several members of the protein kinase 
C (PKC) family, ERK, STAT3, and JNK, which play important roles in the activation 
of MMP-2 and Bcl-2, thereby leading to deregulation of cell transformation and 
apoptosis524. It has been shown that antiviral therapy in patients with HCV results in 
significant reduction in the risk of hepatocellular carcinoma, indicating the critical role 
of HCV in the carcinogenesis of hepatocellular carcinoma525.  
Besides the direct role of HCV in inducing hepatocellular carcinoma, several indirect 
factors contribute to the initiation and progression of hepatocellular carcinoma. 
Chronic inflammation induced by HCV infection accelerates liver fibrosis and 
increases the risk for hepatocellular carcinoma via turning hepatocytic TGF-β 
signaling from tumor-suppression to fibrogenesis526. Elevated levels of reactive 
oxygen species (ROS) also contributes to HCV-associated pathogenesis527.  
Like HBV, HCV is also involved in conferring the stemness properties of liver cancer 
cells. Ali et al. reported that chronic HCV infection predisposes liver cancer cells 
toward requiring cancer stem cell traits by inducing DCAMKL-1528. Kwon and 
colleagues have shown that HCV infection potentiates the generation of liver cancer 
stem cells by upregulation of c-Kit expression529. HCV infection can increase the 
population of liver cancer stem cells530 and enhances chemoresistance of hepatocellular 
carcinoma via HIFs and by promoting cancer stem cell properties531, 532.  
1.4.6.3 Aflatoxin B1, alcohol and high fat diet 
Besides HBV and HCV, several other factors also play roles in inducing the stemness 
properties of hepatocellular carcinoma. The fungal toxin aflatoxin B1 (AFB1) is one 
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of the most prevalent causative agents of hepatocellular carcinoma. Ju et al. have 
demonstrated that AFB1 mediates mutation and induces the conversion of liver cancer 
cell to liver cancer stem cells533. Alcohol intake is a risk factor for hepatocellular 
carcinoma. Machida et al. demonstrated that alcohol enhances HCV-induced liver 
cancer through Toll-like receptor 4 (TLR4)-dependent mechanism which involves 
stem cell marker Nanog534. Uthaya et al. investigated the role of diet high in cholesterol 
and saturated fat (HCFD) in the development of liver cancer stem cells. The results 
showed that HCFD and HCV-NS5A together stimulate TLR-Nanog signaling pathway, 
resulting in liver carcinogenesis with high expression of Twist1 in liver cancer stem 
cells535. 
1.5 Clinical trials of ABC transporter inhibitors 
1.5.1 MDR1 inhibitors 
1.5.1.1 First generation MDR1 inhibitors 
A series of first generation MDR1 inhibitors were identified in the 1980s, among which 
verapamil, Cyclosporine A (CsA) were the best studied.  
Verapamil is a calcium channel blocker and used in clinics to treat hypertension, angina 
and  supraventricular tachycardia. It was found that verapamil can enhance 
intracellular accumulation of many anti-cancer agents in various cancer cell lines536. 
Verapamil entered phase I clinical trials in 1985 to sensitize the effect of vinblastine 
chemotherapy537. However, verapamil exhibited cardiotoxicity and neurotoxicity due 
to its ability to block the calcium channel. Cairo et al. optimized the dose of verapamil 
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to treat drug-resistant pediatric tumors in combination with vinblastine and 
etoposide538. The level of verapamil achieved in this study can augment the in vitro 
cytotoxicity of vinblastine and etoposide to resistant cancer cell lines. However, 
verapamil exhibited a narrow therapeutic window, indicating a need for a more specific 
ABCB1 inhibitor. 
Cyclosporine A (CsA) is an immunosuppressant used to treat graft-versus-host 
disease in bone-marrow transplantation and to prevent rejection of transplantation of 
kidney, heart, and liver. Researchers found that CsA can sensitize human acute 
lymphatic leukemia to anti-cancer drugs and solid tumors to doxorubicin treatment539. 
CsA binds to the same site of MDR1 drug efflux pump to vinblastine indicating CsA 
as a competitive MDR1 inhibitor540. Chan et al. used CsA in combination with 
chemotherapy to treat patients with retinoblastoma and achieved high cure rate, which 
raises the interest of using CsA to drug-resistant cancers541. However, in the following 
phase I clinical trials, CsA reduced the clearance of etoposide and mitoxantrone by 71% 
and 42%, respectively, resulting in significantly increased systemic drug exposure 
which is difficult to manage542, 543.  
The overall conclusion of the first-generation ABCB1 inhibitors is that their clinical 
potency is too low accompanied by considerable cardiotoxicity and pharmacokinetic 
interaction with chemotherapeutic drugs. 
1.5.1.2 Second-generation ABCB1 inhibitors 
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The failure of clinical trials of verapamil and CsA led to the development of the second-
generation ABCB1 inhibitors which exploited verapamil and CsA as lead compounds 
in drug design. 
The clinical preparation of verapamil is a racemic mix of L- and D-forms. The D-
isomer of verapamil, dexverapamil, has a 10-fold lower calcium channel blocker 
activity than its L-isomer counterparts while maintains equal ABCB1 inhibitor activity 
compared with the racemic544-546. In a phase I study, dexverapamil increased the 
steady-state concentration of doxorubicin nearly 2-fold, and increased hematopoietic 
toxicity of chemotherapy, but the toxicity was mid and tolerable547. In a cross-over 
clinical trial in 1995, dexverapamil was used in combination with chemotherapy for 
the treatment of lymphoma548. The results showed that dexverapamil only has modest 
effect to sensitize patients to chemotherapy, which might be explained by two reasons. 
First, the level of dexverapamil may be insufficient to inhibit the MDR1 drug pump. 
Second, non- MDR1 mechanisms may exist to play a role in the drug resistance. In two 
Phase II clinical trials against metastatic breast cancer, dexverapamil exhibited 
tolerable toxicity. However, the addition of dexverapamil to chemotherapeutic agents 
such as epirubicin or anthracycline cannot increase tumor response549, 550. Therefore, 
this approach was not pursued any more. 
Valspodar (PSC833) is a non-immunosuppressant cyclosporine derivative, which is 
10- to 20-fold more potent than CsA in reversing drug resistance in cancer cell lines551, 
552 and effective in sensitizing solid tumor using animal models553. It was reported that 
valspodar not only inhibits ABCB1, but transcriptionally downregulates ABCB1 
  
 
56 
 
expression as well554. Unfortunately, phase I clinical trials showed that valspodar 
significantly reduced metabolism and elimination of chemotherapeutic drugs, 
including mitoxantrone, etoposide, vinblastine, doxorubicin, paclitaxel, leading to 
increased systemic exposure of cytotoxic agents to patients555-558. In a phase II study, 
the addition of valspodar failed to improve outcomes for patients with acute myeloid 
leukemia559. In phase II trials against breast or ovarian cancer, combined valspodar and 
paclitaxel cannot show benefit compared with single paclitaxel560, 561. In a phase III 
study, it was shown that the addition of valspodar to paclitaxel and carboplatin cannot 
improve disease progression or overall survival, but was more toxic562. These studies 
indicated that valspodar cannot provide clinical benefit but may potentially increase 
treatment toxicity by increasing exposure of chemotherapeutic agents.  
1.5.1.3 Third-generation MDR1 inhibitors 
The third-generation MDR1 inhibitors used more rational design based on the data 
from the first- and second-generations. A series of criteria were identified as critical 
features for the novel MDR1 inhibitors: 1) highly effective at nanomolar concentration 
range to inhibit MDR1; 2) high selectivity for MDR1; 3) do not affect the 
pharmacokinetics of anti-cancer drugs. Several third-generation MDR1 inhibitors are 
in clinical trials including elacridar (GF120918), zosuquidar (LY335979), tariquidar 
(XR9576) and CBT-1. 
Elacridar was the first of the third-generation compounds developed by Glaxo using 
combinatorial chemistry563. Elacridar showed MDR1 inhibition activity at ~20 nM in 
MDR1 expressing cancer cells563. Using animal models, single i.v. dose of elacridar 
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restored the antiproliferative action of doxorubicin563. Unlike other MDR1-specific 
inhibitor, elacridar can reverse mitoxantrone resistance in cells overexpressing MDR1. 
A series of phase I clinical trials have been carried out to investigate the safety and 
pharmacokinetics of elacridar in healthy volunteers and cancer patients. When used in 
combination with doxorubicin, elacridar achieved plasma concentrations that can 
reserve drug resistance in experimental models and it did not, or only marginally 
change the pharmacokinetics of doxorubicin in cancer patients564, 565. In another study, 
elacridar significantly increased systemic exposure of paclitaxel in cancer patients566. 
Co-administration of elacridar and topotecan significantly increased the oral 
bioavailability of topotecan from 40% to 97.1%, resulting in complete apparent oral 
bioavailability of topotecan, indicating elacridar is suitable for phase II clinical trials567, 
568. Recently, elacridar was reported as a positron emission tomography (PET) tracer 
for MDR1 and ABCG2 transporters569, 570. 
Zosuquidar is one of the most potent MDR1 inhibitor with a Ki of 59 nM571. Unlike 
elacridar, zosuquidar is a highly specific MDR1 inhibitor, which lacks the ability to 
interact with either ABCG2 or ABCC1572. Using animal models, zosuquidar 
significantly reduced tumor mass and enhanced survival rate of tumor-bearing mice571. 
Importantly, zosuquidar showed a low affinity for CYP3A compared with that of 
ABCB1, indicating it cannot interfere with the metabolism of chemotherapeutic 
agents573. In phase I clinical trials, zosuquidar can be well tolerated and showed little 
to moderate effect on doxorubicin toxicity and pharmacokinetics574, 575. Another phase 
I study showed that zosuquidar may moderately inhibit vinorelbine clearance in 
patients with advanced solid tumors576. When combined with daunorubicin and 
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cytarabine to treat acute myeloid leukemia, a 75% response rate was observed, 
suggesting zosuquidar as a promising drug for phase II clinical trials577. In a phase I/II 
trial against non-Hodgkin’s lymphoma, zosuquidar did not change the 
pharmacokinetics of doxorubicin and had moderate effect on the pharmacokinetics of 
vincristine578. However, a phase II trial showed that zosuquidar cannot provide clinical 
benefit when combined with docetaxel to treat breast cancer579. In another study, 
zosuquidar does not improve the clinical outcome of patients with acute myeloid 
leukemia580. 
Tariquidar was developed by Xenova PLC (Slough, UK), which can reverse resistance 
to doxorubicin, etoposide, paclitaxel and vincristine at a concentration of 25-80 nM in 
drug resistance cancer cell lines581. The most critical feature of tariquidar is that its 
pharmacological effects can last for 22 h after its removal from the system, which is 
significantly longer than that of the first-generation inhibitors such as verapamil and 
CsA, whose effect last for around 1 h544. Tariquidar is a substrate for ABCB1 protein 
which plays its role via allosteric reduction in the binding affinity of vinblastine and 
paclitaxel on ABCB1 protein582, 583. Since hepatic CYP3A4 isoform plays a critical 
role in the pharmacokinetics of ABCB1 inhibitors and the anti-cancer agents, tariquidar 
is not involved in metabolism via CYP3A4, indicating that it lacks the ability to affect 
the clearance of anti-cancer drugs584, 585. The first phase I trial has shown that tariquidar 
has no effect on the pharmacokinetics of vinorelbine and is well tolerated586. The 
following phase I/II trials showed that tariquidar cannot change the pharmacokinetics 
of paclitaxel, docetaxel or doxorubicin587-589. A positive correlation for volume of 
distribution at steady state with tariquidar was observed in a phase I trial, indicating 
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transporter saturation at high tariquidar doses590. In a recent clinical trial, tariquidar 
decreased the clearance of docetaxel and vinorelbine, indicating the pharmacokinetic 
interaction between tariquidar and anti-cancer agents is complex591. A phase II study 
showed that tariquidar has limited clinical activity to restore the anti-cancer capacity 
of doxorubicin or taxane against chemoresistant breast cancer587. Furthermore, 
subsequent clinical trials (NCT00042302, NCT00042315) were terminated due to 
toxicities associated with combined tariquidar and chemotherapy592.  
CBT-1 is an oral-administered MDR1 inhibitor. In vitro studies showed that it was 10-
fold more potent in inhibiting MDR1 than ABCC1 while it cannot inhibit ABCG2 at a 
concentration as high as 25 µM593. Phase I studies have shown that CBT-1 has no effect 
on the pharmacokinetics of doxorubicin or paclitaxcel594, 595. Recent pharmacodynamic 
study has revealed that CBT-1 has minimal toxicity when combined with paclitaxel in 
cancer patients596. In 2017, a clinical study was carried out to assess the anti-tumor 
efficacy of combined CBT-1 and doxorubicin in patients with metastatic sarcomas 
(NCT03002805). It would be interesting to see how effective CBT-1 is to sensitize 
doxorubicin because the other ABCB1 inhibitors failed to prove clinical benefit to 
cancer patients.  
1.5.2 ABCG2 inhibitors 
The expression of ABCG2 protein defines the side population (SP)597, which is 
considered to represent the cancer stem cell population in a number of cancer types115, 
201, 205, 598-602.  
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The strategy of inhibiting ABCG2 drug efflux pump showed promise using in vitro 
resistant cancer cell model. The first selective ABCG2 inhibitor fumitremorgin C was 
able to reverse the chemoresistance of cancer cells to anti-cancer drugs202, 603-605. 
However, fumitremorgin C was shown to be clinically useless due to its severe 
neurotoxicity606. The compound ko143 is a nontoxic analog of fumitremorgin C, which 
can reverse resistance of several ABCG2 overexpressed cancer cell lines in vitro607, 608. 
However, the poor oral bioavailability of ko143 prevents its in vivo applications, 
making it still under pre-clinical studies609. The ABCB1 inhibitor tariquidar and 
elacridar can also inhibit ABCG2, however, as we mentioned above, their clinical trials 
failed to prove efficacy against several types of cancer.  
Interestingly, tyrosine kinase inhibitors, including sunitinib, nilotinib, sorafenib, and 
imatinib, have shown their efficacy as ABCG2 modulator610, 611. Studies have shown 
that tyrosine kinase inhibitors and ABCG2 inhibitors share a common binding site thus 
tyrosine kinase inhibitors act as competitive inhibitors of ABCG2612, 613. Mazard et al. 
have demonstrated that sorafenib can enhance the intracellular concentration of SN-38, 
an irinotecan active metabolite614. Combined sorafenib and irinotecan improved the 
survival rate of irinotecan-resistant tumor bearing mice614. A phase I/II clinical trial 
has shown promising results in patients who have received the combination treatment 
of sorafenib and irinotecan after they had failed irinotecan-containing therapy615. 
However, in a phase II clinical trial, the combination treatment of the tyrosine kinase 
inhibitor lapatinib and topotecan failed to demonstrate a clinical benefit compared to 
topotecan alone in recurrent ovarian cancer616. In addition, a phase III study has 
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indicated that sunitinib plus chemotherapy is not superior that chemotherapy alone, 
and is more toxic to patients617.  
Trans-arterial chemoembolisation (TACE) with doxorubicin is used for unresectable 
hepatocellular carcinoma or a temporary treatment while patients are waiting for liver 
transplant. It is a standard treatment for intermediate stage hepatocellular carcinoma. 
For advanced hepatocellular carcinoma, sorafenib is the only drug which can increase 
survival rate of hepatocellular carcinoma patients. Since both ABCG2 and ABCB1 are 
involved in the chemoresistance of doxorubicin, and their activity can be inhibited by 
sorafenib618, it would be interesting to see the efficacy of combination treatment of 
doxorubicin and sorafenib in hepatocellular carcinoma patients. Abou-Alfa et al. have 
demonstrated that in patients with advanced hepatocellular carcinoma, combined 
sorafenib and doxorubicin is superior than doxorubicin monotherapy in terms of 
overall survival and median time to progression619. A recent clinical trial demonstrated 
that in patients with advanced hepatocellular carcinoma, the addition of doxorubicin to 
sorafenib resulted in increased toxicity and cannot improve overall survival or 
progression-free survival, suggesting the end for the use of chemotherapy in the 
treatment of advanced hepatocellular carcinoma620.  
1.5.3 ABCC1 inhibitors 
ABCC1 (MRP1) is involved in the chemoresistance hepatocellular carcinoma to 
doxorubicin621. The expression of ABCC1 is correlated with tumor differentiation and 
mean survival time of patients and indicates the hepatic progenitor cell origin of 
hepatocellular carcinoma622.  
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A number of compounds have been reported to inhibit ABCC1, including 
sulfinpyrazone, biricodar, probenecid, MK571, LTC4, raloxifene-based inhibitors 
(LY117018, LY329146 and indomethacin), and ABCB1 inhibitors (CsA, verapamil, 
valspodar and CBT-1)623.  
A phase I clinical trial has shown that, in combination with doxorubicin, the ABCB1 
and ABCC1 inhibitor biricodar is tolerable in cancer patients, and plasma 
concentrations of biricodar is two to four-fold higher than that required to reverse drug 
resistance in in vitro624. A safety and efficacy clinical study has shown that biricodar 
can re-sensitize breast cancer patients to paclitaxel which supports further evaluation 
of this compound625. A phase II study has revealed that biricodar with paclitaxel has 
modest activity in patients with paclitaxel-resistant ovarian cancer626. Another phase II 
clinical trial evaluated the efficacy of the combination treatment of biricodar and 
doxorubicin and vincristine in patients with recurrent small cell lung cancer627. 
However, biricodar failed to enhance anti-cancer activity or survival627.  
To summarize, it appears to be disappointing when one took a glance at the slow 
progress scientists have made over the last 20 years in finding clinically effective drugs 
that can reverse multidrug resistance. The clinical trials failed to show desired efficacy 
of multidrug resistance inhibitors, due to the issues with their innate toxicity, 
pharmacokinetic interaction with anti-cancer drugs leading to systemic over-exposure 
of these anti-cancer agents in patients. Although we expect a compound that can target 
a specific ABC transporter but does not interact with others, the experience from pre-
clinical and clinical studies indicated that it may be to sufficient by just inhibiting one 
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drug efflux pump because in most cases the chemotherapeutic agents are the substrate 
of a number of ABC transporters, therefore, it would be usual to give more than one 
multidrug resistance inhibitors to reverse clinical multidrug resistance536. In addition, 
it has been revealed that the ABC transporters are more than just drug efflux pumps 
but play a role in cancer development which makes the development of multidrug 
resistance inhibitors more complicated628. We have been aware of the existing and 
future potential problems and how to solve these problems, which leads us to develop 
better multidrug resistance inhibitors.  
1.6 Clinical trials of autophagy inhibitor hydroxychloroquine 
Significant progress has been observed in the development of potential autophagy 
inhibitors. Table 2 summarizes the targets of various autophagy inhibitors629-632. 
However, most of them lack specificity, limiting their clinical application except 
hydroxychloroquine (HCQ), the analog of chloroquine (CQ), which has shown its 
capacity to sensitize resistant cancer cells to chemotherapy in clinical trials629, 633, 634.  
Table 1.2. Overview of autophagy inhibitors. 
Target Inhibitor 
Class I and III 
PI3K 
3-Methyladenine (3-
MA) 
Wortmannin 
LY294002 
VPS34 
SAR405 
VPS34-In1 
PIK-III 
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Table 1.2. (Continued) 
Target Inhibitor 
ULK1 complex 
MRT68921 
MRT67307 
SBI-0206965 
Lysosome 
Chloroquine (CQ) 
Hydroxychloroquine 
(HCQ) 
Lys05 
Clomipramine 
Lucanthone 
ARN5187 
Oblongifolin C 
V-ATPase Bafilomycfin A1 
 
HCQ was not initially designed as an autophagy inhibitor but serve as antimalarial 
agent in the past 60 years635. Other uses include inflammatory-related diseases 
including rheumatoid arthritis636 and lupus erythematosus637, and porphyria cutanea 
tarda638. Figure 4 showed the major events in the development of HCQ as an anti-
cancer agent (Modified from Solitro et al.633).  
 
Figure 1.4. Key historical events of HCQ. 
Cinchona bark is 
transported from 
Peru to Europe
Quinine is 
extracted from 
cinhona bark
CQ is used to 
treat malaria
HCQ is developed 
with less toxicity 
than CQ
HCQ is approved 
to treat malaria
CQ reveals 
anti-caner 
properties
CQ shows autophagy 
inhibition property in 
vitro
HCQ shows anti-
cancer properties
Results of first 
HCQ clinical trial 
against cancer 
published 
Start of Phase III trial to 
evaluate the anti-cancer 
effect of HCQ
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HCQ and CQ mainly function by inhibiting lysosomal acidification. They diffuse 
across the plasma membrane freely at neutral pH. In the acidic environment, CQ and 
HCQ get protonated and trapped in lysosomes which leads to an increase of lysosomal 
pH resulting in deactivation of lysosomal enzymes639, 640. Therefore, cells that are 
treated with HCQ or CQ are unable to be digested in lysosomes, thus blocking 
autophagy in the final stages633. HCQ was synthesized in 1959 to reduce the retinal 
toxicity of CQ due to the addition of a single hydroxyl group to the structure of CQ 
which limits the ability of the compound to cross the blood-brain barrier causing retinal 
toxicity641. Preclinical studies have indicated that HCQ is 2 to 3 times less toxic than 
CQ642. 
Activation of autophagy has shown to play a role in the chemoresistance of cancer cells, 
therefore the autophagy inhibitor HCQ or CQ is expected to sensitize cancer cells to 
chemotherapy. Belounis et al. have shown that autophagy is associated with 
chemoresistance in neuroblastoma, and the combination treatment of HCQ and 
vincristine significantly decreased tumor progression in mice643. In another study, 
inhibition of autophagy by HCQ can sensitive ovarian clear cell carcinoma cells to 
platinum therapy644. Besides its role as a sensitizer in cancer treatment, HCQ has 
shown the capacity to induce apoptotic cell death by its own through regulation of 
autophagy in various cancer types, such as cytosine arabinoside-resistant human 
myeloid leukemia645, chronic lymphocytic leukemia646 and bladder cancer647.  
Both autophagy and cancer stem cells play critical roles in the resistance of anti-cancer 
therapy. Researchers demonstrated that CQ increased the susceptibility of pancreatic 
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cancer stem cells to gemcitabine648. Similarly, CQ can sensitize triple negative breast 
cancer cells to paclitaxel treatment and reduce the cancer stem cells population649. Ojha 
et al. have shown that gemcitabine and mitomycin increased the proportion of cancer 
stem cells in urothelial carcinoma and CQ decreased the proportion of cancer stem 
cells and glycolytic gene expression650. Song et al. reported that autophagy is essential 
for the survival of liver cancer stem cells while CQ could impair their in vivo tumor-
forming ability449. 
Until the end of May 2017, the ClinicalTrials website has reported 52 trials of HCQ in 
the treatment of cancer, which most of them are at phase I or II level, and 9 clinical 
trials have been completed (Table 3). Results from the clinical trials showed that HCQ 
is tolerable in cancer patients up to 1200 mg daily, and its maximum tolerated dose 
varies in patients with different cancer types and combination strategies. The LC3-II 
levels in peripheral lymphocytes can be used as a potential marker of autophagy 
inhibition. Further evidence is needed to demonstrate the efficacy of HCQ in the 
treatment of cancer either by itself or in combination with chemotherapy. 
Table 1.3. HCQ in clinical trials. 
Cancer type 
Phase 
for trial 
Treatment 
regimen 
Major findings 
Year of 
start 
Trial ID 
Advanced 
Non–Small-
Cell Lung 
Cancer 
I 
Erlotinib 
and HCQ 
•HCQ with or without 
erlotinib was well tolerated. 
The recommended phase II 
dose of HCQ was 1000 mg. 
2009 
NCT01026844
651 
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Table. 1.3. (Continued) 
Cancer type 
Phase 
for trial 
Treatment 
regimen 
Major findings 
Year of 
start 
Trial ID 
Glioblastom
a 
I/II 
HCQ, 
temozola
mide and 
radiation 
•HCQ is tolerable at 600 
mg/day. 
•No significant 
improvement in overall 
survival was observed. 
•LC3-II was and correlated 
with higher HCQ exposure. 
2007 
NCT00486603
652 
Advanced 
solid tumors 
I 
HCQ and 
vorinostat 
A dose of 600 mg of HCQ 
was recommended for phase 
II trial. 
2009 
NCT01023737
653 
Relapsed/re
fractory 
myeloma 
I 
HCQ and 
bortezomi
b 
•A dose of 600 mg twice 
daily of HCQ was 
recommended for phase II 
trial. 
•45% of patients had a 
period of stable disease. 
•Accumulation of 
autophagic vesicles was 
observed in bone 
marrow cells. 
2011 
NCT01323751
654 
Advanced 
solid tumors 
and 
melanoma 
I 
HCQ and 
temsirolim
us 
•The recommended phase II 
dose was HCQ 600 mg 
twice daily. 
•74% of patients with 
melanoma achieved stable 
disease. 
•Temsirolimus and HCQ 
has significant antitumor 
activity. 
 
2009 
NCT00909831
655 
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   Table. 1.3. (Continued)   
Cancer type 
Phase 
for trial 
Treatment 
regimen 
Major findings 
Year of 
start 
Trial ID 
Relapsed or 
refractory 
multiple 
myeloma 
I 
HCQ, 
Rapamyci
n, 
cyclophos
phamide 
and 
dexametha
sone 
•HCQ is safe and tolerable 
at 800 mg. 
•Clinical benefit rate of 61% 
•Therapy-associated 
modulation of autophagic 
vesicles was apparent in 
bone marrow plasma cells. 
•The response rates suggest 
the possibility of synergistic 
activity of this combination. 
2011 
NCT01396200 
and 
NCT01689987
656 
Advanced 
solid tumors 
and 
melanoma 
I 
HCQ and 
temozolo
mide 
•Recommended phase II 
dose was HCQ 600 mg 
twice daily. 
•Melanoma patients 
responded better than those 
with other malignancies. 
•a significant accumulation 
in autophagic vacuoles in 
peripheral blood 
mononuclear cells was 
observed in response to 
combined therapy. 
2008 
NCT00714181
657 
Metastatic 
Pancreatic 
Adenocarci
noma 
II HCQ 
•LC3-II levels in peripheral 
lymphocytes as a potential 
marker of autophagy 
inhibition. 
•HCQ monotherapy 
achieved inconsistent 
autophagy inhibition and 
demonstrated negligible 
therapeutic efficacy. 
2011 
NCT01273805
658 
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Table. 1.3. (Continued) 
Cancer type 
Phase 
for trial 
Treatment 
regimen 
Major findings 
Year of 
start 
Trial ID 
Pancreatic 
Adenocarci
noma 
I/II 
HCQ and 
Gemcitabi
ne 
•HCQ was safe and 
tolerable up to 1200 mg 
daily. 
•61 % of patients had a 
decrease in cancer marker 
CA 19-9 after treatment. 
•Patients who had a CA 19-
9 response to treatment had 
an improvement in disease 
free survival and overall 
survival. 
2010 
NCT01128296
659 
 
1.7 Aptamers and their applications in targeted cancer therapy 
Active specific targeting of drugs is a potentially powerful technology with widespread 
applications in the treatment of cancers. Aptamers have become attractive molecules 
for diagnostic and therapeutic purposes. Nucleic acid aptamers are short, single-
stranded DNA or RNA oligonucleotides that fold into three-dimensional structures 
which mediate specific target binding mainly by structural compatibility, and from a 
combination of van der Waals forces, shape complimentary, base stacking, and 
hydrogen bonding660. To date, thousands of aptamers have been developed against a 
wide range of targets, including proteins, whole cells, small metal ion and organic 
molecules, peptides, viruses and bacteria661. In general, RNA aptamers have more 
diverse three-dimensional conformations than DNA aptamer, which may increase the 
binding specificity and affinity. DNA aptamers are inherently more stable than RNA 
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aptamers, thus less chemical modifications are needed making their manufacturing cost 
lower662. 
1.7.1 Aptamer versus antibody 
1.7.1.1 Advantages of oligonucleotide aptamers 
In contrast to other nucleic acid probes, aptamers bind to their targets via structural 
recognition which is similar to that of an antigen-antibody reaction. Therefore, 
aptamers are also referred to as chemical antibodies. However, due to their small size 
and oligonucleotide nature, aptamers are superior to antibodies in several aspects663, 
664. 1) Aptamers can penetrate tissues and reach their target sites faster and more 
efficiently than protein antibodies due to their lower molecular weight (8-25 kDa of 
aptamers versus ~150 kDa of antibodies). 2) Aptamers are screened in vitro and 
amplification through polymerase chain reaction (PCR). Therefore, there are smaller 
batch-to-batch variations and the production cost is cheaper than antibodies which 
require animals for selection. 3) The simpler structures of aptamers are easily 
amendable to further modifications. 4) Aptamers are thermal stable based on the 
intrinsic property of oligonucleotides. Just before use, they can re-refold into their 
correct three-dimensional structure once cooled in room temperature after a 95oC 
denaturation. In contrast, protein antibodies may lose their activity permanently after 
extensive expose to room temperature. 5) Aptamers have low immunogenicity while 
antibodies can lead to an anti-antibody response. 6) Aptamers can specifically 
recognize a variety of target molecules that one cannot generate antibodies against as 
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they are not immunogenic in the process of antibody production. Of all the advantages, 
the in vitro selection could be highlighted as the most critical strength of aptamers663. 
1.7.1.2 Limitations of oligonucleotide aptamers 
There are still some barriers for the clinical application of aptamers. Due to its nucleic 
acid nature with a low molecular weight, aptamer can be degraded in serum by nuclease 
and clear rapidly in the circulation. Therefore, further chemical modifications are 
needed to increase its serum stability and circulation time. For example, RNA aptamer 
bases can be modified at the 2’-OH group, with a substitution of methoxy, fluoro, thio 
or amino groups665. Another strategy is to introduce the locked nucleic acid 
modifications after the selection procedure, which has improved the in vivo stability of 
aptamers666. Conjugation of aptamers with polyethylene glycol (PEG) is commonly 
used to prolong the lifetime of aptamers in vivo667. In contrast to the general assumption 
that PEGylation substances lack immunogenicity, recently it has been revealed that the 
PEG-coating can trigger immune activation after repeated administration of PEG-
conjugated substances resulting in pharmacokinetic alteration - the so-called 
accelerated blood clearance phenomenon668.  
1.7.2 Generation of aptamers - the SELEX technology 
The methodology of in vitro selection of oligonucleotides was almost simultaneously 
published by two independent groups in 1990 and the term aptamer was coined by 
Ellington and Szostak while the selection process called SELEX (systematic evolution 
of ligands by exponential enrichment) was first published by Tuerk and Gold in 1990669, 
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670. Since its invention, SELEX has been the gold standard methodology for the 
generation of nucleic acid aptamers.  
A DNA library from combinatorial chemical synthesis is the starting material for 
SELEX. This library usually consists of 1015-1016 random regions of 20-60 nucleotides 
flanked by constant 5' and 3' ends that serve as anchors for PCR primers. The length 
of the random region determines the complexity and molecular diversity of the library. 
In addition, all known single-stranded oligonucleotide motifs can be built within this 
length671. 
Figure 5 shows a schematic diagram depicting the principles of SELEX process. The 
sequences in the DNA library are exposed to target ligand including proteins, viruses, 
drugs, cells etc. The random nucleotide pools and the targets are incubated together 
and aptamers that do not bind to the target are removed by separation methods such as 
affinity chromatography or capillary electrophoresis672, 673. The bound DNA or RNA 
sequences are eluted from their target and amplified by PCR and reverse transcription 
PCR (RT-PCR) respectively to obtain an enriched pool for the next round of SELEX. 
The progress of sequence enrichment can be monitored by binding assays. Usually, 5-
12 cycles are needed and then the selection process is stopped. Sequences in the 
enriched pool are cloned and characterized. The sequence with the highest binding 
affinity to the target is chosen. 
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Figure 1.5. Aptamer screening process. This figure is adapted from Zhou and 
Rossi661. 
 
Since its invention in 1990, SELEX has undergone great changes and improvements 
in the last 27 years. Compared with the conventional way of selection a new aptamer 
which took several weeks, nowadays it only requires hours for the completion of the 
SELEX experiment with the assistance of in silico computational docking which 
enables the prediction of aptamer structures and binding affinity before the experiment 
was performed674. In addition, post-SELEX optimization approaches, which have been 
developed recently, increases the stability of aptamers providing a way to overcome 
the limitation of applying aptamers into clinical use675.  
1.7.2.1 Protein-based SELEX 
The conventional in vitro SELEX requires purified target proteins. One of the most 
critical steps in aptamer selection is selection partitioning, in which target-bound 
sequences are separated from the unbound ones. Besides the traditional approaches, 
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such as nitrocellulose membrane, resin chromatography, magnetic bead and chip-based 
segmentation, novel isolation strategies have been developed to accelerate the 
separation procedure, including capillary gel electrophoresis676, flow cytometry677, and 
microfluidic system678. So far, most of the cell-specific aptamers have been developed 
via protein-SELEX, such as the anti-EpCAM aptamers679, anti-epidermal growth 
factor receptor (EGFR) aptamers680, anti- transferrin receptor (TfR) aptamers681, and 
anti-CD44 aptamers682. Despite these successes, the purified protein-SELEX is not 
applicable for insoluble protein, unknown proteins, or proteins that only functionalizes 
in the native conformation or multi-protein complex661. 
1.7.2.2 Cell SELEX 
As mentioned above, protein-based SELEX needs identification and purification of the 
target proteins. However, only a few target proteins have been identified, and the 
identified proteins can be very expensive or not commercially available. Instead of 
using purified proteins, cell SELEX uses live cells to select aptamers for target 
recognition which does not need the prior knowledge of the target. In addition, cell 
SELEX strategy provides a way to select aptamers against a target in its native 
conformation. In principle, the aptamers in pool recognize the differences between the 
target cell population and a control cell population. After several rounds of selection, 
the aptamers against the target cell population are enriched. A target protein can be 
over-expressed using plasmid vector in negative cells, thereby producing positive cells 
for selection. In contrast, the CRISPR-Cas9 technology can be used to knock out the 
target gene in the positive cells, which produces negative cells for counter-selection. 
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Furthermore, cell SELEX provides the opportunity for biomarkers discovery683. The 
aptamers obtained from cell SELEX can be used to purify their targets through affinity 
separation. 
1.7.2.3 in vivo SELEX 
Researchers have indicated that therapeutic aptamers selected in vitro may not 
necessarily function in vivo684, 685. The aim of in vivo SELEX is to generate aptamers 
directly using animal disease models. In brief, the RNA or DNA aptamer library is 
injected intravenously into animals. The tissue or organ of interest is harvested, and 
the bound sequences are extracted and amplified for the next round of selection. Mi et 
al. have identified an nuclease-resistant RNA aptamer that binds to p68 and localizes 
to hepatic colon cancer metastases686. Cheng et al. identified aptamers that penetrate 
the parenchyma and bind to brain capillary endothelia687. Using subcutaneous 
pancreatic cancer xenograft model, Barbas el al. have enriched aptamers that binds to 
pancreatic tumor688. Recently, Mi and colleagues selected an RNA aptamer against 
human colorectal cancer xenografts that binds to RNA helicase protein DHX9 which 
is known to be up-regulated in colon cancer689.  
1.7.3 Aptamer-based cancer therapeutics 
In general, aptamer-based therapeutics utilize one of the two strategies: 1) Aptamers 
serve as antagonist or agonist to block or activate the target. 2) Aptamers can serve as 
vehicle to deliver therapeutic agents such as drugs690, small interfering RNA 
(siRNA)691, microRNA692, CRISPR system693 to target cells or organs. 
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1.7.3.1 Aptamers as therapeutic agents for cancer therapy 
Several aptamers have been developed as therapeutic agents against cancer, macular 
degeneration, coagulation and inflammation661, 694. The DNA aptamer (AS1411) and 
the RNA aptamer (NOX-A12) have undergone clinical trials for cancer therapy. 
AS1411 is a 26-nucleotide guanine-rich DNA aptamer with G-quadruplex structure. It 
was identified by antiproliferation selection but not the classic SELEX695. AS1411 is 
the first aptamer which has undergone clinical trials for cancer treatment. After being 
taken into tumor cells, AS1411 binds to the external domain of nucleolin, a Bcl-2-
mRNA-binding protein over-expressed on the surface of tumor cells which is 
responsible for cell survival, growth and proliferation, leading to cell apoptosis695, 696. 
In in vitro studies, AS1411 is capable of inhibiting over 80 types of cancer cells. 
Preclinical studies have demonstrated its inhibition efficacy in cancer xenograft models 
including kidney cancer, breast cancer and non-small cell lung cancer694. It was well 
tolerated in a phase I clinical trial in patients with advanced solid tumors 
(NCT00881244). In a phase II trial in patients with metastatic renal cell carcinoma, 
AS1411 showed dramatic effect, 84% reduction in tumor burden, in patient with 
missense mutations in mTOR and fibroblast growth factor receptor 2 (FGFR2) genes697. 
A phase II efficacy study has demonstrated its efficacy to acute myeloid leukemia 
(NCT00512083). However, a following phase II trial for renal cell carcinoma showed 
that AS1441 has therapeutic effect in only 2.9% of patients (NCT00740441). Only one 
patient with FGFR2 and mTOR mutations have good response, indicating the need for 
reliable biomarkers to predict the efficacy of AS1411 therapy.  
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NOX-A12 is a 45-nucleotide L-RNA aptamer, also known as spiegelmer, targeting 
chemokine C-X-C motif ligand 12 (CXCL-12)698. Its binding to CXCL-12 can 
decrease tumor proliferation, metastasis, angiogenesis and drug resistance699. As 
spiegelmers have mirror-image configuration, which confers plasma stability and 
immunological passivity, it does not require chemical modifications for in vivo 
studies699. In preclinical studies, NOX-A12 exhibited therapeutic efficacy against 
chronic lymphocytic leukemia700, 701 and myeloma702. In phase I studies NOX-A12 can 
be well tolerated in healthy individuals (NCT00976378 and NCT001194934). 
Currently, two phase II trials are in progress to evaluate the therapeutic efficacy of 
NXO-A12 in patients with relapsed chronic lymphocytic leukemia (NCT01486797) or 
relapsed multiple myeloma (NCT01521533). 
Pegaptanib was originally developed for cancer treatment but it failed to meet 
expectation in cancer therapy in preclinical studies661. In 2004 pegaptanib was 
approved by US FDA for the treatment of age-related macular degeneration (AMD). 
Pegaptanib is a 27-nucleotide RNA aptamer with a 40kDa PEG molecule at the 5’-end. 
It binds to VEGF165, one of the major VEGF isoforms responsible for pathological 
ocular neovascularization and vascular permeability703. However, pegaptanib failed to 
compete with anti-VEGF monoclonal antibody ranibizumab (Genetech, California, US) 
since the introduction of ranibizumab in UK in 2007 because the antibody blocks all 
isoforms of VEGF rather than the VEGF165 isoform only
704. Following studies have 
shown that blocking all VEGF isoforms may increase the risk of hypertension705. Thus, 
pegaptanib may be better than ranibizumab for long term maintenance treatment. There 
are several nucleic aptamers currently in the clinic as shown in Table 4. 
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Table 1.4. Therapeutic nucleic acid aptamers in on-going or completed clinical trials 
 
 
1.7.3.1.1 Aptamers for targeted delivery 
Aptamer-drug delivery systems consist of therapeutic agents and aptamers. With their 
small size, aptamers show promise in targeting tumor cells and delivering small 
Drug name Condition Target Current status 
Pegaptanib 
Macular 
degeneration 
VEGF165 
Approved in 2014 in the United 
States and the European Union 
ARC1905 
Macular 
degeneration 
 
complement factor 
C5 
Phase II/III, recruiting 
(NCT02686658) 
E10030 
Macular 
degeneration 
PDGF 
phase III, recruiting 
(NCT01940887, NCT01944839) 
REG1 Coagulation 
Coagulation 
factor IXa 
Phase III, terminated due to 
serous anaphylactic reactions 
(NCT01848106) 
ARC1779 Coagulation 
A1 domain of von 
Willebrand factor 
Phase II, terminated 
(NCT00742612) 
NU172 Heart disease Thrombin 
Phase II, status unknown 
(NCT00808964) 
BAX499 Hemophilia 
Tissue factor 
pathway 
inhibitor (TFPI) 
Phase I, terminated, 
(NCT01191372) 
NOX-H94 
Anemia of Chroni
c Disease 
Hepcidin peptide 
hormone 
phase I/II, completed 
(NCT02079896) 
NOX-E36 
Chronic 
inflammatory 
diseases 
chemokine ligand 2 
(CCL2) 
Phase II, completed 
(NCT01547897) 
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molecules such as drugs, siRNA and protein. The conjugation of aptamer to therapeutic 
agents can be through physical intercalation or chemical connection. 
1.7.3.1.2 Physical intercalation 
Chemotherapeutic agents could be conjugated with aptamers by intercalation in mild 
condition without any chemical modification of either drugs or aptamers. One classical 
example is doxorubicin which intercalates within GC pairs at certain molecular ratio 
due to the presence of flat aromatic rings in its structure706. Vaishali et al intercalated 
doxorubicin into the A10 prostate-specific membrane antigen (PSMA) aptamer and 
they formed a physical complex through noncovalent conjugation.707. The A10 PSMA 
aptamer-doxorubicin conjugate targets the surface marker of prostate cancer cells and 
doxorubicin is subsequently internalized into the cells. Shieh et al. used an AS1411 
DNA aptamer as a carrier to deliver a photosensitizing agent TMPyP4 into breast 
cancer cells via physical conjugation showing good specificity708. Subramanian et al. 
used a simple conjugation to intercalate doxorubicin into an EpCAM RNA aptamer for 
the treatment of retinoblastoma showing inhibition of retinoblastoma cells proliferation 
but not noncancerous Müller glial cells709. The superiority of this physical conjugation 
includes high binding affinity, efficient internalization and the ability to pass through 
the blood/tumor barriers710. Nevertheless, it should be taken into account that based on 
the molecule’s structure of aptamers, very few agents could be physically intercalated 
into aptamers. 
1.7.3.1.3 Aptamer-nanoparticle complex 
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Nanoparticles provide large surface areas which are excellent platforms to conjugate 
multiple aptamers. Moreover, large quantities of drug molecules can be stored in the 
interior volumes of nanoparticles thus enhancing loading capacity. To date, the most 
commonly used vehicles are aptamer-nanoparticles which encapsulate hydrophobic 
chemotherapeutic agents. These nanoparticles can be classified as polymeric 
nanoparticles711, gold nanoparticles712, magnetic nanoparticles (e.g., Fe3O4)
713, carbon 
nanotubes714, serum albumin nanoparticles715, and dendrimers716. Most of these studies 
have shown high encapsulation efficacy (up to 90%) and prolonged in vitro release 
profiles over 48 hours.  
1.7.3.2 Aptamers in the treatment of hepatocellular carcinoma 
Aptamers, either as therapeutic agent or drug delivery carriers, were used to treat 
hepatocellular carcinoma. Meng et al. developed an DNA aptamer TLS11a against 
human liver cancer LH856 cells. The aptamer is intercalated with doxorubicin, making 
the aptamer-doxorubicin conjugate potential candidate for targeted liver cancer 
therapy717. Jiang et al. developed salinomycin-load poly lactic-co-glycolic acid (PLGA) 
nanoparticles with aptamers against epidermal growth factor receptor (EGFR) and 
CD133 to target hepatocellular carcinoma, which showed improved therapeutic 
effect718. Using cell SELEX, Wang et al. selected the DNA aptamer LY-1 which binds 
to metastatic hepatocellular carcinoma cells719. The aptamer-magnetic particles can 
capture hepatocellular carcinoma cells in whole blood, indicating LY-1 aptamer as a 
promising molecule to recognize hepatocellular carcinoma cells719. Zhang et al. used 
hepatocellular carcinoma specific aptamer TLS11a to deliver a gold nanoplatform 
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consisting of a prodrug AQ4N and Cu(II) 720. In cancer cells the prodrug AQ4N is 
cleaved and Cu(II) is released which induces electrostatic aggregation of the gold 
nanoparticle for photothermal ablation720. Weigum et al. developed a biodegradable 
nanoparticle which encapsulates doxorubicin with TLS11a aptamer as a carrier to 
target hepatocellular carcinoma cells721. The aptamer-guided nanoparticles showed 
significant improvement versus controls for hepatocellular carcinoma treatment721. 
Cho et al. modified the aptamer AS1411, which is capable of suppressing 
hepatocellular carcinoma cell growth both in vitro and in vivo722. Liu et al. developed 
a nanoparticle which contains peptide-modified aptamer ST21 to target hepatocellular 
carcinoma cells, miRNA-195 to inhibit VEGF, and fasudil to suppress vasculogenic 
mimicry723. The ST21-modified nanoparticles showed higher therapeutic efficacy 
against hepatocellular carcinoma723. Pilapeng et al. reported a nanoparticle which 
encapsulates the DNA aptamer against EpCAM as a target probe, using magnetic iron 
oxide as imaging material, and doxorubicin as an anti-cancer drug, for the theranostics 
of hepatocellular carcinoma724.  
1.7.3.3 Aptamers for cancer stem cell-targeted therapy 
Conventional chemotherapeutic treatment often leads to severe side effects to patients. 
The cancer stem cell theory provides a promising method to develop effective 
anticancer therapy. Aptamers can be conjugated to chemotherapeutic agents for 
targeted delivery into cancer stem cells but not normal cells thereby overcoming the 
side effects. Recent research has revealed that cancer stem cell-targeted therapy can 
eliminate cancer stem cells and minimize cancer recurrence725, 726. Wang and 
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colleagues selected aptamers linked with gold nanorods against prostate cancer stem 
cells727. The conjugates successfully target and kill cancer stem cells by near-infrared 
laser irradiation727. McAuliffe et al. have shown that targeting cancer stem cell-
associated Notch pathway can increase tumor sensitivity to platinum treatment725. 
Using cell SELEX, Kim et al. and Zhou et al. have developed aptamers that can select 
and internalize into brain cancer stem cells728, 729. Ababneh et al. have generated an 
RNA aptamer that specifically binds to CD44, a marker for breast cancer stem cells 
which is associated with cancer metastasis capacity730. Using microfluidic chip, Hung 
et al. have selected aptamers against colon cancer stem cells with high binding affinity 
comparable to that of antibodies731. Kim and colleagues reported a DNA aptamer 
which binds to pancreatic cancer stem cells, which can potentially serve for diagnostic 
and therapeutic agents for pancreatic cancer732. Shigdar et al. selected EpCAM and 
CD133 RNA aptamers which show superior binding affinity to cancer stem cell surface 
makers and tumor penetration and retention679, 733. Wang et al. reported the synergistic 
effect of doxorubicin and RNA EpCAM aptamer-survivin siRNA chimera to eradicate 
breast cancer stem cells734. Gilboa-Geffen used RNA EpCAM aptamer to deliver anti- 
PLK1 siRNA into triple negative breast cancer cells, which suppresses tumor growth 
in a mouse model735. Song et al. have developed DNA aptamer against EpCAM736. 
To summarize, nucleic acid aptamers represent a combination of the features of both 
small molecules and antibodies, including tumor penetration capacity and high 
specificity and binding affinity. There are 11 aptamers in clinical trials, nearly 100 
aptamers waiting for approval for clinical studies, over 900 aptamers developed by 
SELEX for diagnostics and therapeutics of a variety of diseases, more than 6500 
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reports on aptamer research in Pubmed737. A trial-and-error process is needed to 
develop aptamers with improved specificity, binding affinity against target, stability 
against nucleases and pharmacokinetic profile.  As more researchers devote themselves 
to aptamer development, aptamers that meet clinic demands are highly anticipated.  
1.3 Conclusion 
Although several questions remain open on the cancer stem cell theory, mounting 
evidence has demonstrated that the presence of cancer stem cells is crucial for the 
initiation, propagation, metastasis and chemoresistance of hepatocellular carcinoma. 
The liver cancer stem cells can be considered as the Achilles’ heel of hepatocellular 
carcinoma, therefore effectively therapeutic approaches are clearly required to 
eradicate the liver cancer stem cell population. The liver cancer stem cells use a series 
of defense lines against attacks by the chemotherapeutic agents, among which the 
overexpression of ABC transporters is probably the most important one738. 
Doxorubicin is the first line treatment of intermediate-stage hepatocellular carcinoma. 
However, intravenous administration of doxorubicin cannot provide clinical benefit 
for patients with liver cancer due to the fact that the liver cancer stem cells are resistant 
to doxorubicin treatment and high dose of doxorubicin results in cardiac toxicity739. It 
has been shown that the ABCB1 and ABCG2 drug efflux pumps are overexpressed in 
the side population (SP) hepatocellular carcinoma cells740, 741. Furthermore, 
doxorubicin is the substrate of ABCB1 and ABCG2 protein742. Therefore, inhibition 
of the ABCB1 and/or ABCG2 drug efflux pumps may sensitize liver cancer stem cells 
to the treatment of doxorubicin leading to improved clinical outcome. Besides directly 
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inhibiting ABCB1 and/or ABCG2 proteins, the emergence of aptamers provides a way 
for doxorubicin to bypass the ABC transporters on the plasma membrane of cancer 
cells. Doxorubicin can be conjugated with aptamers that are against liver cancer stem 
cell surface markers, such as EpCAM or CD133, and be delivered into cancer cells via 
endocytosis679, 733. Several studies have revealed the important role of autophagy in the 
chemoresistance of liver cancer stem cells, which has attracted the attention of 
scientists as to whether inhibition of autophagy can potentially provide clinical benefit 
to patients with hepatocellular carcinoma.  
1.4 Hypothesis and aims of the study 
1.4.1 Hypothesis 
The following are thesis hypothesis: 
1. Inhibition of the drug efflux pump MDR1 or ABCG2 can sensitize liver cancer 
stem cells to the treatment of doxorubicin. 
2. Doxorubicin can be efficiently deliver into liver cancer stem cells by aptamers 
with enhanced cellular internalization, increased cell apoptosis and enhanced 
capacity to eliminate cancer stem cells. 
3. The capacity of the aptamer-doxorubicin conjugate to eliminate liver cancer 
stem cells can be augmented by the inhibition of autophagy. 
1.4.2 Study aims 
The specific aims of this thesis are: 
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1. To investigate the efficacy of inhibiting MDR1 or ABCG2 to sensitize liver 
cancer stem cells to the treatment of doxorubicin.  
2. To investigate the capacity of the aptamer-doxorubicin conjugate to eliminate 
liver cancer stem cells. 
3. To investigate the efficacy of autophagy inhibition to augment the capacity of 
aptamer-doxorubicin conjugate to eliminate liver cancer stem cells. 
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Chapter 2 
Materials and methods 
2.1 Materials and equipment 
2.1.1 Chemicals and reagents 
16% Formaldehyde solution (Thermo Scientific, Cat No: 28908)  
3-Methyladenine (3-MA, Sigma, Cat No: M9281) 
3 M sodium acetate (pH 5.2) (Invitrogen, Cat No: 46-0236) 
40 µm cell Strainers (BD Falcon, Cat No: 352340)  
7-AAD Viability Staining Solution. (Biolegend, Cat No: 420404) 
8- chamber cover glass slides (Lab-Tek, Cat No: 155409)  
Acetonitrile (Merck, Cat No: UN1648) 
Acrylamide (Bio-Rad, Cat No: 161-0156) 
Annexin V binding buffer (Biolegend, Cat No: 422201) 
B27 supplement (Gibco, Cat No: 10889-038) 
Bisbenzimide Hoechst 33342 (Sigma, Cat No: 14533) 
Bovine serum albumin (BSA, Sigma, Cat No: A4503) 
Bromophenol blue (Bio-Rad, Cat No: 161-0404) 
CaCl2 (Merck, Cat No: 172570) 
Cell staining buffer (Biolegend, Cat No: 420201) 
Chloroform (Sigma, Cat No: 366927) 
  
 
87 
 
Chloroquine (Sigma, Cat No: C6628) 
TUNEL Alexa Fluor 488 imaging assay kit (ThermoFisher, Cat No: C10245) 
Costar Ultra-low attachment surface 6-well plates (Corning, Cat No: 3471)  
Costar Ultra-low attachment surface 96-well plates (Corning, Cat No: 3474) 
DEPC-treated water (Santa Cruz, Cat No: sc-204391A) 
Dimethyl sulfoxide (DMSO, Merck, Cat No: 1.02952.1000) 
DMEM medium (Invitrogen, Cat No: 12800-017) 
DMEM/F-12 media (Invitrogen, Cat No: 12500-096) 
DNA ladder (ThermoFisher, Cat No: 10416014) 
Doxorubicin (Sigma, Cat No: 44583) 
Epidermal growth factor (EGF, Sapphire Bioscience, Cat No: 701-02360)  
Ethanol (Merck, Cat No: 1434543) 
Ethylenediaminetetraacetic acid (EDTA, Scharlau, Cat No: AC0965) 
Basic fibroblast growth factor (bFGF, Sapphire Bioscience, Cat No: 701-23300) 
Foetal bovine serum (FBS, Bovogen, Cat No:  SFBS-F) 
Glutamax (Life Technologies, Cat No: 35050-061)  
Glycerol (Ajax Finechem, Cat No: 0810081) 
Glycine (MP Biomedical, Cat No: 808831) 
Ham’s F12 medium (Invitrogen, Australia, Cat No: 11765-054)  
HCl (Merck, Cat No: K37835117 737) 
HEPES (Applichem, Cat No: A3724, 0100) 
High-Capacity cDNA Reverse Transcription Kit. (Applied Biosystems, Cat 
No: 4368814) 
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Human transferrin conjugate Alexa Fluor 488 (Life technologies, Cat No: T13342) 
Insulin (Sigma, Cat No: 19278)  
Isopropyl alcohol (Fluka, Cat No: 59304) 
KCl (Sigma, Cat No: P9541) 
KH2PO4 (Sigma, Cat No:  P0662) 
Ko143 (Cayman Chemical, Cat No: 15215) 
Lipofectamine 2000 (Life Technologies, Cat No: 11668-030) 
Methanol (Merck, Cat No: 6.10158.2511) 
MgCl2 (Ajax Finechem, Cat No: A296) 
Na2HPO4 (Riedel-de Haen, Cat No: 30435) 
NaCl (Merck, Cat No: K37303004) 
NaHCO3 (Sigma, Cat No: 30435) 
Opti-MEM reduced serum medium (Gibco, Cat No: 31985070) 
Penicillin/Streptomycin (Invitrogen, Cat No: 15070-063)  
Phosphate saline buffer (PBS, Medicago, Cat No: 09-7400-100)  
Precision Plus Protein™ Dual Color Standards (Bio-Rad, Cat No: 1610394) 
Protease inhibitor cocktails (Roche, Cat No: 11697498001).  
Salmon sperm DNA (Sigma, Cat No: D1626)  
Skim milk powder (Diploma, Cat No: 28510001) 
Sodium dodecyl sulfate (SDS, Medicago, Cat No: 09-2026-1000) 
Stripping buffer (Thermo Scientific, Cat No: 21059) 
Super Signal West Dura substrate (Thermo Scientific, Cat No: 34075) 
SuperBlock blocking buffer (Thermo Scientific, Cat No: 37537)  
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SYBR™ Green PCR Master Mix (ThermoFisher, Cat No: 4309155) 
TEMED (Invitrogen, Cat No: 15524-010) 
Thiazolyl Blue Tetrazolium Bromide (Sigma, Cat No: M5655) 
Tris Base (Sigma, Cat No: T6066) 
Triton X-100 (Merck, Cat No: 1.08603.2500) 
Trizol reagent (Invitrogen, Cat No: 15596-026)  
Trypan Blue (Sigma, Cat No: T8154) 
Trypsin-EDTA (Gibco, Australia, Cat No: 15400-054)  
Tween 20 (MP Biomedicals, Cat No: Tween201) 
Valspodar (PSC833, Sigma, Cat No: SML0572) 
Vectashield® Mounting medium (Vector Laboratories, Cat No: H-1000) 
(±)-Verapamil hydrochloride (Sigma, Cat No: V4629) 
All the organic reagents, including methanol and chloroform, used in this study were 
analytical or high-performance liquid chromatography (HPLC) grade. All other 
chemicals were of the highest grade available.  
2.1.2 Equipment, services and consumables 
Cellstar 6-well plate (Greiner Bio One, Cat No: 657160) 
Cellstar 96-well plates (Greiner Bio One, Cat No: 657185) 
Cellstar Cell culture dish (Greiner Bio One, Cat No: 664160) 
Corning 96-well black polystyrene plate (Corning, Cat No: CLS3603) 
Costar Ultra-Low attachment 6-well plates (Corning, Cat No: CLS3471) 
Costar Ultra-Low attachment 96-well plates (Corning, Cat No: CLS3474) 
Electrical homogenizer (Glas-Col, S/N CTM0500082)  
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FACS Canto II flow cytometer (Becton Dickinson)  
FACSAria II flow cytometer (BD Biosciences)   
Flowjo 7.6.1 (Tree star) 
Fluostar OPTIMA plate reader (BMG Labtech) 
FluoView FV10i confocal microscope (Olympus, Japan) 
FrameStrip 8 Clear Tubes & Caps (Integrated Sciences, Cat No: 4ti-0751) 
HERA cell 150i CO2 incubator (Thermo Scientific) 
Hitachi CT15RE Bench-top Refrigerated Centrifuge (Japan, Cat No: 90560701) 
HPLC with fluorescence detector (Waters, Cat No: e2695, 2475) 
ImageJ software (National Institute of Health, NIH, US) 
Image-Pro software (Media Cybernetics) 
ImageQuant LAS-4000 Chemiluminescence & Fluorescence Imaging System 
(Fujitsu Life Sciences) 
LAS-4000 Imaging software (GE Healthcare Life Sciences) 
Microtome (Leica, Cat No: RM 2125RT) 
Milli-Q® Advantage A10 Water System (Millipore) 
Nanodrop 2000c spectrophotometer (ThermoFisher) 
Nitrocellulose membranes (Whatman, Cat No: 10401196) 
Olympus SC20 camera (B & B Microscopes, USA) 
Orbital shaking incubator (Ratex, Cat No: OM15) 
Petri dish (Global Science, Cat No: 031604-000110) 
pH meter (Hanna, Cat No: pH211)  
Poly-l-lysine coated glass slides (Sigma, Cat No: S9027-1PAK) 
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PVDF membrane (Thermo Scientific, Cat No: 77010) 
Semi-Micro Analytical Balances (A&D, Cat No: GR-200) 
Sephadex®G-10 medium column (Sigma, Cat No: 11814427001) 
Slid-A-Lyzer Dialysis Cassette (MW cut off 3.5 kDa, Thermo Scientific, Cat No: 
66333) 
T25 flask (Cellstar, Cat No: 690175) 
T75 flask (Cellstar, Cat No: 658170) 
T175 flask (Cellstar, Cat No: 660175) 
The limiting dilution formula on the website of Walter and Eliza Hall Institute of  
Medical Research (http://bioinf.wehi.edu.au/software/elda/index.html).     
Victor TM X5 Plate Reader (PerkinElmer Life and Analytical Sciences).  
2.1.3 Antibodies 
Anti-ABCG2 antibody (Abcam, Cat No: ab108312) 
Anti-ATG5 antibody (Cell Signaling, Cat No: 2630) 
Anti-beta actin antibody (Abcam, Cat No: ab6276) 
Anti-CD133/1 (AC133)-VioBright FITC (Miltenyl Biotec, Cat No: 130-105-225) 
Anti-LC3B antibody (Cell Signaling, Cat No: 2775) 
Anti-SQSTM1 / p62 antibody (Abcam, Cat No: ab56416) 
APC/Fire™ 750 anti-human CD326 (EpCAM) antibody (Biolegend, Cat No:324234) 
APC/Fire™ 750 mouse IgG2b, κ isotype control (Biolegend, Cat No: 400372) 
APC Mouse anti-human CD338 (BD Biosciences, Cat No: 561451) 
APC Mouse IgG2b κ isotype control (BD Biosciences, Cat No: 555745) 
BV421 Mouse anti-human CD243 (BD Biosciences, Cat No: 566015) 
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BV421 mouse IgG2a, κ isotype control (BD Biosciences, Cat No: 562439) 
FITC conjugated mouse anti-human EpCAM antibody (BD Biosciences, Cat No: 
347197)  
Goat anti-mouse HRP-conjugated antibody (Thermo Fisher, Cat No: 31430)  
Goat anti-rabbit HRP-conjugated antibody (Cell Signaling, Cat No: 7074) 
Mouse IgG1-VioBright FITC isotope control (Miltenyl Biotec, Cat No: 130-104-513) 
Anti-MDR-1 antibody (D-11) (Santa Cruz, Cat No: sc-55510) 
Pacific Blue™ Annexin V (Biolegend, Cat No: 640918) 
2.1.4 Aptamers used in this study 
The EpCAM aptamer and its negative control aptamer were synthesized by IBA GmbH 
(Rudolf-Wissell-Straße 28, 37079 Göttingen, Germany) followed by HPLC 
purification. The CD133 aptamer and its negative control aptamer were synthesized by 
RiboTask (Frydenlundsvej 4, DK-5550, Langeskov, Denmark) followed by HPLC 
purification. 
EpCAM aptamer: 5’ - Cy5 – c g c g c g c c g c A (2’-F-C) G (2’-F-U) A (2’-F-U) 
(2’-F-C) (2’-F-C) (2’-F-C) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-C) (2’-F-C) 
(2’-F-U) g c g g c g c g c g - idT -3’ 
CD133 aptamer: 5’ - c g c g c g c c g c A (2’-F-C) G (2’-F-U) A (2’-F-U) A (2’-F-C) 
(2’-F-U) A (2’-F-U) g c g g c g c g c g - C6NH2 - Alexa 647 - 3’ 
Negative control EpCAM aptamer: 5’- Cy5- c g c g c g c c g c A (2’-O-Me-C) G 
(2’-O-Me-U) A (2’-O-Me-U) (2’-O-Me-C) (2’-O-Me-C) (2’-O-Me-C) (2’-O-Me-U) 
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(2’-O-Me-U) (2’-O-Me-U) (2’-O-Me-U) (2’-O-Me-C) G (2’-O-Me-C) G (2’-O-Me-U) 
c g g c g c g c g -3’ 
Negative control CD133 aptamer: 5’ - c g c g c g c c g c A (2’-O-Me-C) G (2’-O-
Me-U) A (2’-O-Me-U) A (2’-O-Me-C) (2’-O-Me-U) A (2’-O-Me-U) g c g g c g c g c 
g - C6NH2 - Alexa 647 - 3’ 
 
In the above sequences, the uppercase letters indicate RNAs while 2’-F represents 2’-
fluoropyrimidine and 2’-O-Me represents 2’-O-methyl modification. The lowercase 
letters indicate DNAs in which deoxycytidines were modified with 5’-methyl-
deoxycytidine (5-Methyl-dC), which increases the Tm by as much as 0.5 °C per 
insertion. The long DNA GC tail was added to both the EpCAM and CD133 aptamers 
for the intercalation of doxorubicin. The negative control aptamers are aptamers of the 
same sequence as the EpCAM and CD133 aptamer but with a 2’-O-methyl 
modification at the pyrimidines that changes the three-dimensional structure of 
aptamer and thus abolishing the binding of the control aptamers to either EpCAM or 
CD133743. The EpCAM aptamer and the CD133 aptamer have a 3’-inverted 
deoxythymidine (iDT) and hexylamine cap respectively which provide significant 
resistance to nuclease in the blood744, 745.  
The aptamers were labelled with either fluorochrome Cy5 at the 5'-end or Alexa 647 
at the 3’ therefore the distribution of aptamers within the cells can be studied by 
confocal microscopy. Prior to conducting all the experiments using aptamers, the 
aptamers were prepared in PBS containing either 5 mM MgCl2 for EpCAM aptamer or 
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2.5 mM MgCl2 for CD133 aptamer, and then folded by denaturation at 85 °C for 5 min, 
followed by 10 min incubation at room temperature and re-folding at 37 °C for at least 
15 min. 
2.1.5 siRNAs and primers used in the study 
The primers were designed using the software tool primer-BLAST746. The Dicer-
substrate double-strand short interfering RNAs (siRNAs) were designed according to 
the methods described by Kim et al.747 and Amarzguioui et al.748. The scrambled 
siRNAs were designed using InvivoGen siRNA wizard software tool 
(http://www.invivogen.com/sirnawizard/scrambled.php) and were verified using the 
BLAST software tool (https://blast.ncbi.nlm.nih.gov/Blast.cgi). The primers and 
siRNAs were synthesized by Integrated DNA Technologies (IDT) followed by HPLC 
purification.  
Table 2.1. Sequences of primers and siRNAs used in this study 
Name Sequence (5’ – 3’) 
MDR1 primer 
Sense: 5’-ATATCAGCAGCCCACATCAT-3’ 
Antisense: 5’-GAAGCACTGGGATGTCCGGT-3’ 
ABCG2 primer 
Sense: 5′-TTTCCAAGCGTTCATTCAAAAA-3′ 
Antisense: 5′-TACGACTGTGACAATGATCTGAGC-3′ 
GAPDH primer 
Sense: 5’-GAGCCCCAGCCTTCTCCATG-3’ 
Antisense: 5’-GAAATCCCATCACCATCTTCCAGG-3’ 
MDR1 siRNA 
Sense: 5’-GGAAAAGAAACCAACUGUCAGUGdTdA-3′ 
Antisense: 5′-UACACUGACAGUUGGUUUCUUUUCCUU-3′ 
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Table 2.1. (Continued) 
Name Sequence (5’ – 3’) 
ABCG2 siRNA 
Sense: 5'-CUGGAGAUGUUCUGAUAAAUGGAdGdC-3′ 
Antisense: 3'-UAGACCUCUACAAGACUAUUUACCUCG-3′ 
ATG5 siRNA 
Sense: 5'-GGCAUUAUCCAAUUGGUUUGCUAdTdT-3′ 
Antisense: 5'-AAUAGCAAACCAAUUGGAUAAUGCCAU-3′ 
Scrambled MDR1 
siRNA 
Sense: 5’-AUAAGCGGAAUCAACGAACAAUGdTdA-3′ 
Antisense: 5′-UACAUUGUUCGUUGAUUCCGCUUAUUU-3′ 
Scrambled 
ABCG2 siRNA 
Sense: 5'-GCAUUGUGAGACGAAUAUUUGGAdGdC-3′ 
Antisense: 3'-UACGUAACACUCUGCUUAUAAACCUCG-3′ 
Scrambled ATG5 
siRNA 
Sense: 5'-GGACUCUUCGGGAUUUACUAUUAdTdT-3′ 
Antisense: 3'-AAUAAUAGUAAAUCCCGAAGAGUCCAU-3′ 
 
2.2 Methods 
2.2.1 Culture and passage of adherent cells and tumorspheres 
PLC/PRF/5 (human hepatocellular carcinoma, ATCC® CRL-8024™) cell line, A549 
(human lung carcinoma, ATCC® 185™) and HEK-293T (human embryonic kidney, 
ATCC® CRL-11268™) cell line were purchased from American Type Culture 
Collection (ATCC, Manassas, US). Huh7 (human hepatocellular carcinoma, Japanese 
Collection of Research Bioresources) cell line was kindly provided by Dr. Liang Qiao 
(Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead 
Clinical School at Westmead Hospital, Sydney, Australia). All the above cells were 
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cultured in DMEM (Invitrogen, Australia) medium supplemented with 10% fetal 
bovine serum (FBS, Bovogen, Australia), penicillin (50 U/mL, Invitrogen, Australia), 
and streptomycin (50 µg/mL, Invitrogen, Australia) and 1 × Glutamax (Life 
Technologies) in a humidified atmosphere containing 5% CO2 at 37 °C. For sub-
culturing cells from monolayer, cell culture medium was removed and cells were 
rinsed gently with sterilized PBS twice, followed by detachment with 0.05% trypsin-
EDTA (Gibco, Australia) at 37 °C until cells were rounded up and detached from the 
surface of flasks. Then, complete medium was used to inactivate the trypsin. Cells were 
centrifuged at 350 × g for 5 min and collected at room temperature, followed by 
resuspension with appropriate buffer or medium. 
For sphere culture and passage, the adherent cells were collected and washed with PBS 
to remove serum, and then suspended in serum free DMEM/F12 supplemented with 
20 ng/ml human epidermal growth factor (EGF, Sapphire Bioscience), 20 ng/ml human 
basic fibroblast growth factor (bFGF, Sapphire Bioscience), 5 µg/ml insulin (Sigma) 
and 2% B27 supplement (Gibco). The cells were plated into a 6-well flat bottom ultra-
low attachment plate (Corning) at a density of 20,000 cells/well. After Seven to ten 
days, the formation of tumorspheres were analyzed using an inverted microscope. Only 
spheres with a size larger than 50 µm in diameter and a well-defined border were 
counted as tumourspheres. The tumorspheres were collected and dissociated with 
trypsin to generate single cells and re-suspended in serum-free medium and allowed to 
re-form spheres. The tumorspheres were passaged every 7-8 days. The sphere-forming 
cells from Huh7 and PLC/PRF/5 were used in the subsequent studies. 
2.2.2 Determination of cytotoxicity 
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The cytotoxicity of doxorubicin and salinomycin in Huh7 and PLC/PRF/5 cells was 
studied by determining their half maximum inhibitory concentrations (IC50). First, a 
series of Huh7 and PLC/PRF/5 cell concentrations were plated in a 96-well culture 
plate to determine the optimum cell density and the dose-dependent linear range. Both 
Huh7 and PLC/PRF/5 cells were diluted and seeded at 1 × 104, 8 ×103, 5 × 103 and 1 
× 103 cells/well in a 96-well plate and incubated at 37 °C and 5% CO2 for 24 hours and 
48 hours respectively. Cells were treated with 1 mg/ml thiazolyl blue tetrazolium 
bromide (MTT) and incubated for 3 hours. The yellow MTT is reduced to its purple 
reduction product formazan in the mitochondria of living cells. After the incubation 
period, the culture medium was removed and replaced with 150 µL dimethyl sulfoxide 
(DMSO). The light absorbance was read at 570 nm in a plate reader (Perkin Elmer, 
Australia). To measure the cytotoxicity effects of doxorubicin and salinomycin, both 
the Huh7 and PLC/PRF/5 cells were plated in a 96-well plate at 6 × 103, 4 × 103 and 2 
× 103 cells/well respectively and treated with 0.05, 0.1, 0.2, 0.5, 1, 5, 10, 20 µg/ml of 
doxorubicin and 0.1, 0.5, 1, 2, 5, 10, 50 µg/ml of salinomycin respectively. The cells 
were incubated at 37 °C and 5% CO2 for 24, 48 and 72 hours respectively prior to 
MTT treatment as mentioned above. 
To measure the cytotoxicity of MDR1 inhibitor verapamil and valspodar, the Huh7 and 
PLC/PRF/5 cells were plated in a 96-well plate with 6,000 cells per well and incubate 
overnight. The cells were treated with verapamil (10 µM, 20 µM, 50 µM and 100 µM) 
and valspodar (1 µM, 2 µM, 5 µM and 10 µM) respectively for 3 hours respectively.  
Twenty µL of MTT (5 mg/ml) was added into each well and cells were incubated for 
3 hours. The medium was removed and 150 µL of DMSO was added into each well. 
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The absorbance of light at 570 nm was detected using a plate reader. Cell viability (%) 
was determined as = (Drug treatment - media control)/(Nontreatment - media control) 
× 100%. The IC50 is calculated by nonlinear regression analysis using the Graphpad 
software.  
2.2.3 siRNA transfection 
Twenty-four hours prior to siRNA transfection, cells were plated in a 6-well cell 
culture plate at a density of 30 × 104 cells/well in 1.5 mL/well DMEM medium without 
antibiotics. The MDR1 siRNA, ABCG2 siRNA, ATG5 siRNA and their corresponding 
scrambled siRNAs at a concentration of 20 nM were gently diluted in 250 µL of Opti-
MEM reduced serum medium respectively. In parallel, 10 µL of Lipofectamine 2000 
was diluted in 250 µL Opti-MEM medium. Following incubation of 5 min at room 
temperature, the diluted siRNA and Lipofectamine 2000 were mixed gently and 
incubated for 10 min at room temperature, followed by the addition of 500 µL of 
siRNA-Lipofectamine complexes to each well (containing cells and 1.5 mL full 
DMEM medium). The plate was mixed gently by rocking back and forth and the cells 
were incubated in a humidified atmosphere containing 5% CO2 at 37 °C for 48 hours 
followed by the assessing of for expression levels of MDR1, ABCG2 by qRT-PCR and 
Western analysis.  The level of ATG5 was studied 72 h after transfection. 
2.2.4 MDR1 function assay using calcein-AM extrusion  
The calcein acetoxymethylester (calcein AM) assay was used to determine the 
functionality of MDR1 according to a modified method749. Briefly, Huh7 and 
PLC/PRF/5 cells were seeded in black 96-well plates respectively at a density of 10 × 
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104 cells per well overnight and treated with 50 µL of verapamil (10, 20 and 50 µM) 
and valspodar (0.5, 1 and 2 µM) respectively. Black plates were chosen as they yielded 
much smaller background fluorescence than colorless plates when irradiated in the UV. 
After 30 min at 37 °C, 50 µL of 2 µM calcein AM (Sigma) were added into each well 
and the fluorescence of calcein was immediately measured every 5 min for 1 hour using 
a microplate reader with 485/589 excitation/emission at room temperature. For 
pretreatment experiments, cells were incubated for 0.5 hour and washed, and then 50 
µL of fresh saline buffer was added before addition of calcein AM. The % relative 
fluorescence (FL) in the cells was expressed as: % FL = [(FLtreatment - 
FLnontreatment)/FLnontreatment] × 100%. To assess cell membrane integrity, cells were 
treated with the same samples for 0.5 hour at 37 °C, and then incubated for 1 hour at 
room temperature. Then, cells were trypsinized and 50 µL of 0.4% trypan blue solution 
was added. Membrane integrity was normalized to untreated control and expressed as 
(viable cells/total cells) × 100%. 
2.2.5 ABCG2 function assay using Hoechst 33342 extrusion 
The Hoechst 33342 accumulation assay is used to investigate the functionality of 
ABCG2 drug efflux pump750. The ABCG2 inhibitor ko143 was dissolved in DMSO. 
The highest concentration of DMSO in dilutions for the assays was not more than 0.1%. 
After the preparation of different concentrations of ko143, 20 µL of each concentration 
was placed into black 96-well plates. The prepared cells were added into each well of 
the plate at a density of 3 × 104 cells per well to a total volume of 180 µL. The 96-well 
plate was stored under 5% CO2 at 37 °C for 30 min. After this preincubation period, 
  
 
100 
 
20 µL of a 10 µM Hoechst 33342 solution (protected from light) was added to each 
well. Fluorescence was measured immediately at constant intervals (60 seconds) for a 
period of 120 min with an excitation of 355 nm and an emission wavelength of 460 nm 
at 37 °C using a plate reader. The % relative fluorescence (FL) in the cells was 
expressed as: %FL = [(FLtreatment - Fnontreatment)/FLnontreatment] × 100%. 
2.2.6 Protein extraction and western blot assays 
Cells from adherent or non-adherent culture were collected either by trypsinization and 
transferred into either a 1.5 or 15 mL tube. The cells were washed twice with PBS by 
centrifugation at 1,000 × g for 5 min and the pellet was suspended in Lysis buffer (20 
mM Tris HCl pH 7.5, 135 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA, 1% Triton X-100, 
10% Glycerol, and 1 × protease inhibitor cocktails (Roche) at a ratio of 0.2 mL/1 × 106 
cells. Following 10 min of incubation on ice, the lysates were centrifuged at 21,500 × 
g at 4 °C for 30 min. The supernatant was then collected and used for western blot 
analysis with the remainder stored in -80 °C for long term storage. Lysates were 
separated with SDS-polyacrylamide gel electrophoresis gels (PAGE) and the proteins 
were transferred onto a nitrocellulose membrane (Whatman) or PVDF membrane 
(Thermo Scientific). Following extensive blocking with 5% skim milk (4 hours at room 
temperature or overnight at 4 °C), primary antibodies were incubated according to the 
manufacturers’ suggestions. Specific mouse or rabbit anti-human antibodies to MDR1 
(Santa-Cruz), ABCG2 (Abcam), LC3B (Cell Signaling), ATG5 (Cell Signaling), p62 
(Abcam) and β-actin (Sigma) were detected using goat anti-mouse antibody (Sigma) 
or goat anti-rabbit antibody (Cell Signaling) and visualized using the Super Signal 
West Dura substrate (Thermo Scientific). Relative quantification was conducted using 
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a LAS-4000 Imaging System (GE Healthcare Life Sciences) with β-actin as a loading 
control. 
2.2.7 RNA extraction and reverse transcription 
Total RNA was extracted using Trizol (Invitrogen) according to the manufacturer’s 
protocol. Approximately 5-10 × 106 of cells were collected via trypsinization and then 
washed 2-3 times with ice cold PBS. The cells were then suspended with 1.0 mL of 
Trizol reagent and vortexed for 15 seconds followed by incubation at room temperature 
for 5 min. Following the incubation, 0.2 mL of chloroform was added to the 
homogenized mixture and was shaken vigorously for 30 seconds prior to incubation at 
room temperature for 3 min. The mixture was centrifuged at 12,000 × g at 4 °C and the 
upper aqueous phase was carefully collected into a new 1.5 ml Eppendorf tube, in 
which the RNA was precipitated with 0.5 mL of isopropyl alcohol at room temperature 
for 10 min. The supernatant was removed and 1 mL of 75% ethanol was added into 
each tube. Followed by centrifugation at 7,500 × g at 4 °C for 5 min, the supernatant 
was removed and the RNA pellet was air dried for 5 – 10 min at room temperature and 
dissolved in 10 – 20 µL DEPC-treated water. The RNA was quantified using the 
Nanodrop (ThermoFisher) and later used for reverse transcription with the remainder 
stored at -80 °C for long term storage. One microgram of the extracted total RNA was 
used in a 20 µL reverse transcription reaction using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) and following the manufacturer’s instructions. 
The cDNA product was stored at -20 °C. 
2.2.8 Real-time quantitative reverse transcription PCR (qRT-PCR) assay 
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Fast SYBR Green Master Mix (ThermoFisher) and Stratagene Mx3000P system 
(Agilent Technologies) were used to carry out qRT-PCR assays, and all primers used 
in this study had a melting temperature of approximately 58 °C to meet the optimum 
working condition of the PCR Master Mix. In a single reaction mix, 2 µL of cDNA 
was mixed with 10 µL master mix, 1 µL of each forward and reverse primer (final 
concentration was 200 nM), and the reaction mix was completed to 20 µL with H2O. 
The anneal/extension temperatures were set to 60 °C for 30 seconds and fluorescence 
was detected at 72 °C to minimize primer dimers. GAPDH was used as an internal 
control. Data analysis was performed with MxPro software (Agilent Technologies). 
The amplification efficiency of the primers was determined by performing qRT-PCR 
reactions with serial dilutions of the cDNA (1-fold, 2-fold, 4-fold to 20-fold dilution). 
The amplification efficiency was calculated with the equation: E = 10(-1/slope) - 1, 
where E is the efficiency of the reaction and slope represents the slope of CT value 
plotted against the log of the input template amount. An amplification efficiency 
between the values 0.8 and 1.2 was considered acceptable. The relative quantification 
was calculated with the Pfaffi method using the following equation: Fold change = 
(Ep-target gene) ΔCt-target / (Ep-GAPDH) ΔCt-GAPDH, where Ep (Pfaffi efficiency) 
equals E + 1, ΔCt is the difference of Ct between compared samples. Table 2-1 shows 
the primers used for qRT-PCR. 
2.2.9 Development of aptamer-drug conjugates 
EpCAM aptamer and CD133 aptamer were designed for conjugation with a 
chemotherapy agent doxorubicin (Sigma) which was prepared at concentrations of 100 
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µM and stored at 4 °C. Doxorubicin was mixed well with folded aptamer in 
conjugation buffer containing 0.1 M sodium acetate, 0.05 M NaCl, and 5 mM MgCl2 
(for EpCAM aptamer) or 2.5 mM MgCl2 (for CD133 aptamer) and incubated in orbital 
mixer/incubator (RATEK) for 30 min - 1 hour at 75 r.p.m. The conjugate mixture was 
then passed through Sephadex®G-10 medium column (Sigma) to separate the 
conjugates from free doxorubicin. After conjugation, the amount of doxorubicin loaded 
onto aptamers was evaluated as following. Thirty micro-liters of aptamer-doxorubicin 
conjugate was added into 90 µL of acetonitrile and vortex for 1 min. This solution was 
then centrifuged for 5 min at 21 000 × g, and 50 µL of the supernatant was diluted in 
150 µL PBS and mixed well prior to another centrifugation for 5 min at 21,000 × g. 
Sixty to one hundred micro-liters of supernatant was analyzed in a fluorescence Victor 
TM X5 Plate Reader (PerkinElmer Life) for determination of doxorubicin 
concentrations at an excitation and emission wavelength of 470 nm and 585 nm, 
respectively. A standard curve of free doxorubicin was prepared in parallel. 
2.2.10 Determination of molar ratio of aptamer to doxorubicin 
The secondary structure of EpCAM and CD133 aptamers were predicted by Vienna 
software (http://rna.tbi.univie.ac.at/). Doxorubicin has fluorescence properties and its 
natural fluorescence becomes quenched after intercalation into DNA due to the 
formation of charge-transfer complexes between the anthracyclines ring structure in 
doxorubicin and the DNA751. This property is utilized to study as to how many 
doxorubicin molecules can be intercalated into one EpCAM or CD133 aptamer 
molecule. First, the two aptamers were folded with the presence of Mg2+ in PBS by 
heating at 85 °C for 5 min, cooling to room temperature over 10 min, followed by 
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incubation at 37 °C for 15 min. The folding procedure provides the aptamers with 
correct three-dimensional structure. After folding, doxorubicin was mixed well with 
different concentration of aptamers in conjugation buffer and incubated at 37 °C in 
orbital mixer/incubator (RATEK) for 1 hour at 75 r.p.m. The conjugation process was 
studied using different aptamer-doxorubicin molar ratios (0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 
0.7, 0.8, 0.9 and 1) and doxorubicin fluorescence was detected using a plate reader with 
excitation wavelength at 485 nm and emission wavelength at 585 nm (Perkin Elmer, 
Australia) after intercalating with different concentrations of aptamers. The percentage 
of quenching is calculated as   
Quenching%
=
doxorubicin fluorescence in the presence of aptamer –  background fluorescence
doxorubicin fluorescence in the absence of aptamer −   background fluorescence
× 100% 
2.2.11 Determination of doxorubicin loading efficiency 
From the quenching assay, we determined the molar ratio of doxorubicin to EpCAM 
and CD133 aptamers. To determine the loading efficiency, doxorubicin was 
intercalated with EpCAM or CD133 aptamer as described above with a fixed 
aptamer/doxorubicin molar ratio. The EpCAM aptamer-doxorubicin (EpCAM-
doxorubicin) and the CD133 aptamer-doxorubicin (CD133-doxorubicin) 
conjugates were eluted from a Sephadex® G-10 column to remove the free 
doxorubicin. Thirty microlitres of the eluate was mixed with 90 µL acetonitrile and 
vortexed for 1 min to extract doxorubicin from the aptamer-doxorubicin conjugates. 
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This solution was then centrifuged at 21,000 × g for 5 min and 60 µL supernatant 
was added into the wells of low-fluorescence plate. The fluorescence of the solution 
containing doxorubicin was detected using a plate reader at the wavelength 485 nm 
for excitation and 585 nm for emission. Concentration of doxorubicin was 
determined using a standard curve generated by plotting fluorescence versus 
doxorubicin with known concentration. The loading efficiency study was repeated 
three times with 5 replicates. Doxorubicin loading efficiency (DLE) was calculated 
as 
DLE% =
doxorubicin loaded in the conjugate
doxorubicin added in the conjugate
 ×  100% 
2.2.12 Determination of the stability of CD133-doxorubcin conjugate 
The release of doxorubicin from CD133-doxorubicin conjugate was studied by 
monitoring the release of doxorubicin from the conjugate using a dialysis method 
using a Slide-A-Lyzer Dialysis Cassette (ThermoFisher). To determine the stability, 
CD133-doxorubicin conjugate at an equivalent doxorubicin concentration of 1 
µg/mL was dialyzed against conjugation buffer at 37 °C. At various time points (0.5 
h, 1 h, 2h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, 48 h and 72 h), 200 µL of each sample 
outside the dialysis cassette were collected and the concentration of free 
doxorubicin in the dialysis buffer was measured.  
2.2.13 Inhibition of endocytosis 
This experiment was performed essentially as described for confocal microscopy with 
minor modifications. Briefly, cells were pre-treated with a potassium-depleted buffer 
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(50 mM HEPES, 140 mM NaCl, 2.5 mM MgCl2, and 1 mM CaCl2) for 1 hour at 37 °C 
prior to incubation with the aptamers. The buffer was also used in the incubation step 
with aptamers and all rinsing steps. The effectiveness of these treatments in inhibiting 
endocytosis was evaluated by qualitatively characterizing the internalization of human 
transferrin conjugated to Alexa Fluor 488 (Life Technologies). Transferrin (5 µg/mL) 
was added to the cells following pre-treatment followed by a 30 min incubation at 
37 °C. The cells were washed three times in their respective buffers and visualized 
using the FluoView FV10i confocal microscope. 
2.2.14 Cellular uptake and retention 
Huh7 and PLC/PRF/5 cells were seeded at 8 × 103 cells per well in an 8-chamber slide 
(Lab-Tek® II, Nunc, US) for 24 hours in preparation for confocal microscopy. After 
24 hours the medium in the chamber slide was removed and 200 µL blocking buffer 
(PBS with 10% FBS, 0.1 ml/ml yeast tRNA and 0.1 mg/ml herring sperm DNA) was 
added into each well followed by 20 min incubation at room temperature. The blocking 
buffer was then removed and cells were washed twice with PBS. The concentrations 
of doxorubicin used was 400 nM. Bisbenzimide Hoechst 33342 (3 µg/ml) (Sigma) was 
added to the cells during the final 10 min of incubation. Cells were washed with PBS 
three times prior to visualization using laser scanning confocal microscopy (FluoView 
FV10i, Olympus, Australia).  
To quantitatively determine the accumulation of doxorubicin inside cancer cells, 
cellular uptake and retention of to that of free doxorubicin was determined. After 
trypsinization, the cells were washed with PBS and lysed with 200 µL of cell lysate 
buffer (50 mM Tris pH 7.5, 375 mM NaCl, 1 mM EDTA pH 8.0, 8% glycerol, and 
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protein inhibitor cocktail). Four hundred microliter of acetonitrile was added into each 
sample precipitate protein. The samples were vortexed for 30 seconds and centrifuged 
at 20,000 × g for 10 min. The supernatant was injected into the HPLC system (Waters 
e2695, Milford, US) and the fluorescence of doxorubicin was determined using a 
fluorescence detector (Waters 2475, Milford, US) and calibrated using a standard curve. 
2.2.15 Chromatographic instrumentation and system 
The HPLC system used in this study consists of a Waters e2695 separation module and 
a Waters 2475 Multi λ fluorescence detector. The excitation and emission wavelengths 
were set at the 470 nm and 585 nm, respectively. Chromatographic separation was 
performed using a Nova-Pak® C18 column (3.9 × 150 mm i.d., 4 µm, Waters, US) with 
a Nova-Pak® C18 guard column (3.9 × 20 mm i.d., 4 µm, Waters, US). A mixture 
(27:73, v/v) of acetonitrile and 10 mM phosphate buffer (pH = 3.0, Fluka) was used as 
the mobile phase. The flow-rate used in the assay was 1 mL/ minute and the column 
was maintained at 35 ± 5 °C throughout the chromatographic process. All solvents for 
HPLC procedures were prepared freshly and filtered with 0.22 µm membrane before 
using. 
2.2.16 Determination of binding affinity  
The equilibrium dissociation constant (K’d) of the CD133 aptamer to CD133 proteins 
expressed on the cell surface was determined using flow cytometry. Huh7, PLC/PRF/5 
or HEK293T cells (5  105) were first incubated with blocking buffer (PBS 
supplemented with 5 mM MgCl2, 0.1 mg/mL tRNA, 0.1 mg⁄mL salmon sperm DNA, 
and 5% FBS) for 20 min at room temperature followed by two washes with PBS prior 
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to incubation at serial concentrations (0 nM, 10 nM, 20 nM, 40 nM, 60 nM, 80 nM, 
100 nM, 150 nM and 200 nM) of Alexa 647-labeled CD133 aptamer, Alexa 647-
labeled negative control aptamer in a 100 µL blocking buffer at 37 °C for 30 min. The 
cells were washed three times, resuspended in 150 µL assay buffer containing 2.5 mM 
MgCl2 and subjected to flow cytometric analyses. The binding affinity was calculated 
after subtracting the mean fluorescence intensity (MFI) obtained from target cells to 
that of negative control cells according to a method described by Li and colleagues752. 
Fluorescent histograms were recorded by BD FACS-Canto II flow cytometer and 
analyzed using BD FACSDiva software (v6.0).  
2.2.17 In vitro tumorsphere formation assay 
The tumorsphere assay was conducted according to previously reported protocols240, 
753. Briefly, cells were harvested at 80% confluence with trypsin digestion and 
resuspended as single cells in DMEM/F12 serum-free media supplemented with B27 
(100 units/mL), Insulin (5 µg/mL), EGF (20 ng/mL), bFGF (20 ng/mL) following 
centrifugation (350 × g for 5 min). Cells were plated into round-bottom 96-well ultra-
low attachment plates at a density of 10, 20 and 50 cells per well respectively for 
tumorsphere formation at 37 °C. After 7-10 days, the formation of tumorspheres were 
visualized by light microscopy. The frequency of cancer stem cells was calculated 
using the Extreme Limiting Dilution Analysis software 
(http://bioinf.wehi.edu.au/software/elda/index.html). For secondary and tertiary 
tumorsphere formation, the first-generation tumorspheres cultured from the ultra-low 
attachment 6-well plate were digested using 0.25% trypsin for 5-7 min at 37 °C 
followed by gentle dispersing. The tubes containing the mixture of spheres and trypsin 
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were placed back in the incubator followed by 5 min incubation and gentle dispersing. 
This process was repeated for 3-5 cycles more until the spheres were sufficiently 
digested when observed under an inverted microscope. The single cell suspension was 
pelleted and re-plated under the same conditions as the first generation.  
2.2.18 Cell surface marker analysis 
For cell surface marker analysis, cells from cell culture were dissociated into single 
cells, washed with PBS containing 0.1% BSA and stained with human-specific 
antibodies to APC/Fire™ 750-conjugated EpCAM (Biolegend), VioBright FITC-
conjugated CD133 (Miltenyl Biotec), BV421-conjugated MDR1 (BD Biosciences) 
and APC-conjugated ABCG2 (BD Biosciences) for 20 min at 4 °C. After thorough 
washing with PBS, the cells were stained with 7-AAD for 5 min and the population of 
liver cancer stem cells (defined as EpCAM+CD133+) and the expression of MDR1 and 
ABCG2 were analyzed using flow cytometer. A minimum of 10,000 events were 
analyzed for each sample from three independent experiments.  
2.2.19 Apoptotic assay  
The TUNEL assay was used for the determination of late-stage cell apoptosis754. The 
apoptotic responses were determined using Click-iT® TUNEL Alexa Fluor® 488 
imaging assay kit according to the manufacturer's protocol (ThermoFisher). In brief, 
cells were fixed with 4% paraformaldehyde for 10 min at room temperature. One 
hundred microliter of cell suspension was moved to a microscope slide, followed by 
washing with 2 changes of PBS. The cells were then incubated with permeabilization 
reagent Triton X-100 (0.25%) for 20 min at room temperature. The Terminal 
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deoxynucleotidyl transferase (TdT) reaction cocktail was applied to the coverslips and 
the cells were incubated for 60 min at 37 °C in a humidified chamber. After being 
washed twice with 3% BSA, the coverslips were incubated with reaction cocktail for 
30 min at room temperature and prevented from light. The reaction cocktail was 
removed and the coverslips were washed with 3% BSA. The coverslips were incubated 
with Hoechst 343342 (2 µg/mL) to stain cell DNA for 15 min at room temperature, 
followed by washed with PBS twice. The cells were visualized with Fluoview FV10i 
laser scanning confocal microscope (Olympus, NSW, Australia). 
The 7-AAD/Annexin V assay was used to determine both the early-stage and late-stage 
apoptosis of cells755. The cells were trypsinized and stained with annexin V (Biolegend, 
1:20 dilution) and 7-AAD (Biolegend, 1:20 dilution) for 15 min at room temperature 
in the dark for the determination of cell apoptosis. The apoptosis of cells was 
determined using flow cytometer.  
2.3 Statistical analysis  
All statistical analyses were performed using GraphPad Prism 6.0 (San Diego, US). 
An unpaired t test was used for comparisons between two experimental groups, and 
one-way analysis of variance (ANOVA) was used for comparisons of more than two 
groups. Unless otherwise indicated, all results were averaged from biological 
triplicates and values are reported as means ± SD. P < 0.05 was considered statistically 
significant. 
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Chapter 3  
Inhibition of MDR1 (ABCB1, P-glycoprotein) sensitizes 
liver cancer stem cells to the treatment of doxorubicin 
3.1 Introduction 
Liver cancer is highly refractory to chemotherapy and has a frequent fatal prognosis. 
First-line treatment includes trans-arterial chemoembolization (TACE) with 
doxorubicin for patients who are in the intermediate stage of the disease, and the 
multikinase inhibitor sorafenib which is the only drug approved for the treatment of 
advanced hepatocellular carcinoma22. However, none of the above treatments are 
curative, which provide an extension of survival of 6.1 and 3 months respectively40, 20.  
It has been shown that, the heterogeneity of liver cancer may occur as a consequence 
of cancer cells being hierarchically organized with a subset of cells, termed cancer stem 
cells, or tumor initiating cells, which are the main culprits of the initiation, propagation, 
metastasis and therapy relapse of tumor90, 91. However, the liver cancer stem cells are 
resistant to many conventional treatments including doxorubicin and sorafenib19, 739, 
756. In order to improve the survival of patients with liver cancer, the liver cancer stem 
cells must be effectively eliminated.  
The over-expression of ATP-binding cassette (ABC) transporters is one of the major 
mechanisms that leads to chemoresistance in liver cancer. The ABC transporters can 
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extrude endogenous substances and exogenous chemicals such as doxorubicin out of 
the cells. Therefore, the insufficient cellular concentration of doxorubicin fails to kill 
cancer cell resulting in treatment relapse. The multidrug resistance protein 1 (MDR1), 
also named ABCB1/P-glycoprotein), has been identified as a ABC transporter for over 
20 year250. Doxorubicin has been shown as the substrate of the MDR1 drug efflux 
pump757. It has been reported that over 80% of liver cancer showed positive expression 
of MDR1254. The expression of MDR1 is inversely related to the response to 
doxorubicin chemotherapy and to overall survival of liver cancer patients251, 256. 
Researchers have reported that inhibition of MDR1 can reverse the chemoresistance of 
liver cancer cells758. The liver cancer stem cells, but not the bulk tumor cells, are 
thought to play a major role in the initiation, propagation and metastasis of the disease.  
However, whether inhibition of MDR1 can sensitize liver cancer stem cells to 
doxorubicin treatment is unknown. The focus of this chapter is to evaluate the 
effectiveness of MDR1 inhibition in killing liver cancer stem cells. To achieve this, 
both pharmacological inhibitor valspodar (PSC833) and RNA interference (RNAi) 
were used to either inhibit MDR1 function or reduce the expression of MDR1 protein. 
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Figure 3.1. Schematic illustration of sensitizing liver cancer stem cells to doxorubicin 
(DOX) by knockdown of MDR1 gene. The liver cancer stem cells have elevated 
expression of MDR1 compared with the bulk cancer cells which may result in the 
chemoresistance of liver cancer stem cells to doxorubicin. Anti-MDR1 siRNA can 
degenerate the mRNA of MDR1 leading to reduced expression of MDR1 protein. By 
doing this, increased amount of doxorubicin can accumulate in the cancer stem cells 
and cause programmed cell death.  
3.2 Results 
3.2.1 Cytotoxicity of doxorubicin and salinomycin 
Doxorubicin is a commonly used chemotherapeutic drug for the treatment of 
hepatocellular carcinoma. Despite its efficacy in killing the bulk liver cancer cells, it 
remains inefficient in eradicating liver cancer stem cells739. Salinomycin has been 
shown by high-throughput screening as a selective agent against cancer stem cells by 
sequestering iron in lysosomes759. In this experiment, salinomycin was used as a 
positive control for the ability of an agent to kill liver cancer stem cells. To clearly 
evaluate the efficacy of aptamer-doxorubicin conjugates treatment in targeting liver 
cancer stem cells, an optimal concentration of the drugs needed to be identified. Firstly, 
the linearity between cell density and absorbance in the MTT assay was examined. As 
shown in Figure 3.2, all the coefficients of determination (R squares) are >0.96, 
indicating good linear relationship between absorbance and cell densities from 0 to 
10000 cells per well. Next, the Huh7 and PLC/PRF/5 cells were treated with a series 
of concentrations of doxorubicin and salinomycin at 24, 48 and 72 hours respectively 
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and the cell viability were determined. The IC50 was calculated by non-linear 
regression analysis via transforming the drug concentrations to their corresponding 
logarithm values (Table 3.1). In the two liver cancer cell lines, the cytotoxicity of both 
doxorubicin and salinomycin increased with higher concentrations of drugs and longer 
incubation time as shown in Figure 3.3. Therefore, we used 200 nM and 100 nM of 
doxorubicin for Huh7 and PLC/PRF/5 cells respectively, and 2 µM and 0.6 µM of 
salinomycin for Huh7 and PLC/PRF/5 cells respectively in subsequent tumorsphere 
assays. 
 
Figure 3.2. The linear relationship between different cell densities of (A) Huh7 and 
(B) PLC/PRF/5 cells and their absorbance. Data shown are means ± SD, (n = 3). 
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Figure 3.3. Effect of doxorubicin (DOX) and salinomycin (SAL) on the cell viability 
of Huh7 and PLC/PRF/5 assessed by the MTT assay. Both DOX and SAL inhibited 
the viability of Huh7 and PLC/PRF/5 cell lines in a dose-dependent and time-
dependent manner. Data shown are means ± SD, (n = 3).   
 
Table 3.1. IC50
 of doxorubicin (DOX) and salinomycin (SAL) on Huh7 and 
PLC/PRF/5 at 24, 48 and 72 hours.a 
Cell line Treatment 
IC50 24 h 
(µg/ml) 
IC50 48 h 
(µg/ml) 
IC5072 h 
(µg/ml) 
Huh7 
DOX 2.84 ± 1.66 0.12 ± 0.05 0.04 ± 0.01 
SAL 4.60 ± 1.61 1.61 ± 0.59 1.32 ± 0.39 
PLC/PRF/5 
DOX 1.45 ± 0.58 0.34 ± 0.11 0.14 ± 0.04 
SAL 6.17 ± 1.81 0.47 ± 0.05 0.23 ± 0.06 
aData shown are means ± SD, (n = 3) 
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3.2.2 Cytotoxicity of MDR1 inhibitors valspodar and verapamil in liver cancer 
cells 
Two pharmacological MDR1 inhibitors were used in the study. Verapamil is a calcium 
channel blocker which has been used in clinics to treat hypertension, angina 
and  supraventricular tachycardia. It has been identified as a MDR1 inhibitor with 
capacity to enhance intracellular accumulation of many anti-cancer agents including 
doxorubicin in various cancer cell lines536. Valspodar (PSC833) is a second-generation 
MDR1 inhibitor with high specificity to the MDR1 protein over other drug efflux 
pumps such as the ATP-biding cassette G sub-family G member 2 (ABCG2, BCRP) 
and ATP-biding cassette G sub-family C member 1 (ABCC1, MRP1). It was also 
reported that valspodar not only inhibits MDR1, but also transcriptionally 
downregulates ABCB1 expression554. 
In order to optimize the concentration of MDR1 inhibitors in the experiment, the 
cytotoxicity of MDR1 inhibitor valspodar and verapamil in liver cancer cells was 
determined by MTT assay. In brief, the Huh7 and PLC/PRF/5 cells were treated with 
a serial concentration of verapamil and valspodar for 48 hours. Verapamil was shown 
to display toxicity to Huh7 and PLC/PRF/5 liver cancer cells at 20 µM and 100 µM 
respectively while valspodar didn’t show any toxicity to both the two cell lines even 
with a concentration as high as 10 µM (Figure 3.4). 
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Figure 3.4. The viability of Huh7 and PLC/PRF/5 cells after 48 hours’ treatment of 
different concentrations of verapamil and valspodar respectively using MTT assay. 
Verapamil with a concentration from 20 µM to 100 µM caused cytotoxicity in huh7 
and PLC/PRF/5 cells while valspodar revealed minimum cytotoxicity with a 
concentration as high as 10 µM. Data shown are means ± SD, (n = 3). *p<0.05; 
***p<0.001; ****p<0.0001; compared with the PBS control.  
3.2.3 Measurement of MDR1 functionality by calcein-AM inhibition assay 
Calcein-AM is a non-fluorescent, hydrophobic MDR1 substrate which diffuses into 
intact cells through passive diffusion. It is converted by intracellular esterases to 
fluorescent calcein which is well-retained in the cell cytoplasm. In the presence of 
MDR1 inhibitor (e.g., verapamil or valspodar), more calcein-AM is retained in the cells 
leading to increased formation of calcein therefore the fluorescence increases (Figure 
3.5). The fluorescence can be determined by plate reader. 
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Figure 3.5. The principle of measuring MDR1 function with calcein-AM assay. 
Calcein-AM can be converted to fluorescent calcein in viable cells. The presence of 
MDR1 inhibitors blocks the extrusion of calcein-AM leading to increased formation 
of fluorescent calcein. 
 
The functionality of MDR1 protein was determined in two liver cancer cell lines Huh7 
and PLC/PRF/5 (Figure 3.6). It was found that different concentrations of valspodar 
(1-10 µM) and verapamil (10-100 µM) can facilitate the formation of calcein. However, 
the fluorescence decreased after treatment of 50 µM and 100 µM of verapamil in Huh7 
cells, which was likely due to the toxicity of verapamil. In the valspodar treatment 
group, cells treated with 1 µM or 2 µM of valspodar have similar fluorescence increase. 
Therefore, having considered the potential toxicity of verapamil and valspodar, a 
concentration of 10 µM of verapamil and 1 µM of valspodar was used in all subsequent 
experiments.  
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Figure 3.6. The functionality of MDR1 in the liver cancer cell lines. The cells were 
plated in black 96-well plates and treated with varied concentrations of verapamil and 
valspodar respectively for 1 hour followed by incubation of calcein-AM for 30 min. 
The fluorescence of calcein was detected using a plate reader with wavelength of 
excitation/emission of 485/535 nm. The results showed that 10 µM of verapamil or 1 
µM of valspodar significantly increased the fluorescence calcein in Huh7 and 
PLC/PRF/5 cells. Data shown are means ± SD. (n = 3). ***p<0.001; ****p<0.0001; 
compared with PBS treatment. 
3.2.4 The expression of EpCAM and CD133 at the plasma membrane of liver 
cancer cells 
The expression of the cancer stem cell markers EpCAM and CD133 was determined 
using flow cytometry as shown in Figure 3.7. The first gating strategy is to find viable, 
single cell events using forward scatter (SSC) and side scatter (SSC) to exclude debris, 
dead cells or doublets. The cellular debris is often FSC-low, while dead cells are FSC-
low and SSC-high than viable cells. Figure 3.7 A showed the gating strategy to exclude 
unwanted events with low FSC and high SSC. EpCAM and CD133 were co-expressed 
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in both the Huh7 and PLC/PRF/5 cells. The majority of Huh7 cells express EpCAM 
(>90%) while in PLC/PRF/5 cells its expression is low (Figure 3.7 B). The expression 
of CD133 in Huh7 cells is also higher than that in PLC/PRF/5 cells ((Figure 3.7 C). 
Less than 1% of PLC/PRF/5 cells was found to express both EpCAM and CD133, 
while 45% of Huh7 cells was found to co-expressed EpCAM and CD133 
(EpcCAM+CD133+) (Figure 3.7 D). As a control of non-specific binding of 
fluorophore-labelled antibodies to cells, the corresponding isotope control IgG proteins 
labeled with the same fluorochromes were used. As shown in Figure 3.7 E, over 99.9% 
of the cells exhibited negligible binding to the isotype-matched negative control 
antibodies, indicating the antibodies used in the experiment is highly specific. 
Figure 3.7. The expression of EpCAM and CD133 in the Huh7 and PLC/PRF/5 cells. 
(A) The gating of viable and single cells using forward scatter (FSC) and side scatter 
(SSC). (B) The percentage of EpCAM-expressing cells in the Huh7 and PLC/PRF/5 
cells. (C) The percentage of CD133-expressing cells in the Huh7 and PLC/PRF/5 cells. 
(D) The percentage of EpCAM+CD133+ cells in the Huh7 and PLC/PRF/5 cells. (E) 
The Huh7 and PLC/PRF/5 cells were stained with isotope-matched control antibodies. 
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The negative control antibodies showed minimum binding to the cells. Horizontal and 
vertical axes denote expression intensity. One representative experiment of three is 
shown.  
3.2.5 The expression of MDR1 in the bulk tumor population and EpCAM+CD133+ 
population of the liver cancer cells 
MDR1 in the bulk tumor population and the EpCAM+CD133+ cancer stem cell 
population of liver cancer cells was determined using flow cytometry as shown in 
Figure 3.8. The percentage of MDR1-expressing is more than 15% in Huh7 cells but 
less than 1% in PLC/PRF/5 cells (Figure 3.8 A). In the EpCAM+CD133+ cancer stem 
cell population, the expression of MDR1 increased in both Huh7 and PLC/PRF/5 cells 
(Figure 3.8 C). MDR1 expression increased dramatically in the EpCAM+CD133+ 
PLC/PRF/5 cells compared with that in the bulk tumor population. Figure 3.8 (B) 
showed that the isotope control antibodies have only minimum binding to these two 
liver cancer cells.  
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Figure 3.8. The expression of MDR1 in Huh7 and PLC/PRF/5 cells. (A) The 
percentage of MDR1 expression in Huh7 and PLC/PRF/5 cells. (B) The isotope-
matched antibody control showed minimum binding to either the Huh7 or PLC/PRF/5 
cells. (C) The expression of MDR1 in the EpCAM+CD133+ cancer stem cell population 
of Huh7 and PLC/PRF/5 cells. One representative experiment of three is shown.  
3.2.6 MDR1 siRNAs transfection 
Pharmacological inhibitors have off-target effect. For example, besides inhibiting 
MDR1 drug efflux pump, verapamil and valspodar inhibit other drug pumps like 
ABCG2 and MRP1. To further confirm the role of MDR1 in the resistance of liver 
cancer cells to doxorubicin, anti-MDR1 siRNA was used. The siRNA used was derived 
from a previously published 21-mer which was confirmed to have a high knockdown 
efficiency760, and was extended to 27-mer dicer substrate siRNA for this study to 
enhance the silencing efficiency747, 761. The scrambled siRNA has the same 
composition of nucleotide as the MDR1 siRNA but lacks significant sequence 
homology to the human genome. The scrambled siRNA was designed using the 
InvivoGen online tool (http://www.invivogen.com/sirnawizard/scrambled.php) and 
verified using BLAST software tool (https://blast.ncbi.nlm.nih.gov/Blast.cgi). After 
incubated with MDR1 siRNA (20 nM) or scrambled siRNA (20 nM) for 6 hours, the 
medium was refreshed with cell culture medium and the cells were cultured for another 
42 hours. The silencing efficacy of the MDR1 siRNA was tested on Huh7 and 
PLC/PRF/5 cells at both RNA level using quantitative PCR and protein level using 
immunoblotting analysis. A reduction of 77% and 79% knockdown efficiency at RNA 
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level 74% and 65% knockdown efficiency at protein level was achieved in Huh7 and 
PLC/PRF/5 cells respectively (Figure 3.9). 
 
Figure 3.9. The knockdown efficacy of MDR1 siRNA. The 27-mer anti-MDR1 siRNA 
induced over 75% knockdown at RNA level in Huh7 and PLC/PRF/5 cells as 
determined by quantitative PCR (A and B) and over 65% knockdown at protein level 
as determined by Western blotting analysis in Huh7 (C and E) and PLC/PRF/5 cells 
(D and F). Data shown are means ± SD. (n = 3). 
3.2.7 MDR1 inhibitors or anti-MDR1 siRNA can facilitate the uptake of 
doxorubicin into liver cancer cells 
The capacity of MDR1 inhibitors to facilitate the uptake of doxorubicin was analyzed 
semi-quantitatively using confocal microscopy. The liver cancer cells Huh7 and 
PLC/PRF/5 were plated on the 8-chamber slides and incubated in cell culture medium 
for 24 hours. The Huh7 and PLC/PRF/5 cells were treated with MDR1 inhibitor 
verapamil (10 µM) or valspodar (1 µM) at 37 °C for 1 hour followed by incubation 
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with doxorubicin (400 nM) for 40 min and visualized using confocal microscopy. 
Following 40 min incubation, stronger doxorubicin fluorescence was observed in the 
valspodar plus doxorubicin or verapamil plus doxorubicin treatment groups than the 
doxorubicin group in both the Huh7 and PLC/PRF/5 cell lines (Figure 3.10). 
 
Figure 3.10. The effectiveness of MDR1 inhibitors valspodar and verapamil in 
facilitating the internalization of doxorubicin. The Huh7 (A) and PLC/PRF/5 (B) cells 
were treated with MDR1 inhibitor verapamil (10 µM) or valspodar (1 µM) at 37 °C for 
1 hour followed by incubation with doxorubicin (400 nM) for 40 min and visualized 
using confocal microscopy. (C) Quantification analysis of MDR1 inhibitor valspodar 
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or verapamil in facilitating doxorubicin internalization in Huh7 and PLC/PRF/5 cells. 
Scale bar is 20 µm. ****p<0.0001, compared with those treated with doxorubicin. Data 
shown are means ± SD. (n = 3).  
 
Having determined the cellular accumulation of doxorubicin semi-quantitatively, we 
sought for quantitative determination of valspodar or MDR1 knockdown in facilitating 
the uptake of doxorubicin in liver cancer cells. Four treatments were performed in this 
experiment. In two of the four groups, MDR1 was knocked down as was described in 
3.2.6, and the scrambled siRNA was used as a control. In the other two groups, cells 
were treated with PBS or MDR1 inhibitor valspodar (1 µM) for 1 hour. The cells in 
the four groups were treated with doxorubicin (100 nM) for three hours, followed by 
being trypsinized and washed with PBS for 3 times prior to being lysed with cell lysate 
buffer. Then acetonitrile containing the internal standard daunorubicin was added into 
each sample to precipitate protein. After vortexing and centrifuging, the supernatant 
was injected into the HPLC system. 
The analytical method was successfully established and the specificity and linear range 
were validated. The HPLC condition includes a fluorescence detector with 485 nm 
(ex)/575 nm (em), mobile phase containing acetonitrile and phosphate buffer (10 mM, 
pH 2.2) with a ratio of 27:73 (v:v) and a reverse phase Waters Novapak C18 column. 
Figure 3.11 showed the selectivity of the method for the detection of doxorubicin. The 
blank cell lysate spiked with the internal standard daunorubicin (100 nM) in the 
absence or presence of doxorubicin (10 nM). The endogenous substances did not 
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interfere with the peak of doxorubicin. The calibration curves were established over a 
range of 2-30 nM.  
 
Figure 3.11. Representative chromatograms of blank cell lysate spiked with the 
internal standard daunorubicin (DAU) (100 nM) in the absence or presence of 
doxorubicin (DOX) (10 nM). Doxorubicin and daunorubicin were eluted at 4.0 min 
and 6.7 min respectively. The endogenous substances showed no interference with the 
peak of doxorubicin. Doxorubicin and daunorubicin were well separated.  
 
The results showed that both valspodar and siRNA treatment significantly increased 
the cellular concentration of doxorubicin in Huh7 by more than 69.1% and 15.8% in 
PLC/PRF/5 cells compared with doxorubicin treatment (p<0.05) (Figure 3.12). The 
treatment of scrambled siRNA did not affect the accumulation of doxorubicin 
(p>0.05). 
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Figure 3.12. Valspodar or MDR1 siRNA facilitates the internalization of doxorubicin 
in Huh7 and PLC/PRF/5 cells. (A) and (B) The cells were treated with doxorubicin 
(100 nM) or doxorubicin (100 nM) plus valspodar (1 µM) for 3 hours. (C) and (D) The 
cells were incubated with MDR1 siRNA (20 nM) for 6 hours and the cell culture 
medium was refreshed followed by 42 hours’ incubation with full cell culture medium. 
Then doxorubicin was added into the cells followed by 3 hours’ incubation. The cells 
were washed 3 times with PBS and lysed with cell lysate buffer. The cell lysate was 
treated with acetonitrile for protein precipitation and the supernatant was injected into 
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the HPLC system. *p<0.05; **p<0.01; ****p<0.0001 compared with those treated 
with doxorubicin. Data shown are means ± SD. (n = 3).  
3.2.8 Determination of self-renewal of liver cancer stem cells by tumorsphere 
formation assay 
Having established that the MDR1 inhibitor valspodar or the knockdown of MDR1 can 
facilitate the internalization of doxorubicin into liver cancer cells, we sought to 
evaluate the effect of MDR1 inhibition on impairing the self-renewal of liver cancer 
stem cells. The Huh7 and PLC/PRF/5 cells were treated with PBS, salinomycin, MDR1 
siRNA, scrambled control siRNA, valspodar, doxorubicin, doxorubicin plus valspodar, 
doxorubicin plus MDR1 siRNA or doxorubicin plus scrambled control siRNA. The 
concentration of siRNAs was 20 nM; doxorubicin concentration was 100 nM 20 
PLC/PRF/5 cells and 200 nM to Huh7 cells; valspodar concentration was 1 µM; 
salinomycin concentration was 2 µM to Huh7 cells and 0.6 µM to PLC/PRF/5 cells. 
After treatment of 48 hours, the cells were harvested and plated in stem cell culture 
media in ultra-low attachment 96 plates with 50, 20 and 10 cells per well respectively. 
The formation of tumorsphere was visualized using light microscopy after 5-7 days.  
The typical morphology of tumorspheres was shown in Figure 3.13. The treatment of 
MDR1 inhibitor verapamil or valspodar, MDR1 and scrambled siRNA respectively did 
not decrease the cancer stem cell frequency in both the Huh7 and PLC/PRF/5 cell lines 
compared with PBS treatment (p>0.05). In contrast, the addition of verapamil or 
valspodar to doxorubicin treatment resulted in the decrease of the cancer stem cell 
frequency by more than 90.8% (p<0.001), while the addition of MDR1 knockdown to 
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doxorubicin showed more than 58.1% decrease (p<0.05) in the Huh7 and PLC/PRF/5 
cells compared with doxorubicin (Figure 3.14). The positive control treatment 
salinomycin showed strong efficacy in impairing the self-renewal of liver cancer stem 
cells resulting a cancer stem cell frequency of less than 0.3% in Huh7 and PLC/PRF/5 
cells demonstrating the validity of the method. These data indicate that the increased 
accumulation of doxorubicin in liver cancer cells translates into effective 
pharmacological outcome of eliminating liver cancer stem cells in both Huh7 and 
PLC/PRF/5 cells. 
 
3.13. Representative tumorsphere images derived from (A) Huh7 and (B) PLC/PRF/5 
cells. The liver cancer cells were grown in serum-free, non-adherent conditions for the 
enrichment of cancer stem cells as only the cancer stem cells can survive and 
proliferate in this environment by self-renewal while differentiated cells undergo 
necrosis. A tumorsphere is defined as a solid, round structure with a clear border and 
a diameter of over 50 µm. 
  
 
130 
 
Figure 3.14. The percentage of tumorsphere formation after 5-7 days culture in serum-
free and non-adherent conditions. (A) and (B) The addition of verapamil (10 µM) or 
valspodar (1 µM) to doxorubicin (200 nM to Huh7, 100 nM to PLC/PRF/5) 
significantly reduced cancer stem cell (CSC) frequency compared with doxorubicin 
treatment (***p<0.001). (C) and (D) The treatment of MDR1 siRNA plus doxorubicin 
significantly reduced cancer stem cells frequency in Huh7 cells (**p<0.01) and in 
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PLC/PRF/5 cells (*p<0.05) compared with that treated with doxorubicin. Data shown 
are means ± SD. (n = 3).  
3.2.9 Detection of apoptosis and cellular accumulation of doxorubicin in the whole 
population and the EpCAM+CD133+ liver cancer stem cell population using flow 
cytometry 
Doxorubicin is known to induce apoptosis via intercalating between neighboring DNA 
base pairs and poisoning the topoisomerase II52, 55. We have established that MDR1 
inhibition can facilitate the internalization of doxorubicin into liver cancer cells and 
can sensitize liver cancer stem cells to doxorubicin treatment. In this study, we 
investigated the efficacy of MDR1 inhibition to enhance apoptosis induced by 
doxorubicin in the bulk tumor and cancer stem cell population of liver cancer cells. 
The capacity of combined treatment of MDR1 inhibition and doxorubicin to induce 
apoptosis was evaluated by 7-AAD/Annexin V assay using flow cytometric method. 
7-AAD (7-amino-actinomycin D) and Pacific Blue-conjugated Annexin V are standard 
methods for the detection of apoptosis progression. 7-AAD is a nucleic acid dye which 
can be efficiently excluded by intact cells. Therefore, it is used for dead cell 
discrimination during flow cytometry analysis. In viable cells, phosphatidylserine (PS) 
is located on the inside of the plasma membrane. During apoptosis, PS residues flip 
from the inside to the outside of the cell membrane, and can be detected by Annexin 
V, which is a phospholipid-binding protein. Viable cells are 7-AAD-negative and 
Annexin V-negative (7-AAD-/Annexin V-); early apoptotic cells are 7-AAD-negative 
and Annexin V-positive (7-AAD-/Annexin V+); late apoptotic cells are 7-AAD-
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positive and Annexin V-positive (7-AAD+/Annexin V+); and damaged cells are 7-
AAD-positive and Annexin V-negative (7-AAD+/Annexin V-). The cells in the early 
and late stages of apoptosis respectively were considered as the apoptotic cells. The 
cellular accumulation of doxorubicin can be detected in PE channel using flow 
cytometry. 
Figure 3.15 showed the percentage of apoptotic cells from the bulk cell population 
after treatment with doxorubicin, doxorubicin plus MDR1 inhibition and the 
corresponding controls. It was found that compared with doxorubicin, the addition of 
MDR1 inhibition with siRNA or pharmacological inhibitor valspodar significantly 
increased the percentage of apoptotic cells by more than 90.5% and 79.0% respectively 
(p<0.01). The treatment of siRNA or valspodar alone did not increase the percentage 
of apoptotic cells compared with PBS treatment (p>0.05). 
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Figure 3.15. The contour diagram of 7-AAD/Annexin V flow cytometry. (A) Huh7 
cells and (C) PLC/PRF/5 cells were treated with doxorubicin (100 nM), doxorubicin 
(100 nM) plus MDR1 knockdown (20 nM of siRNA), doxorubicin (100 nM) plus 
MDR1 inhibitor valspodar (1 µM) and the corresponding controls for 24 hours. Lower 
left quadrants indicate viable cells (7-AAD-/Annexin V-); lower right quadrants 
indicate early apoptotic cells (7-AAD-/Annexin V+); upper right quadrants contain late 
apoptotic cells (7-AAD+/Annexin V+). One representative experiment of three is 
shown. The percentage of Huh7 and PLC/PRF/5 cells in the upper right quadrant and 
lower right quadrant were considered as the total apoptotic cells and were shown in (B) 
and (D) respectively. Data shown are mean ± SD, n = 3. **p<0.01; ****p<0.0001. 
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The cellular doxorubicin accumulation in the bulk population of Huh7 and PLC/PRF/5 
cells was determined as shown in Figure 3.16. Knockdown of MDR1 by siRNA or 
inhibition of valspodar enhanced the cellular accumulation of doxorubicin by more 
than 2.73-fold in Huh7 cells and 0.91-fold in PLC/PRF/5 cells (p<0.0001). 
 
Figure 3.16. Flow cytometric measurement of doxorubicin accumulation in (A) Huh7 
and (C) PLC/PRF/5 cells. The cells were treated with doxorubicin (100 nM), 
doxorubicin (100 nM) plus MDR1 knockdown (20 nM of siRNA), doxorubicin (100 
nM) plus MDR1 inhibitor valspodar (1 µM) and the corresponding controls for 24 
hours. One representative experiment of three is shown. The fluorescence intensity of 
doxorubicin in Huh7 and PLC/PRF/5 cells were shown in (B) and (D) respectively. 
Data shown are mean ± SD, n = 3. ****p<0.0001. 
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The percentage of apoptotic cells in the EpCAM+CD133+ cancer stem cell population 
of the Huh7 and PLC/PRF/5 cells was analyzed and shown in Figure 3.17. It was found 
that the addition of MDR1 siRNA or valspodar significantly increased the percentage 
of apoptotic cells by more than 2.8-fold in the two cell lines (p<0.0001). It is worth 
noting that the EpCAM+CD133+ population of the two types of cells are more resistant 
than their bulk population to doxorubicin treatment (p<0.01). However, the combined 
treatment of doxorubicin and MDR1 inhibition with either siRNA or valspodar has 
resulted in similar percentage of apoptotic cells in the bulk and EpCAM+CD133+ 
population of the two types of liver cancer cells ((p>0.05), indicating that the inhibition 
of MDR1 drug efflux pump can significantly potentiate the efficacy of doxorubicin in 
eliminating liver cancer stem cells. 
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Figure 3.17. The contour diagram of 7-AAD/Annexin V flow cytometry of the 
EpCAM+CD133+ subpopulation of Huh7 cells (A) and PLC/PRF/5 cells (C) with 
doxorubicin (100 nM), doxorubicin (100 nM) plus MDR1 knockdown (20 nM of 
siRNA), doxorubicin (100 nM) plus MDR1 inhibitor valspodar (1 µM) and the 
corresponding controls for 24 hours. One representative experiment of three is shown. 
Lower left quadrants indicate viable cells (7-AAD-/Annexin V-); lower right quadrants 
indicate early apoptotic cells (7-AAD-/Annexin V+); upper right quadrants contain late 
apoptotic cells (7-AAD+/Annexin V+). One representative experiment of three is 
shown. The percentage of Huh7 and PLC/PRF/5 cells in the upper right quadrant and 
lower right quadrant were considered as the total apoptotic cells and were shown in (B) 
and (D) respectively. Data shown are mean ± SD, n = 3. ****p<0.0001. 
 
The accumulation of doxorubicin in the EpCAM+CD133+ population of Huh7 and 
PLC/PRF/5 cells has been studied as shown in Figure 3.18. The results showed that 
doxorubicin accumulation was increased after the treatment with doxorubicin plus 
MDR1 siRNA or inhibitor valspodar by 4.6 and 2.1-fold in Huh7 and PLC/PRF/5 
cancer stem cells respectively compared with doxorubicin treatment. The cellular 
concentration of doxorubicin in the EpCAM+CD133+ population of Huh7 and 
PLC/PRF/5 cells were lower than that in the bulk tumor population (p<0.05) which is 
likely due to the increased expression of MDR1 in the EpCAM+CD133+ population in 
Huh7 and PLC/PRF/5 cells (Figure 3.8). 
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Figure 3.18. Flow cytometric measurement of doxorubicin accumulation in the 
EpCAM+CD133+ population of (A) Huh7 and (C) PLC/PRF/5 cells. The cells were 
treated with doxorubicin (100 nM), doxorubicin (100 nM) plus MDR1 knockdown (20 
nM of siRNA), doxorubicin (100 nM) plus MDR1 inhibitor valspodar (1 µM) and the 
corresponding controls for 24 hours. One representative experiment of three is shown. 
The fluorescence intensity of doxorubicin in Huh7 and PLC/PRF/5 cells were shown 
in (B) and (D) respectively. Data shown are mean ± SD, n = 3. ****p<0.0001. 
3.3 Conclusion and discussion 
This chapter is aiming at elucidating the role of MDR1 protein in the chemoresistance 
of liver cancer stem cells to doxorubicin. Two approaches were used to inhibit the 
MDR1 efflux pump: the anti-MDR1 siRNA can reduce the expression the MDR1 
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protein while the pharmacological inhibitor valspodar can inhibit the function of 
MDR1 protein in a non-competitive manner762. The results revealed that inhibition of 
MDR1 can facilitate the internalization of doxorubicin, enhance doxorubicin-induced 
apoptosis in both the bulk and EpCAM+CD133+ population of Huh7 and PLC/PRF/5 
cells. More importantly, such effects can translate into effective pharmacological 
outcome: the combination of MDR1 inhibition and doxorubicin significantly reduced 
the frequency of liver cancer stem cells using tumorsphere assay.  
The concentrations of these two compounds used in this study were carefully titrated 
so that they are capable of inhibiting MDR1 function with minimum cytotoxicity and 
non-specificity, otherwise interpreting the assays to detect apoptosis and doxorubicin 
accumulation can be difficult. The cytotoxicity and MDR1 functionality studies 
showed valspodar generated only minimum toxicity to the two types of liver cancer 
cells even at a concentration of 10 µM. In addition, the MDR1 functionality test 
indicated that high concentration of valspodar seems to be more potent in inhibiting 
MDR1 function especially in the PLC/PRF/5 cell. However, in this study, 1 µM, but 
not 10 µM of valspodar is used due to two considerations. First, it has been reported 
that valspodar itself can reduce tumor burden in a liver cancer bearing rat model, 
indicating the capacity of valspodar as an intrinsic anti-tumor substance but not only a 
chemo-sensitizer763. Second, although commonly considered as a selective MDR1 
inhibitor, a high concentration of valspodar can inhibit MRP1 function764. The MTT 
assay also indicated that verapamil can be toxic to liver cancer cells from 20 µM to 
100 µM. In addition, verapamil is also a weak inhibitor of ABCG2765. Therefore, 1 µM 
of valspodar and 10 µM of verapamil, respectively, were used in this study. 
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The Annexin V assay is a standard method for the detection of apoptotic cells. 
Propidium iodide (PI) and 7-AAD are the most commonly used reagents for the 
exclusion of nonviable cells in flow cytometric assays. In this study, 7-AAD is used 
because the fluorescence of PI overlaps with the fluorescence of doxorubicin. In 
addition, researchers have found that unlike PI, 7-AAD did not leach from cells and its 
fluorescence remained stable for a longer time766. In viable cell, the phosphatidylserine 
(PS) is on the inside of the plasma membrane. During apoptosis, the PS residues flip 
from the inside to the outside of the cell membrane, and can be detected by 
fluorescence-labeled Annexin V which is a cellular protein. Early apoptotic cells have 
intact plasma membrane which can exclude 7-AAD, while late apoptotic cells have 
lost their membrane integrity and can be stained with 7-AAD. As a standard way to 
analysis the capacity of drugs to induce cell apoptosis, in this study, the percentage of 
cells in either the early stage or late stage apoptosis were added to represent the whole 
population of apoptotic cells. It has been reported that PS exposure is a universal 
phenomenon during apoptosis as ubiquitous as apoptosis itself and constitutes an 
integral part of programmed cell death767. Therefore, in this study, the cells appeared 
in the first quadrant of the contour diagram flow cytometry results which have 7-
AAD+/Annexin V- staining are damaged cells but not apoptotic cells due to their 
inability to be stained with Annexin V. 
In summary, the data obtained in this chapter provides evidence for a strategy to 
overcome the resistance of liver cancer stem cells to doxorubicin by inhibition of 
MDR1.  Following treatment of anti-MDR1 siRNA or MDR1 inhibitor valspodar, the 
innate chemoresistance of liver cancer stem cells was reversed, leading to increased 
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cellular accumulation of doxorubicin, enhanced apoptosis, and sensitization to 
doxorubicin. 
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Chapter 4  
Inhibition of ABCG2 (BCRP) sensitizes liver cancer stem 
cells to the treatment of doxorubicin 
4.1 Introduction 
ATP-binding cassette (ABC) sub-family G member 2 (ABCG2), also called breast 
cancer resistance protein (BCRP), is one member of the ABC transporters responsible 
for drug resistance. It was reported that the expression of ABCG2 is higher in 
hepatocellular carcinoma than in adjacent normal tissue of patients, but its expression 
is scanty in hepatocellular carcinoma cell lines and patient hepatocellular carcinoma 
tissues147, 287. Although ABCG2 expression in liver cancer cells is not as high as the 
the expression of MDR1 which was found in over 80% of liver cancer, it is correlated 
with differentation stage in human patient liver cancer tissues and liver cancer cell lines. 
Doxorubicin is the substrate of ABCG2 drug efflux pump. The exposure to 
doxorubicin resulted in enrichment of ABCG2-expression liver cancer cells287. It was 
revealed that  ABCG2 served as a determinant of the side population (SP) cells, and 
stem cells from ABCG2-deficient mice were more sensitive to mitoxantrone which is 
an ABCG2 substrate292, 293. Furthermore, researchers have reported that ABCG2 is a 
liver cancer stem cell marker147. Therefore, inhibition of ABCG2 may reverse the 
resistance of liver cancer stem cells to doxorubicin treatment. This chapter focuses on 
evaluating the effectiveness of ABCG2 inhibition in eliminating liver cancer stem cells. 
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To achieve this, both anti-ABCG2 siRNA and pharmacological inhibitor ko143 were 
used. 
4.2 Results 
4.2.1 Measurement of ABCG2 functionality by Hoechst 33342 inhibition assay 
The Hoechst 33342 dye accumulation assay was used to evaluation the functionality 
of ABCG2 protein. Hoechst 33342 is a hydrophobic, cell-permeable dye which is the 
substrate actively extruded by ABCG2 drug efflux pump147. It becomes fluorescent 
only in a complex with DNA. The cells were incubated in the absence or presence of 
the specific ABCG2 inhibitor ko143 for 30 min prior to treatment with Hoechst 33342 
for 2 hours. The human lung carcinoma cell line A549, which is known to highly 
express ABCG2, is used as a positive control. The results showed that liver cancer cell 
PLC/PLF/5 exhibited strongest ABCG2 activity among the three cell lines, while Huh7 
showed the weakest ABCG2 activity and the lung carcinoma A549 cell line, which 
was used as a positive control for ABCG2-expressing cells, exhibited moderate 
ABCG2 activity (Figure 4.1). 
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Figure 4.1. Measurement of ABCG2 functionality. Cells were pre-treated with a series 
concentration of ko143 for 30 min prior to being incubated with 10 µM Hoechst 33342 
for 2 hours. The Hoechst 33342 was removed and its fluorescence was determined by 
plate reader with an excitation/emission wavelength of 355/460 nm. The relative 
fluorescence intensity of Hoechst was defined as the ratio of the Hoechst fluorescence 
of ko143 treated cells to untreated cells and was expressed as percentage increase. Data 
shown are means ± SD, (n = 3). ****p<0.0001 compared with untreated cells. 
4.2.2 The expression of ABCG2 in the bulk tumor population and 
EpCAM+CD133+ population of the liver cancer cells 
The expression of the ABCG2 in the bulk tumor population and the EpCAM+CD133+ 
cancer stem cell population of liver cancer cells was determined using flow cytometry 
and shown in Figure 4.2. The percentage of ABCG2-expressing cells was lower in 
Huh7 cells line (5.39%) compared with in PLC/PRF/5 (16.6%) (Figure 4.2 A).  In 
contrast, in the EpCAM+CD133+ cancer stem cell population, the expression of 
ABCG2 dramatically increased in both Huh7 and PLC/PRF/5 cells by 1.6- and 2.5-
fold, respectively (Figure 4.2 C). Figure 4.2 B showed that the isotope control has only 
minimum binding to these two liver cancer cells. 
  
 
144 
 
 
Figure 4.2. The expression patterns of ABCG2. (A) and (C) The percentage of 
ABCG2-positive cells was determined in the PLC/PRF/5 cells and Huh7 cells in both 
the bulk population and EpCAM+CD133+ cancer stem cell population. (B) The isotope 
control showed minimum binding to the cells. One representative experiment of three 
is shown. 
4.2.3 ABCG2 siRNAs transfection 
This experiment is to determine the knockdown efficacy of ABCG2 siRNA in Huh7 
and PLC/PRF/5 cells. After incubated with ABCG2 siRNA (20 nM) or scrambled 
siRNA (20 nM) for 6 hours, the medium was refreshed with cell culture medium and 
the cells were cultured for another 42 hours. The silencing efficacy of the ABCG2 
siRNA was tested on Huh7 and PLC/PRF/5 cells at both RNA level using quantitative 
PCR and protein level using immunoblotting analysis. An 81.5% and 71.4% reduction 
in ABCG2 RNA in Huh7 and PLC/PRF/5 cells were achieved respectively (Figure 4.3 
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A). At protein level, a reduction of 72.2% and 74.0% was evident by Western blot 
analysis in Huh7 and PLC/PRF/5 cells, respectively (Figure 4.3 B and C). 
 
Figure 4.3. The knockdown efficacy of ABCG2 siRNA in Huh7 and PLC/PRF/5 cells. 
Treatment with 20 nM ABCG2 siRNA resulted in efficient ABCG2 knockdown by >70% 
at RNA level determined by quantitative-PCR (A and B) and protein level as 
determined by immunoblotting analysis (C-F). Data shown are means ± SD, (n = 3). 
****p<0.0001 compared with PBS and scrambled control groups. 
 
4.2.4 ABCG2 Inhibitor ko143 or anti-ABCG2 siRNA facilitates the 
internalization of doxorubicin into liver cancer cells 
As an alternative approach of verifying the role of ABCG2 in chemoresistance, the 
functional outcome of inhibition of ABCG2 via a pharmacological inhibitor ko143 was 
studied. To this end, the Huh7 and PLC/PRF/5 cells were plated on an 8-chamber slides 
and allowed to grow for 24 hours. The liver cancer cells Huh7 and PLC/PRF/5 were 
plated on the 8-chamber slides and incubated in cell culture medium for 24 hours. The 
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Huh7 and PLC/PRF/5 cells were treated with ABCG2 inhibitor ko143 (1 µM) at 37 °C 
for 1 hour followed by incubation with doxorubicin (400 nM) for 40 min and visualized 
using confocal microscopy. As shown in Figure 4.4, stronger doxorubicin fluorescence 
was observed in the cells treated with ko143 plus doxorubicin than doxorubicin.  
 
Figure 4.4. The effectiveness of ABCG2 inhibitor ko143 to facilitate the 
internalization of doxorubicin. The liver cancer cells Huh7 and PLC/PRF/5 were plated 
on the 8-chamber slides in incubated in cell culture medium for 24 hours. The Huh7 
and PLC/PRF/5 cells were treated with ABCG2 inhibitor ko143 (1 µM) at 37 °C for 1 
hour followed by incubation with doxorubicin (400 nM) for 40 min and visualized 
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using confocal microscopy. (C) Quantification analysis of ABCG2 inhibitor ko143 in 
facilitating doxorubicin internalization in Huh7 and PLC/PRF/5 cells. Scale bar = 40 
µm. ****p<0.0001, compared with those treated with doxorubicin. Data shown are 
means ± SD. (n = 3).  
The preceding results were obtained by using pharmacological inhibitor to ABCG2. In 
order to ascertain the role of ABCG2 in chemoresistance to doxorubicin, and 
alternative molecular approach was adopted.  To this end, the knockdown of ABCG2 
protein via RNAi was used and the uptake of doxorubicin by liver cancer cells was 
quantified using HPLC with fluorescence detection, which has been described in 3.2.7.  
Huh7 and PLC/PRF/5 cells were treated with ABCG2 siRNA (20 nM) or scrambled 
siRNA (20 nM) for 6 hours and the cell culture medium was refreshed followed by 42 
hours’ incubation. Cells were then incubated with 100 nM doxorubicin for 3 hours. In 
the other two groups, cells were treated with doxorubicin alone or doxorubicin (100 
nM) plus ko143 (1 µM) for 3 hours. Cells were collected and lysed. Doxorubicin was 
extracted and quantified using HPLC. 
The results revealed that ko143 or ABCG2 siRNA enhanced the internalization of 
doxorubicin by more than 19.7% in Huh7 cells (Figure 4.5 A and C) and 38.0% in 
PLC/PRF/5 cells (Figure 4.5 B and D), respectively. The treatment of scrambled 
siRNA did not promote the uptake of doxorubicin in either Huh7 or PLC/PRF/5 cells. 
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Figure 4.5. Ko143 or ABCG2 siRNA facilitates the internalization of doxorubicin in 
liver cancer cells. (A) and (B) The Huh7 or PLC/PRF/5 cells were treated with 100 nM 
doxorubicin alone or doxorubicin (100 nM) plus ko143 (1 µM) for 3 hours. (C) and 
(D) The Huh7 and PLC/PRF/5 cells were treated with siRNA (20 nM) for 6 hours and 
the medium was refreshed to remove siRNA and incubated with cell culture medium 
for 42 hours, followed by incubation with 100 nM doxorubicin for 3 hours. The cells 
were washed 3 times with PBS and the cellular doxorubicin was quantified by HPLC. 
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Data shown are means ± SD. (n = 3). *p<0.05; ***p<0.001; ****p<0.0001; compared 
with that treated with free doxorubicin. 
4.2.5 Determination the effect of combined treatments of ABCG2 inhibition and 
doxorubicin on self-renewal of liver cancer stem cells  
 Having demonstrated that ABCG2 inhibition enhanced the internalization of 
doxorubicin in liver cancer cell line Huh7 and PLC/PRF/5, we proceeded to investigate 
if the increased cellular concentration of doxorubicin results in the elimination of 
cancer stem cells. ABCG2+ liver cancer cells are thought to be liver cancer stem cells147, 
and the EpCAM+CD133+ cancer stem cell population exhibited higher expression of 
ABCG2 compared with the bulk liver cancer cells (Figure 4.2).  Thus, we hypothesized 
that the inhibition of ABCG2 can sensitize liver cancer stem cells to doxorubicin 
treatment. To test this hypothesis, the liver cancer cells were treated with PBS, 
doxorubicin, ko143, ABCG2 siRNA, scrambled siRNA, doxorubicin plus ko143, 
doxorubicin plus ABCG2 siRNA or doxorubicin plus scrambled siRNA. The 
concentration of doxorubicin was 200 nM to Huh7 cells and 100 nM to PLC/PRF/5 
cells; siRNA concentration was 20 nM; ko143 concentration was 1 µM. After 48 hours 
incubation, the cells were harvested and plated in stem cell media in ultra-low 
attachment 96 plates to evaluate the impact of each treatment on self-renewal. 
As shown in Figure 4.6, the treatment of ABCG2 inhibitor ko143, ABCG2 siRNA and 
scrambled siRNA did not reduce the cancer stem cell frequency in both the Huh7 and 
PLC/PRF/5 cell lines compared with that with PBS treatment (p>0.05). The 
combinatorial treatment of PLC/PRF/5 cells with ko143 or ABCG2 siRNA plus 
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doxorubicin significantly reduced cancer stem cell frequency by 86.3% and 83.7% 
(p<0.01). Interestingly, in Huh7 cells, the addition of ko143 or ABCG2 siRNA alone 
did not enhance the capacity of doxorubicin to reduce cancer stem cell frequency 
(p>0.05). These data indicate that inhibition of ABCG2 can sensitize PLC/PRF/5 
cancer stem cells to doxorubicin treatment.  In contrast, such combined treatment to 
Huh7 cells had no effect on self-renewal, indicating that besides ABCG2, other 
resistance mechanisms such as the expression of MDR1 may play more important roles 
in the Huh7 cells with high level of MDR1 expression but relatively low level of 
ABCG2.  
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Figure 4.6. The percentage of tumorsphere formation after various treatment. (A) and 
(B) The addition of ko143 (1 µM) to doxorubicin (200 nM to Huh7, 100 nM to 
PLC/PRF/5) significantly reduced cancer stem cell (CSC) frequency compared with 
doxorubicin treatment in PLC/PRF/5 cells (***p<0.001) but did not reduce CSC 
frequency in Huh7 cells compared with doxorubicin treatment (p>0.05). (C) and (D) 
ABCG2 knockdown was performed in Huh7 and PLC/PRF/5 cells with siRNA (20 nM) 
or scrambled siRNA (20 nM), followed by incubation with doxorubicin for 48 hours. 
The treatment of ABCG2 siRNA plus doxorubicin significantly reduced CSC 
frequency in PLC/PRF/5 cells (**p<0.01) did not affect the CSC frequency in Huh7 
cells (p>0.05) compared with those treated with doxorubicin. Data shown are means ± 
SD. (n = 3).  
4.2.6 Simultaneous Detection of apoptosis and cellular accumulation of 
doxorubicin in the whole population and the EpCAM+CD133+ liver cancer stem 
cell population using flow cytometry 
To further correlate the cellular concentration of dox and the extent of apoptosis, a flow 
cytometric method was employed, in which the effect of combined treatment of 
ABCG2 inhibition and doxorubicin was studied at the single cell level. Figure 4.7 
showed the percentage of apoptotic cells from the bulk cell population after treatment 
with doxorubicin, doxorubicin plus ABCG2 inhibition and the corresponding controls. 
It is evident that the addition of ABCG2 inhibition either using siRNA or ko143 
enhanced the extend of apoptosis by more than 26.4% in Huh7 cells and 85.9% in 
PLC/PRF/5 cells, respectively (p<0.05). The scrambled siRNA, ko143 or ABCG2 
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siRNA did not affect the percentage of apoptotic cells treated with doxorubicin 
(p>0.05).  
 
Figure 4.7. The contour diagram of 7-AAD/Annexin V flow cytometry. (A) Huh7 cells 
and (C) PLC/PRF/5 cells were treated with doxorubicin (100 nM), doxorubicin (100 
nM) plus ABCG2 knockdown (20 nM of siRNA), doxorubicin (100 nM) plus ABCG2 
inhibitor ko143 (1 µM) and the corresponding controls for 24 hours. Lower left 
quadrants indicate viable cells (7-AAD-/Annexin V-); lower right quadrants indicate 
early apoptotic cells (7-AAD-/Annexin V+); upper right quadrants contain late 
apoptotic cells (7-AAD+/Annexin V+). One representative experiment of three is 
shown. The percentage of Huh7 and PLC/PRF/5 cells in the upper right quadrant and 
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lower right quadrant were considered as the total apoptotic cells and were shown in (B) 
and (D) respectively. Data shown are mean ± SD, n = 3. *p<0.05; ****p<0.0001. 
 
The cellular doxorubicin accumulation in the bulk population of Huh7 and PLC/PRF/5 
cells was determined via flow cytometry as shown in Figure 4.8. The results showed 
that inhibition of ABCG2 by siRNA or ko143 facilitated the internalization of 
doxorubicin by more than 27.8% in Huh7 cells and 66.1% in PLC/PRF/5 cells 
compared with doxorubicin treatment (p<0.05). 
Figure 4.8. Flow cytometric measurement of doxorubicin accumulation in (A) Huh7 
and (C) PLC/PRF/5 cells. The cells were treated with doxorubicin (100 nM), 
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doxorubicin (100 nM) plus ABCG2 knockdown (20 nM of siRNA), doxorubicin (100 
nM) plus ko143 (1 µM) and the corresponding controls for 24 hours. One 
representative experiment of three is shown. The fluorescence intensity of doxorubicin 
in Huh7 and PLC/PRF/5 cells were shown in (B) and (D) respectively. Data shown are 
mean ± SD, n = 3. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001, compared with 
doxorubicin treatment. 
 
The percentage of apoptotic cells in the EpCAM+CD133+ cancer stem cell population 
of the Huh7 and PLC/PRF/5 cells was analyzed as shown in Figure 4.9. The data 
showed that the inhibition of ABCG2 by siRNA or pharmacological inhibitor ko143 
plus doxorubicin generate more apoptotic cells by more than 0.76- and 1.2-fold in the 
EpCAM+CD133+ population of Huh7 and PLC/PRF/5 cells, respectively compared 
with that treated with doxorubicin alone (p<0.01).  
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Figure 4.9. The contour diagram of 7-AAD/Annexin V flow cytometry of the 
EpCAM+CD133+ subpopulation of Huh7 cells (A) and that of PLC/PRF/5 cells (C) 
after treatment with doxorubicin (100 nM), doxorubicin (100 nM) plus ABCG2 
knockdown (20 nM siRNA), doxorubicin (100 nM) plus ABCG2 inhibitor ko143 (1 
µM) and the corresponding controls. Lower left quadrants indicate viable cells (7-
AAD-/Annexin V-); lower right quadrants indicate early apoptotic cells (7-AAD-
/Annexin V+); upper right quadrants contain late apoptotic cells (7-AAD+/Annexin V+). 
One representative experiment of three is shown. The percentage of Huh7 and 
PLC/PRF/5 cells in the upper right quadrant and lower right quadrant were considered 
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as the total apoptotic cells and were shown in (B) and (D) respectively. Data shown are 
mean ± SD, n = 3. **p<0.01; ***p<0.001; ****p<0.0001. 
We also determined doxorubicin accumulation in the EpCAM+CD133+ population of 
Huh7 and PLC/PRF/5 cells as shown in Figure 4.10. The results showed that 
doxorubicin accumulation is increased after treated with doxorubicin plus ABCG2 
siRNA or inhibitor ko143 by more than 0.96- and 1.3-fold in Huh7 and PLC/PRF/5 
compared with that treated with doxorubicin (****p<0.0001). 
 
Figure 4.10. Flow cytometric measurement of doxorubicin accumulation in the 
EpCAM+CD133+ population of Huh7 (A) and PLC/PRF/5 cells (C). The cells were 
treated with doxorubicin (100 nM), doxorubicin (100 nM) plus ABCG2 knockdown 
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(20 nM siRNA), doxorubicin (100 nM) plus ABCG2 inhibitor ko143 (1 µM) and the 
corresponding controls. One representative experiment of three is shown. The 
fluorescence intensity of doxorubicin in Huh7 and PLC/PRF/5 cells were shown in (B) 
and (D) respectively. Data shown are mean ± SD, n = 3. ****p<0.0001. 
4.3 Conclusion and discussion 
The liver cancer stem cells have been studies extensively during the last decades. These 
cells can lead to the invasion, metastasis, drug resistance of liver cancer, and finally 
result in poor clinical outcome. Although efforts have been made to elucidate the 
mechanism of the chemoresistance of liver cancer stem cells, and therapies have been 
developed against liver cancer stem cells in animal models, effective treatment against 
liver cancer stem cells are still unavailable in clinical practice119, 768. Several 
biomarkers, such as EpCAM, CD133, CD90, CD44, CD13, AGCG2, are considered 
as liver cancer stem cell marker119. Although the expression of ABCG2 in liver cancer 
tissue is scanty, the ABCG2-expressing cells may play critical role on the progression 
and prognosis of the disease. Doxorubicin is the most commonly used 
chemotherapeutic agents for liver cancer patients in the intermediate stage of the 
disease. However, it failed to eliminate the liver cancer stem cell population739. In this 
study, increased level of ABCG2 was found in the EpCAM+CD133+ cancer stem cell 
subpopulation of Huh7 and PLC/PRF/5 liver cancer cells. It has been reported that the 
PLC/PRF/5 cell lines represented poorly differentiated malignant hepatocytes, while 
Huh7 is a well differentiated cell line116, 769. Such observations are consistent with our 
discovery here that the expression ABCG2, which is inversely correlated with 
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differentiated grade of liver cancer cells287, is relatively low in Huh7 and high in 
PLC/PRF/5 cells.  
Zhang and colleagues found that ABCG2+ cells are more proliferative than the negative 
counterparts in cells from primary liver cancer tissues and cancer cell lines147. In 
addition, they showed that knockdown of ABCG2 tremendously inhibited the 
proliferation of ABCG2+ cells while upregulation of ABCG2 enhanced proliferation. 
In addition, the activation of PI3K/Akt and STAT3 signaling pathways may be 
involved in such a phenomenon770, 771, indicating ABCG2 is not only a drug efflux 
pump, but can act as a regulator of cancer cell behavior. In this study, we showed that 
knockdown of ABCG2 had no influence on the self-renewal of liver cancer cells. Since 
the capacity to differentiate, self-renew, and form a tumor are the key properties of 
cancer stem cells, it will be interesting to study, in future, the in vivo tumorigenicity of 
liver cancer cells with enhanced or reduced expression of ABCG2. 
In this study, we have revealed that the inhibition of ABCG2 can facilitate the 
internalization of doxorubicin and enhance the apoptosis in in cells treated with 
doxorubicin in both the bulk population and the EpCAM+CD133+ cancer stem cell 
population of Huh7 and PLC/PRF/5 cells. The increased doxorubicin accumulation 
and enhanced apoptosis translated into effective pharmacological outcome as shown 
by tumorsphere formation assay more prominently in PLC/PRF/5 cells than in Huh7 
cells. One possible explanation is the difference of ABC transporters expression level 
in these two cell lines. We have shown that the expression of MDR1 in Huh7 cells is 
18.4-fold higher than that in PLC/PRF/5 cells (Figure 3.8) while the expression of 
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ABCG2 in PLC/PRF/5 cells is 2.0-fold higher than that in Huh7 cells (Figure 4.2), 
indicating that inhibition of ABCG2 only may be not be sufficient to sensitize the liver 
cancer cells with low-expression of ABCG2 but high level of MDR1 to doxorubicin 
treatment. 
To summarize, inhibition of ABCG2 can sensitize liver cancer stem cells from 
PLC/PRF/5 but to a less extent from Huh7 cells to the treatment of doxorubicin. 
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Chapter 5  
Autophagy inhibition augments the capacity of aptamer-
doxorubicin conjugates to eliminate liver cancer stem cells 
5.1 Introduction 
Currently, considerable efforts have been devoted to the use of active tumor targeting 
systems to increase the therapeutic index of anticancer drugs772, 773. Aptamers are novel 
ligands for drug targeting and offer significant advantages over antibodies in terms of 
smaller size which provides better tumor penetration, low immunogenicity and high 
stability, as well as the high reproducibility and ease for chemical modification663, 664.  
It has been well established that liver cancer stem cells can be identified on the basis 
of cell surface proteins including epithelial cell adhesion molecule (EpCAM) and 
CD133116, 123-125, 132-138. Our laboratory has developed RNA aptamers against the 
EpCAM and CD133 protein679, 733. Upon binding to cancer cells which express these 
cancer stem cell markers, the aptamers were efficiently internalized via receptor-
mediated endocytosis. In this project, both the two aptamers were engineered with a 
long DNA GC pair tail for the intercalation of doxorubicin. We have hypothesized that 
the aptamer-doxorubicin conjugates can be efficiently delivered into the liver cancer 
stem cells though endocytosis thus bypassing the active drug efflux pumps such as the 
ATP binding cassette subfamily B member 1 (ABCB1, also known as multidrug 
resistance protein 1, MDR1 or P-glycoprotein, Pgp) and ATP binding cassette 
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subfamily G member 2 (ABCG2, also known as breast cancer resistance protein, 
BCRP).  
Recent studies have revealed the protective role of autophagy in liver cancer cells 
against doxorubicin, sorafenib and bevacizumab treatment, while autophagy inhibition 
potentiates their anti-liver cancer effect774-776. In addition, autophagy contributes to the 
survival of liver cancer stem cells in hypoxic and nutrient-deprived tumor 
microenvironment, whereas the knockdown of autophagy-related genes results in the 
defects of stemness in liver cancer stem cells449, 451. However, the role of autophagy in 
the chemoresistance of live cancer stem cells to the treatment of doxorubicin remains 
uncertain. 
In this study, we explored a novel strategy by utilizing the RNA aptamers against 
EpCAM and CD133 respectively, for targeted-delivered of doxorubicin into liver 
cancer stem cells aiming to eradicate liver cancer (Figure 5.1). In addition, the 
effectiveness of combined CD133 aptamer-doxorubicin conjugate and inhibition of 
autophagy to eliminate liver cancer stem cells was tested. We have reasoned that 
CD133 aptamer-doxorubicin conjugate may be able to effectively target liver cancer 
stem cells followed by enhanced cellular accumulation of doxorubicin, and autophagy 
inhibition may potentiate the capacity of CD133 aptamer-doxorubicin conjugate to 
eradicate liver cancer stem cells.  
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Figure 5.1. Schematic illustration of aptamer-guided targeted delivery of doxorubicin 
(DOX) into liver cancer stem cells. Upon binding to the stem marker-positive cancer 
cells, the aptamers were efficiently internalized via receptor-mediated endocytosis thus 
bypassing the drug efflux mediated by ABC transporters on the plasma membrane. 
After endocytosis, the aptamer-doxorubicin conjugates released doxorubicin in 
endosome or lysosome, and doxorubicin can induce apoptosis by 
poisoning topoisomerase II and binding to the DNA.  
5.2 Results 
5.2.1 Characterization of the aptamer-doxorubicin conjugates 
Doxorubicin is known to preferentially bind to double-stranded 5’-GC-3’ or 5’-CG-3’ 
sequences of the DNA strand777. Previous studies in our lab showed that it is the loop 
of the EpCAM and CD133 aptamers that are the main determinant for target binding 
(in-press in Theranostics). Thus, the original RNA stem in the aptamers were replaced 
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by a DNA segment consisting of 10 GC pairs. The secondary structures of the 
engineered EpCAM aptamer and CD133 aptamer was predicted using the Vienna 
software and shown in Figure 5.2.  
 
Figure 5.2. Schematic illustration of the hybrid RNA-DNA (A) EpCAM aptamer and 
(B) CD133 aptamer. A 10-bp DNA GC stem was engineered to replace the original 
RNA stem in the RNA aptamers, along with 2’-fluoropyrimidine modification of all 
pyrimidines, 5’-Methyl-dC in the stem and a Cy5 and Alexa 647 fluorophore 
conjugation to the 5’-end  of the EpCAM aptamer and the 3’-end of the CD133 aptamer 
respectively. A 3’-inverted deoxythymidine (iDT) or hexylamine cap of the EpCAM 
aptamer or CD133 aptamer were added to the 3’-end to provide significant resistance 
to nuclease in the blood. 
 
To determine the optimal molar ratio for doxorubicin loading into the aptamers, a 
conjugation assay with sequential increases of molar ratio of the aptamer to 
doxorubicin was performed using fluorescence spectrometry. The aptamers were 
prepared in PBS containing either 5 mM MgCl2 for EpCAM aptamer or 2.5 mM MgCl2 
for CD133 aptamer, and then folded by denaturation at 85 °C for 5 min, followed by 
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10 min incubation at room temperature and re-folding at 37 °C for at least 15 min. A 
series of different concentrations of doxorubicin was mixed with folded aptamer in 
conjugation buffer containing 0.1 M sodium acetate, 0.05 M NaCl, and 5 mM MgCl2 
(for EpCAM aptamer) or 2.5 mM MgCl2 (for CD133 aptamer) and incubated in orbital 
mixer/incubator (RATEK) for 30 min - 1 hour at 75 r.p.m. As shown in Figure 5.3, the 
signal of doxorubicin fluorescence was progressively quenched with the increasing 
molar ratio of aptamer to doxorubicin. The EpCAM aptamer and CD133 aptamer 
quenching curves reached their plateaus (80% of quenching) at the 
aptamer/doxorubicin molar ratio of approximate 0.5 and 0.2 respectively, indicating 
that approximate two and five doxorubicin molecules were intercalated into one 
EpCAM aptamer and CD133 aptamer molecule respectively.   
 
Figure 5.3. The intercalation of doxorubicin (DOX) to (A) EpCAM aptamer and (B) 
CD133 aptamer. The fluorescence quenching of doxorubicin at a fixed concentration 
(10 µM) after 30 min incubation with an increasing aptamer to doxorubicin molar ratio 
(0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 and 1). Data shown are means ± SD. (n = 3). 
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To determine the loading efficiency of doxorubicin into aptamers, the EpCAM 
aptamer-doxorubicin conjugate (EpCAM-doxorubicin) and CD133 aptamer-
doxorubicin conjugate (CD133-doxorubicin) were prepared with a 
doxorubicin/aptamer molar ratio of 2:1. The aptamer-doxorubicin conjugates were 
eluted from a Sephadex® G-10 column to remove the free doxorubicin, followed by 
extraction with acetonitrile to obtain the free drug. The concentration of doxorubicin 
was determined with a standard curve measured by a plate reader at the wavelength 
485 nm for excitation and 585 nm for emission. The efficiency of doxorubicin loading 
onto aptamers was determined as 84.9±5.2% for EpCAM-doxorubicin and 96.2±2.1% 
for CD133-doxorubicin.  These results indicate the loading efficiency of doxorubicin 
to the aptamer was high and consistent. 
5.2.2 pH-dependent release of doxorubicin from CD133-doxorubicin 
As a targeted-delivery therapy, the aptamer-doxorubicin conjugates are expected to 
remain stable in the blood stream, but once taken up by cancer cells, doxorubicin 
should be released quickly. To study the pH-dependent stability of CD133-doxorubicin, 
the percentage of release of doxorubicin from the CD133-doxorubicin was determined 
at pH 7.4 or pH 5.0. The experimental condition of pH 7.4 was used as it mimics the 
acidity of physiological condition, whereas that of pH 5.0 was used to simulate the 
environment in the lysosome, which is the end subcellular location for cargos travelling 
via endocytosis. As shown in Figure 5.4, after 8 hours’ incubation in PBS buffer with 
physiological pH of 7.4, less than 15% of doxorubicin was released from CD133-
doxorubicin. In contrast, doxorubicin was rapidly released from CD133-doxorubicin 
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in the initial 2 hours’ incubation at pH of 5.0. Specifically, 88.8% of intercalated 
doxorubicin was released from the aptamer after 72 hours’ incubation at pH of 5.0 
while 26.2% of intercalated doxorubicin was released after 72 hours at pH of 7.4. The 
pH-dependent release of doxorubicin is critically important for CD133-doxorubicin as 
it could potentially minimize the systemic exposure of doxorubicin to sensitive organs 
especially to heart in the circulation system but allow rapid drug release after CD133-
doxorubicin reaches to the target cancer cells and endocytosed.  
 
Figure 5.4. In vitro pH-dependent doxorubicin release from CD133-doxorubicin at pH 
of 5.0 and 7.4. Data shown are means ± SD. (n = 3). 
5.2.3 CD133 aptamer specifically binds to CD133-positive human liver cancer 
cells 
To test whether the CD133 aptamer is able to bind to CD133 on the surface of human 
liver cancer cells, the interaction of CD133 aptamer with CD133-positive expression 
cell lines was studied using flow cytometry. As shown in Figure 5.5, the CD133 
aptamer was able to bind to the liver cancer Huh7 and PLC/PRF/5 cell lines with a K’d 
of 26.50±2.12 nM and 11.03±1.17 nM respectively. In contrast, there was minimum 
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binding of the CD133 aptamer to CD133-negative HEK293T cell line with a K’d of 
over 1000 nM. The specificity of such interaction was further demonstrated by the lack 
of binding to target cells by a negative control CD133 aptamer (K’d>1000 nM) that 
has identical nucleotide sequence but with an altered three-dimensional structure due 
to a different chemical modification at 2’-pyrimidines. 
 
 
 
Figure 5.5. Specificity of CD133 aptamer. Alexa 647-labeled CD133 aptamer was 
incubated with indicated human cell lines and analyzed by flow cytometry. The mean 
fluorescence intensity (MFI) was plotted against varying concentrations of CD133 
aptamer (1–400 nM). (A) Binding of CD133 aptamer to CD133-positive Huh7 and 
PLC/PRF/5 cells. (B) Binding of negative CD133 aptamer to Huh7 and PLC/PRF/5 
cells. (C) Binding of CD133 aptamer to CD133-negative HEK293T cells. Data shown 
are means ± SD. (n = 3). 
5.2.4 CD133 aptamer is internalized via receptor-mediated endocytosis 
For an aptamer to be developed for cancer therapy and molecular imaging, it must be 
efficiently internalized after binding to the cancer cells. We investigated whether the 
CD133 aptamer could internalize upon binding. To this end, we incubated both Huh7 
and PLC/PRF/5 cells with CD133 aptamer at 37 °C for 30 min followed by confocal 
microscopy. As shown in Figure 5.6 A, CD133 aptamer was efficiently internalized 
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into liver cancer cells. In addition, we confirmed that the mode of internalization of 
CD133 aptamer was via receptor-mediated endocytosis as the aptamer fluorescence 
was found outside the cells and displayed a ring pattern along the plasma membrane 
upon the potassium-depletion treatment which is known to be able to block receptor-
mediated endocytosis. The effectiveness of such treatments in blocking receptor-
mediated endocytosis was confirmed using transferrin as a positive control (Figure 5.6 
B).  
 
 
 
Figure 5.6. CD133 aptamer is endocytosed via receptor mediated endocytosis. (A) 
Alexa 647-labeled CD133 aptamer were incubated with Huh7 and PLC/PRF/5 cancer 
cells for 60 min at 37 °C, followed by imaging using laser scanning confocal 
microscopy. (B) Huh7 and PLC/PRF/5 cells were incubated with potassium depleted 
buffer to inhibit endocytosis prior to be incubated with transferrin and Alexa 647-
labeled CD133 aptamer for 60 min at 37 °C, followed by imaging using laser scanning 
confocal microscopy. Cyan: nuclear stain; green: transferrin; blue: CD133 aptamer 
stain. Scale bar = 40 µm. 
5.2.5 Cellular uptake and retention of aptamer-doxorubicin conjugates 
The ABC transporters present on the plasma membrane that efflux doxorubicin is one 
of the mechanisms underlying chemoresistance in liver cancer cells. One way to 
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overcome such defenses is to deliver the cytotoxic drugs via endocytosis, thus 
bypassing the drug efflux pumps on the membrane. Therefore, this project utilized 
EpCAM aptamer and CD133 aptamer mediated endocytosis to deliver doxorubicin to 
bypass ABC transporters. The internalization of the aptamer-doxorubicin conjugates 
was analyzed semi-quantitatively via confocal microscopy followed by analysis using 
ImageJ software. Following 40 min incubation, a larger amount of EpCAM-
doxorubicin and CD133-doxorubicin were located inside the liver cancer Huh7 and 
PLC/PRF/5 cells respectively compared with that of free doxorubicin (Figure 5.7 A 
and B). In addition, after treated with the negative control EpCAM aptamer-
doxorubicin conjugate or negative control CD133 aptamer-doxorubicin conjugate, the 
Huh7 and PLC/PRF/5 cells did not show increased cellular uptake of doxorubicin 
compared with free doxorubicin treatment. Last, the red fluorescence signal of 
doxorubicin in the HEK293T cells, which do not express either EpCAM or CD133 on 
the plasma membrane, treated with EpCAM-doxorubicin, CD133-doxorubicin and 
free doxorubicin respectively was similar (Figure 5.7 C). Taken together, these data 
showed that aptamer-doxorubicin conjugates internalization resulted in a more 
effective accumulation of doxorubicin in the liver cancer Huh7 and PLC/PRF/5 cells, 
both of which express EpCAM and CD133 marker on their plasma membrane. In 
addition, the aptamer-doxorubicin conjugates can discriminate between target such as 
Huh7 and PLC/PRF/5 cells, and non-target such as HEK293T cells, indicating the 
specific binding of aptamer-doxorubicin conjugates to the target cells. 
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Figure 5.7. Cellular uptake of EpCAM-doxorubicin and CD133-doxorubicin in (A) 
Huh7 cells, (B) PLC/PRF/5 cells and (C) HEK293T cells. The Huh7, PLC/PRF/5 or 
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HEK293T cells were incubated with doxorubicin (DOX), EpCAM-doxorubicin 
(EpCAM-DOX), CD133-doxorubucin (CD133-DOX), negative control EpCAM-
doxorubicin (Neg-EpCAM-DOX) or negative control CD133-doxorubicin (Neg-
CD133-DOX) with a doxorubicin concentration of 400 nM for 40 min. (D) 
Quantification analysis of the uptake of aptamer-doxorubicin conjugates in Huh7 and 
PLC/PRF/5 cells. Scale bar = 40 µm. ****p<0.0001, compared with those treated with 
doxorubicin. Data shown are means ± SD. (n = 3).  
 
We next sought to quantitatively evaluate the cellular uptake and retention of aptamer-
doxorubicin conjugates in the liver cancer cells. As shown in Figure 5.8, in the time 
course study over either a 30 min or 60 min period, the cumulative cellular uptake of 
EpCAM-doxorubicin and CD133-doxorubicin were found to increase by 15.2%-24.1% 
compared with that of free doxorubicin (p<0.05). Since the persistence in on-target 
intracellular drug concentration is critical to its clinical efficacy, we further analyzed 
the intracellular retention of doxorubicin as delivered by the EpCAM aptamer and 
CD133 aptamer. Similar results were obtained in cells undergoing a 60 min’ incubation 
with 100 nM doxorubicin, equivalent EpCAM-doxorubicin, and CD133-doxorubicin 
respectively followed by a wash-out period of 1, 2 and 3 hours respectively (Figure 5.8 
A and B). The results have shown that delivering doxorubicin by the EpCAM aptamer 
and CD133 aptamer respectively led to enhanced cellular accumulation in Huh7 and 
PLC/PRF/5 cells, demonstrating that the aptamer-doxorubicin conjugates are capable 
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of efficiently targeting Huh7 and PLC/PRF/5 cells and enhancing the intracellular 
delivery of doxorubicin in a time-dependent manner.  
 
Figure 5.8. The cellular uptake and retention of EpCAM-doxorubicin and CD133-
doxorubicin in the (A) Huh7 cells and (B) PLC/PRF/5 cells. Doxorubicin concentration 
was 100 nM in the EpCAM-doxorubicin (EpCAM-DOX), CD133-doxorubicin 
(CD133-DOX) and free doxorubicin (DOX) treatment respectively. To investigate 
cellular uptake, the cells were incubated with EpCAM-DOX, CD133-DOX, or DOX 
for 30 min and 60 min respectively. To investigate cellular retention, the cells were 
incubated with the EpCAM-DOX, CD133-DOX, or free DOX for 1 hour, and washed 
with PBS three time to remove these reagents in the cell culture medium, followed by 
another 1, 2 or 3 hours incubation with cell culture medium. Data shown are means ± 
SD. (n = 3). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001; compared with free 
doxorubicin treatment.   
5.2.6 Determination of self-renewal of liver cancer stem cells by tumorsphere 
formation assay 
  
 
173 
 
Having established that the EpCAM aptamer and CD133 aptamer are able to deliver a 
large and persistent dose of doxorubicin into liver cancer cells, it is important to 
evaluate if this translates into effective pharmacological outcome of eliminating liver 
cancer stem cells. In addition, it has been shown that autophagy is involved in the 
maintenance of stem cells441, 442, 443. In liver cancer, autophagy has been reported to 
play a role in maintaining the CD133+ cancer stem cell population in the hypoxic and 
nutrient-deprived conditions449. Therefore, we have hypothesized that inhibition of 
autophagy with pharmacological inhibitor 3-methyladenine (3-MA), which inhibits the 
activity of phosphoinositide 3-kinase (PI3K) to  block the formation of 
autophagosomes and autophagic vacuoles, may augment the capacity of doxorubicin 
to eliminate liver cancer stem cells. We used tumorsphere formation assay to determine 
the impact of treatment on a key feature of cancer stem cells, namely the self-renewal 
potential778, 779. Serial dilutions of Huh7 and PLC/PRF/5 cells were seeded in 6-well 
plates and incubated with 200 nM and 100 nM respectively of free doxorubicin or 
equivalent concentration of EpCAM-doxorubicin, CD133-doxorubicin, 2 mM of 3-
MA, doxorubicin plus 3-MA, and CD133-doxorubicin plus 3-MA, respectively for 2 
days. The cells were then harvested and plated in stem cell culture media in ultra-low 
attachment 96 plates with 50, 20 and 10 cells per well respectively. The formation of 
tumorsphere was visualized using light microscopy after 5-7 days.  
As shown in Figure 5.9, cells treated with free doxorubicin and 3-MA showed 
moderate decrease in the frequency of tumoursphere formation respectively. EpCAM-
doxorubicin and CD133-doxorubicin showed 4.0 to 12.1-fold higher capacity to 
eliminate liver cancer stem cells compared with that of doxorubicin. The inhibition of 
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autophagy significantly potentiated the capacity of free doxorubicin to eliminate liver 
cancer stem cells by 8.1 and 8.8-fold in Huh7 and PLC/PRF/5 respectively. 
Furthermore, combined treatment using autophagy inhibitor 3-MA and CD133-
doxorubicin significantly reduced cancer stem cell frequency compared with CD133-
doxorubicin treatment by 2.6 and 2.9-fold in Huh7 and PLC/PRF/5 cells respectively. 
These results indicate that the EpCAM-doxorubicin or CD133-doxorubicin treatment 
could effectively impair the self-renewal of liver cancer stem cells, while autophagy 
inhibition can augment the effect of doxorubicin and CD133-doxorubicin to eliminate 
liver cancer stem cells. 
 
 
 
 
 
Figure 5.9. The percentage of tumorsphere formation determined 5-7 day after the 
treatment indicated. Cells were treated for 2 days, harvested, and plated in stem cell 
culture media in ultra-low attachment 96 plates. Data shown are means ± SD. (n = 3). 
**p<0.01; ***p<0.001 compared with groups receiving free doxorubicin. 
5.2.7 Doxorubicin induces autophagy in liver cancer cells whereas the addition of 
autophagy inhibitor neutralizes such effect 
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It has been shown that doxorubicin can induce autophagy in liver cancer cells774, 780, 
which might be cyto-protective during the response to doxorubicin-caused DNA 
damage781. Since the tumorsphere formation assay has demonstrated the enhanced 
efficacy of combined autophagy inhibitor and doxorubicin in killing liver cancer stem 
cells, this experiment is aiming at clarifying the mechanisms as to how autophagy 
inhibition sensitizes liver cancer stem cells to doxorubicin.  
Autophagic flux can be represented by the differences in the amount of the ubiquitin-
like protein microtubule-associated protein 1 light chain 3 beta (LC3-II)782. The 
autophagic flux can be quantified only when one of the steps in its pathway is blocked 
and the initial rate of accumulation of LC3-II is measured783. However, the 
accumulation of LC3-II is a dynamic progress, in which it was formed by the 
conjugation of LC3-I and phosphatidylethanolamine, and degraded in lysosomes. 
Therefore, for an accurate measurement of autophagic flux, chloroquine was used to 
prevent the degradation of LC3-II protein by inhibiting lysosomal acidification639, 640. 
The incubation of cells with chloroquine should be relatively short to avoid assay 
saturation784. In this experiment, chloroquine was added into the cell culture media 4 
hours before harvesting the cells and LC3-II was detected by Western blotting.  
The results have shown that the treatment of doxorubicin resulted in the elevated 
expression of LC3-II by 127.2% and 38.0% in Huh7 and PLC/PRF/5 cells respectively 
(Figure 5.10). There is no difference between the PBS treatment group and 3-MA 
treatment group in these two types of liver cancer cells. However, the addition of 3-
MA to doxorubicin treatment greatly reduced the expression of LC3-II by 86.8% and 
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93.5% compared with doxorubicin treatment, indicating 3-MA has reversed the 
autophagy-inducing effect of doxorubicin, which might provide a mechanism of the 
efficacy of combined treatment of doxorubicin and 3-MA in eliminating liver cancer 
stem cells.  
 
 
 
 
 
 
 
Figure 5.10. Evaluation of the impact of doxorubicin and 3-MA on autophagy. The 
Huh7 and PLC/PRF/5 were treated with PBS, doxorubicin (200 nM to Huh7 and 100 
nM to PLC/PRF/5), 3-MA (2 mM), and combined doxorubicin and 3-MA for 2 days. 
Four hours before harvesting the cells, the lysosomal inhibitor chloroquine was added 
in the cell culture media to block the degradation of LC3-II. The cells were lysed and 
the amount of LC3-II was determined by Western blotting analysis. (A) Representative 
Western blotting images of LC3-I, LC3-II and β-actin. (B) and (C) The expression of 
LC3-II was normalized with the expression of house-keeping gene β-actin. Data shown 
are mean ± SD, (n = 3). **p< 0.01; ***p< 0.001; ****p< 0.0001. 
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5.2.8 Detection of apoptotic cells by TUNEL assay 
Apoptosis, also called programed cell death, is the process that occur under 
physiological conditions, and can be induced by physical and chemical stimuli. The 
progression of cancer is controlled by the rate of cancer cell proliferation and 
apoptosis785. It has been reported that that the major mode of action for doxorubicin to 
kill cells is via initiating oxidative DNA damage leading to apoptosis of cancer cells786. 
In addition, it has been reported that inhibition of autophagy by 3-MA can induce 
apoptosis in human cancer cells787. Therefore, we have hypothesized that the 
combination of doxorubicin and inhibition of autophagy can lead to apoptosis in liver 
cancer stem cells in an addictive or synergistic way. The Terminal deoxynucleotidyl 
transferase (TdT) dUTP Nick-End Labeling (TUNEL) assay has been used for the 
detection of apoptotic cells which undergo DNA double strand break during the late 
stages of apoptosis. The hallmark of apoptosis is the degradation of DNA, which 
generates double-stranded oligonucleosomal DNA fragments, whose blunt ends can be 
identified by TdT, which catalyzes the addition of fluorescence-labeled dUTP to the 
3’-ends of DNA788. The fluorescent dye can be visualized using fluorescence 
microscope.  
Next, we sought to evaluate the effects of CD133-doxorubicin and 3-MA on apoptosis 
of sphere-forming cells from Huh7 and PLC/PRF/5 cells. The sphere-forming cells 
were treated with PBS, doxorubicin (100 nM), CD133-doxorubicin (100 nM), 3-MA 
(2 mM), doxorubicin plus 3-MA or CD133-doxorubicin plus 3-MA for two days. Then 
the cells were trypsinized and washed with PBS 3 times followed by fixation with 4% 
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paraformaldehyde. As shown in Figure 5.11, while single treatment with doxorubicin 
alone induced limited apoptosis in sphere-forming cells, CD133-doxorubicin treatment 
elicited a 1.9- and 2.0-fold increase in apoptotic tumor cells compared with that in free 
doxorubicin-treated groups in Huh7 and PLC/PRF/5 sphere-forming cells, respectively.  
Autophagy inhibition induced apoptosis, while combined autophagy inhibition and 
doxorubicin or CD133-doxorubicin elicited significant increase in apoptotic sphere-
forming cells compared with cells treated with free doxorubicin or CD133-doxorubicin. 
Furthermore, CD133 aptamer can deliver more doxorubicin into liver cancer sphere-
forming cells than cells treated with free doxorubicin which may explain the 
phenomenon that CD133-doxorubicin induced more apoptosis than free doxorubicin. 
The results showed that autophagy inhibition can augment the capacity of doxorubicin 
and CD133-doxorubicin to induce apoptosis in liver cancer stem cells. 
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Figure 5.11. Combined autophagy inhibitor 3-MA and doxorubicin treatments induce 
enhanced apoptosis in the sphere-forming liver cancer cells in comparison with 
doxorubicin alone treatment. (A) and (B) Representative images of TUNEL apoptosis 
assay on the sphere-forming cells from Huh7 and PLC/PRF/5 cells respectively 
followed by treatments indicated for 48 hours. Cyan: nuclear stain; green: apoptosis; 
red: doxorubicin stain; blue: aptamer stain. Scale bar = 40 µm.  (C) Percentage of 
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apoptotic cells in treated sphere-forming cancer cells as determined by TUNEL assay. 
(D) Relative fluorescence intensity of doxorubicin (fold to doxorubicin treatment) of 
the cells. Data shown are mean ± SD, n = 3. ***p< 0.001; ****p< 0.0001. 
5.2.9 The efficacy of ATG5 siRNA induced inhibition of autophagic activity 
To verify the results obtained from 3-MA treatment, an alternative approach of 
inhibiting autophagy was used by knocking down autophagy protein 5 (ATG5), an 
essential protein for autophagosome formation789. ATG5 can be activated by ATG7 
and forms the ATG12-ATG5 complex, which is essential for the microtubule-
associated protein 1A/1B-light chain 3 α (LC3-I) to conjugate with 
phosphatidylethanolamine (PE) to form LC3-PE conjugate (LC3-II), whose expression 
level is considered to represent autophagic activity789, 790. Therefore, the formation of 
LC3-II was used to measure ATG5 siRNA-induced deactivation of autophagy. After 
incubated with ATG5 siRNA (20 nM) or scrambled siRNA (20 nM) for 6 hours, the 
medium was refreshed with cell culture medium and the cells were cultured for another 
66 hours. ATG5 siRNA reduced autophagic activity of Huh7 and PLC/PRF/5 by 77.1% 
and 83.8% respectively as determined by Western blot analysis (Figure 5.12). 
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Figure 5.12. ATG5 knockdown induced inhibition of autophagic activity. (A) and (B) 
Representative Western blotting images of reduced LC3-II expression induced by 
ATG5 siRNA in Huh7 and PLC/PRF/5 cells. (C) and (D) Treatment with 20 nM ATG5 
siRNA resulted in efficient inhibition of autophagic activity measured by the formation 
of LC3-II by >75% at protein level as determined by immunoblotting analysis. Data 
shown are means ± SD, (n = 3). ***p<0.001; ****p<0.0001 compared with PBS and 
scrambled control groups. 
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5.2.10 Detection of apoptosis and cellular accumulation of doxorubicin in the 
whole population and the EpCAM+CD133+ liver cancer stem cell population using 
flow cytometry 
We have used the sphere-forming cells to investigate apoptosis induced by doxorubicin 
plus 3-MA, or CD133-doxorubicin plus 3-MA. Since it has been shown that 
differentiated liver cancer cells can acquire stemness via epithelial-mesenchymal 
transition (EMT)791, it is also critical to study the efficacy of combined treatment of 
doxorubicin plus 3-MA or CD133-doxorubicin plus 3-MA to induce apoptosis in the 
non-cancer stem cell population. In addition, it was reported that the intermediate 
progenitor cells may also form spheres with different rates of initiation and 
proliferation792, 793. In this study, we studied the efficacy of autophagy inhibition plus 
doxorubicin or CD133-doxorubicin to induce apoptosis in the bulk population of liver 
cancer cells and the EpCAM+CD133+ liver cancer cells, which are also considered as 
cancer stem cells125, to further demonstrate the capacity of combined treatment of 
autophagy inhibition plus doxorubicin or CD133-doxorubicin to induce apoptosis. 
Ten experiment groups were used, PBS, ATG5 siRNA, scrambled siRNA, 3-MA, 
doxorubicin, doxorubicin plus ATG5 siRNA, doxorubicin plus scrambled siRNA, 
doxorubicin plus 3-MA, CD133-doxorubicin and CD133-doxorubicin plus 3-MA. The 
concentrations of the reagents were doxorubicin and CD133-doxorubicin (100 nM), 3-
MA (2 mM), and siRNAs (20 nM). ATG5 siRNA transfection was performed as 
described in 5.2.9. The Huh7 and PLC/PRF/5 were treated as indicated above for 24 
hours, and the cellular accumulation of doxorubicin and percentage of apoptotic cells 
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in both bulk and EpCAM+CD133+ population of liver cancer cells were determined 
using flow cytometry. 
Figure 5.13 showed the percentage of apoptotic cells from the bulk cell population 
after treatment with doxorubicin, doxorubicin plus autophagy inhibition, CD133-
doxorubicin, CD133-doxorubicin plus autophagy inhibition, and the corresponding 
controls. The results revealed that compared with doxorubicin, the addition of 
autophagy inhibition with siRNA or 3-MA significantly increased the percentage of 
apoptotic cells by 0.61 to 1.38-fold. The treatment of CD133-doxorubicin and CD133-
doxorubicin plus 3-MA also significantly induced more apoptotic cells compared with 
doxorubicin treatment.  
 
Figure 5.13. The contour diagram of 7-AAD/Annexin V flow cytometry of (A) Huh7 
cells and (C) PLC/PRF/5 cells after treatment with doxorubicin (100 nM), doxorubicin 
(100 nM) plus 3-MA (2 mM), doxorubicin (100 nM) plus ATG5 knockdown (20 nM 
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siRNA), CD133-doxorubicin (100 nM), CD133-doxorubicin (100 nM) plus 3-MA (2 
mM), and the corresponding controls for 24 hours. Lower left quadrants indicate viable 
cells (7-AAD-/Annexin V-); lower right quadrants indicate early apoptotic cells (7-
AAD-/Annexin V+); upper right quadrants contain late apoptotic cells (7-
AAD+/Annexin V+). One representative experiment of three is shown. The percentage 
of Huh7 and PLC/PRF/5 cells in the upper right quadrant and lower right quadrant 
were considered as the total apoptotic cells and were shown in (B) and (D) respectively. 
Data shown are mean ± SD, n = 3. **p< 0.01; ***p< 0.001; ****p< 0.0001. 
 
We also determined the cellular doxorubicin concentration in the bulk population of 
Huh7 and PLC/PRF/5 cells as shown in Figure 5.14. The results showed that the 
cellular concentration of doxorubicin is higher after treated with CD133-doxorubuicin 
and combined CD133-doxorubicin and 3-MA respectively. Inhibition of autophagy did 
not increase doxorubicin accumulation.  
  
 
185 
 
Figure 5.14. Flow cytometric measurement of doxorubicin accumulation in (A) Huh7 
cells and (C) PLC/PRF/5 cells after treatment with doxorubicin (100 nM), doxorubicin 
(100 nM) plus 3-MA (2 mM), doxorubicin (100 nM) plus ATG5 knockdown (20 nM 
siRNA), CD133-doxorubicin (100 nM), CD133-doxorubicin (100 nM) plus 3-MA (2 
mM), and the corresponding controls for 24 hours. One representative experiment of 
three is shown. The fluorescence intensity of doxorubicin in Huh7 and PLC/PRF/5 
cells were shown in (B) and (D) respectively. Data shown are mean ± SD, n = 3. 
****p< 0.0001. 
 
Having detected the increased doxorubicin accumulation and apoptosis in the bulk 
cancer cells, we proceeded to measuring the doxorubicin uptake and apoptosis in the 
EpCAM+CD133+ population of the Huh7 and PLC/PRF/5 cells. Figure 5.15 showed 
the percentage of apoptotic cells from the EpCAM+CD133+ population after the same 
treatment as mention above. The results have indicated the addition of autophagy 
inhibition with siRNA or 3-MA significantly increased the percentage of apoptotic 
cells in the EpCAM+CD133+ population compared with those treated with doxorubicin. 
In addition, more apoptotic cells in the EpCAM+CD133+ population were observed 
after the treatment of CD133-doxorubicin and CD133-doxorubicin plus 3-MA 
compared with those treated with free doxorubicin.  
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Figure 5.15. The contour diagram of 7-AAD/Annexin V flow cytometry of the 
EpCAM+CD133+ subpopulation of (A) Huh7 cells and (C) PLC/PRF/5 cells after 
treatment with doxorubicin (100 nM), doxorubicin (100 nM) plus 3-MA (2 mM), 
doxorubicin (100 nM) plus ATG5 knockdown (20 nM siRNA), CD133-doxorubicin 
(100 nM), CD133-doxorubicin (100 nM) plus 3-MA (2 mM), and the corresponding 
controls for 24 hours. Lower left quadrants indicate viable cells (7-AAD-/Annexin V-); 
lower right quadrants indicate early apoptotic cells (7-AAD-/Annexin V+); upper right 
quadrants contain late apoptotic cells (7-AAD+/Annexin V+). One representative 
experiment of three is shown. The percentage of EpCAM+CD133+ Huh7 and 
PLC/PRF/5 cells in the upper right quadrant and lower right quadrant were considered 
as the total apoptotic cells and were shown in (B) and (D) respectively. Data shown are 
mean ± SD, n = 3. **p< 0.01; ****p< 0.0001. 
 
  
 
187 
 
Using the same method, we evaluated the doxorubicin accumulation in the 
EpCAM+CD133+ population of Huh7 and PLC/PRF/5 cells as shown in Figure 5.16. 
The results showed that doxorubicin accumulation is increased after treated with 
CD133-doxorubuicin and CD133-doxorubicin plus 3-MA respectively by 3.1 to 6.1-
fold, respectively, compared with cells treated with doxorubicin. Inhibition of 
autophagy did not increase doxorubicin accumulation in the EpCAM+CD133+ 
population. 
 
Figure 5.16. Flow cytometric study of doxorubicin accumulation in the 
EpCAM+CD133+ population of (A) Huh7 cells and (C) PLC/PRF/5 cells after 
treatment with doxorubicin (100 nM), doxorubicin (100 nM) plus 3-MA (2 mM 
siRNA), doxorubicin (100 nM) plus ATG5 knockdown (20 nM siRNA), CD133-
doxorubicin (100 nM), CD133-doxorubicin (100 nM) plus 3-MA (2 mM), and the 
corresponding controls for 24 hours. One representative experiment of three is shown. 
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The fluorescence intensity of doxorubicin in the EpCAM+CD133+ Huh7 and 
PLC/PRF/5 cells were shown in (B) and (D) respectively. Data shown are mean ± SD, 
n = 3. ****p< 0.0001. 
Taken together, the results from this experiment have shown that the addition of 
autophagy inhibition with siRNA or pharmacological inhibitor 3-MA to doxorubicin 
can significantly induce higher level of apoptosis in both the bulk tumor cells and the 
EpCAM+CD133+ liver cancer stem cells population. CD133-doxorubicin treatment can 
increase doxorubicin uptake in both the bulk tumor cells and the EpCAM+CD133+ liver 
cancer stem cells population, and lead to a greater extend of apoptosis in the two 
populations.  
5.3 Discussion and conclusion 
Current strategies in treating liver cancer patients mainly focus on the elimination of 
the bulk cancer cells, which often fail as the cancer stem cells can survive 
chemotherapy and cause tumor recurrences. Both EpCAM and CD133 cell surface 
markers are well-established liver cancer stem cell markers103, 132. It has been revealed 
that the expression of EpCAM or/and CD133 in liver cancer was inversely related to 
the prognosis of the patient, in which CD133 was shown to be an important early stage 
prognostic factor while the role EpCAM was pronounced in advance liver cancer124. 
In addition, while both the EpCAM+ and the CD133+ subpopulations have displayed 
cancer stem cell-related characteristics including enhanced chemoresistance and 
tumorigenicity, the EpCAM+ subpopulation of liver cancer cells are associated with 
rapid growth and the CD133+ subpopulation is capable of promoting angiogenesis, 
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indicating further heterogeneity within sub-types liver cancer stem cell123, 137. A series 
of anti-EpCAM antibodies have been developed and shown strong potency in 
eliminating EpCAM+ cancer cells was demonstrated in preclinical settings794-797. 
However, initial clinical trials with anti-EpCAM antibodies failed to show objective 
clinical response798-801. It was thought that the large size of the antibody may hinder its 
delivery to the tumor. Thus, aptamers which have been shown to possess better tumor-
penetration were used in this study802. 
Both the engineered EpCAM and CD133 aptamers used in this study have a stem 
structure of 10 GC pairs for doxorubicin intercalation. It is very unexpected for us that 
the quenching of doxorubicin reached 80% with a molar ratio of aptamer/doxorubicin 
0.5 for EpCAM aptamer but 0.2 for CD133 aptamer (Figure 5.3) indicating the 
engineered GC stem of the CD133 aptamer can incorporate more doxorubicin 
molecules than the EpCAM aptamer although the DNA sequence of their stems is the 
same. One possible explanation is their different 3’-ends: EpCAM aptamer has an idT 
cap while the CD133 aptamer has a hexylamine cap, which may lead to different three-
dimensional structure of the stem.  In addition, the potential interaction between the 
loop and the stem of the aptamer may contribute to the difference in doxorubicin 
loading to the stem. 
To determine the ability of CD133-doxorubucin conjugate and combined autophagy 
inhibition and doxorubicin respectively in targeting cancer stem cells, an in vitro 
tumorsphere formation was employed. The tumorsphere formation assay measures 
self-renewal, which is a key property of cancer stem cells803. The liver cancer Huh7 
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and PLC/PRF/5 cells were seeded in ultralow attachment cell culture plates with 
serum-free medium supplemented with bFGF, EGF, insulin and B27. In such condition, 
the differentiated cells underwent cell death while undifferentiated tumor cells 
proliferate and grow as floating clusters termed tumorspheres. It has been reported that 
compared with cytotoxicity assay using monolayer cells, the tumorsphere assay 
matches better with the in vivo response to chemotherapeutics804. 
The sphere-forming cells and the EpCAM+CD133+ cells are both considered as the 
liver cancer cells with stem-like properties (cancer stem-like cells). In this chapter, the 
two kinds of cells were used to investigate the efficacy of CD133-doxorubicin and 
doxorubicin plus autophagy inhibition respectively in inducing apoptosis. In addition, 
two different methods, the TUNEL assay and 7-AAD/Annexin V assay, were 
employed to study apoptosis. The TUNEL assay can detect late stage apoptosis while 
the 7-AAD/Annexin V assay can determine the early and late apoptotic cells 
simultaneously. By detecting the percentage of apoptotic cells using the two kinds of 
liver cancer stem-like cells and two methods, our results confirmed the capacity of 
CD133-doxorubicin or doxorubicin plus autophagy inhibition to induce apoptosis of 
liver cancer stem cells. 
We have shown that doxorubicin elevated autophagic activity in liver cancer cells, 
whereas the addition of 3-MA neutralized such effect due to its ability to inhibit 
phosphoinositide 3-kinase (PI3K), which is known to be essential for autophagy 
induction400. However, treatment of 3-MA alone seems to have minimum effect on the 
autophagic activity of the liver cancer cells. Wu and colleagues have reported that 3-
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MA plays a dual role in autophagic activity. They have found that 3-MA can promote 
autophagy activity when treated under nutrient-rich conditions with a prolonged 
treatment period (up to 9 hours), whereas it can suppress starvation-induced 
autophagy805. In the study to investigate the efficacy of doxorubicin or 3-MA on 
autophagic efflux, the cancer cells were incubated with 3-MA for 2 days, much longer 
than the treatment period reported (9 hours), which can have different effect on 
autophagic activity as determined by the expression of LC3-II. 
In summary, the data obtained in this chapter provides evidence for the strategies of 
eliminating liver cancer stem cells. The CD133-doxorubucin treatment leads to higher 
cellular concentration of doxorubicin and more apoptotic cells in both the bulk tumor 
cells and cancer stem cell population compared with doxorubicin. The addition of 
autophagy inhibition sensitizes both the bulk tumor cells and cancer stem cells to either 
doxorubicin or CD133-doxorubicin treatment.  
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Chapter 6 
Discussion and conclusion 
6.1. Discussion 
Being approved by the US Food and Drug Administration (FDA) in 1974, doxorubicin 
has being regarded as one of the most potent chemotherapeutic agents42. Although it 
has been widely used in the treatment of both solid and liquid cancers43-51, its 
intravenous administration failed to produce clinical benefit to liver cancer patients29, 
806. Currently, for intermediate stage hepatocellular carcinoma patients, the standard 
treatment is Trans-arterial chemoembolization (TACE), in which doxorubicin is given 
locally via a catheter into hepatic artery directly supplying a tumor thus avoiding its 
systemic exposure and its concentration within the tumors can be 10 to 100 times 
higher than after systemic administration80. However, TACE can only increase mean 
survival of 5.8 months in patients compared with those underwent systemic 
chemotherapy20. The only drug approved for the treatment for advanced hepatocellular 
carcinoma is sorafenib, a multikinase inhibitor, which increase 3-month survival rate40. 
Thus, liver cancer is thought to be a highly refractory disease with poor prognosis. 
Although several questions remain open about the cancer stem cell model, mounting 
evidence has suggested that the chemoresistant cancer stem cells can be the Achilles’ 
heel of cancer of liver cancer791. This study is aiming at targeting the liver cancer stem 
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cell population, which are thought to play critical roles in the initiation, propagation 
and metastasis of the disease807.  
One way to overcome chemoresistance caused by the over-expression of drug efflux 
pumps is the direct inhibition of these transporters via pharmacological inhibitor or 
siRNA. Among the 49 genes which encode for ABC transporters, the MDR1, MRP1, 
and ABCG2 proteins represent the major drug efflux pumps and have been most 
extensively studied808.  
MDR1 has been to be expressed  in over 80% of liver cancer254. It has been reported 
that inhibition of MDR1 by the inhibitor valspodar or by the antisense RNA can 
improve in vitro chemosensitivity in liver cancer cell lines809, 810. Numerous MDR1 
inhibitors have been developed aby the joint effort of academia and industry to improve 
the efficacy and reduce toxicity of the current available chemotherapeutic agents. 
These MDR1 inhibitors have undergone extensive clinical trial to test their safety and 
efficacy, including the first-generation inhibitors cyclosporine A (CsA) and verapamil, 
the second-generation inhibitors dexverapamil and valspodar, and the third-generation 
inhibitors elacridar, zosuquidar, tariquidar and CBT-1. However, these efforts have 
failed to yield clinical promising outcomes, due to their toxicities, and adverse 
pharmacokinetic and pharmacodynamic interactions with the chemotherapeutic 
agents536, 544.  Such disappointing clinical outcome casts doubts on the clinical efficacy 
and the viability of the strategy of inhibition of MDR1. Liver cancer stem cells, which 
are considered to be responsible for the initiation, propagation and maintenance of the 
disease, are resistant to doxorubicin. Our results have shown that, MDR1 is over 
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expressed in the cancer stem cell population compared with the bulk tumor population 
in liver cancer cell lines Huh7 and PLC/PRF/5 (Chapter 3, Figure 3.8). The addition of 
MDR1 inhibition can greatly improve the efficacy of doxorubicin in killing liver cancer 
stem cells (Chapter 3, Figure 3.14) thus eradicating the roots of liver cancer. The results 
presented in this thesis suggest that MDR1 can be a target for the treatment of liver 
cancer in the context of TACE. 
Although the expression of ABCG2 is scanty in liver cancer tissues in comparison to 
the highly expressed MDR1, the ABCG2+ liver cancer cells are shown to harbor cancer 
stem cell properties. Therefore, we have reasoned that targeting the ABCG2+ liver 
cancer population can be a potential novel approach to treat the disease. Our results 
have revealed that the addition of ABCG2 inhibition can sensitize the sphere-forming 
cells to the treatment of doxorubicin in liver cancer cells. All these three ABC 
transporters, MDR1, ABCG2 and MRP1, can extrude doxorubicin out of the cells.  In 
liver cancer cells with relatively low expression of ABCG2, such as Huh7, inhibition 
of ABCG2 might not be sufficient because other transporters may play a role (Chapter 
4, Figure 4.6 A and C). Besides these three most studied ABC transporters, the ABCB5 
(human ATP-binding cassette, subfamily B, member 5) has shown to be highly 
expressedin the liver cancer stem cells159. Since doxorubicin is also a substrate of 
ABCB5, this protein may mediate the resistance of liver cancer stem cells to 
doxorubicin811.  
It has been well documented that the liver cancer stem cells can originate from normal 
stem cells via alteration of stem cell renewal factors or from their non-cancer stem cell 
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progeny via epithelial-to-mesenchymal transition (EMT)812. Therefore, both the 
diffirentiated and undiffirentiated cells of liver cancer must be eradicated. It has been 
reported that the expression of the ABC transporters can vary greatly in difference liver 
cancer cell lines or patient tissues813, 814. Thus inhibiting multiple ABC transporters 
might be nessesary to sensitize liver cancer (stem) cells to chemotherapy. 
To facilitate the uptake of doxorubicin into liver cancer (stem) cells, besides direct 
inhibition of drug efflux pumps, another way used in this study is via aptamer-guide 
drug delivery system. In this study, aptamers against two robust liver cancer stem cell 
markers EpCAM and CD133 have been used for the delivery of the chemotherapeutic 
agent doxorubicin into the EpCAM+ or CD133+ cancer stem cell population via 
endocytosis thus bypassing the ABC transporters on the plasma membrane, regardless 
of what kind of ABC transporters the cells express, and the level of their expression. 
Our results have shown that the aptamer-doxorubicin conjugates greatly facilitated the 
internalization of doxorubicin and reduced cancer stem cell frequency in both the Huh7 
and PLC/PRF/5 cells with similar efficacy, evident from efficacy of the combinatorial 
treatment MDR1 inhibition plus doxorubicin in Huh7 cells and that of ABCG2 
inhibition plus doxorubicin in PLC/PRF/5 cells. It has been reported that most of the 
MDR1 inhibitors can alter the pharmacokinetic characteristics of the chemotherapeutic 
agents resulting in increased drug accumulation in cancer patients, leading to 
intolerable toxicity and treatment relapse536. The aptamer-doxorubicin conjugate may 
exhibit different pharmacokinetic profiles compared with doxorubicin when given 
intravenously in animal models or patients. When given in vivo, the aptamers are 
normally conjugated with polyethylene glycol (PEG) to one end to avoid renal 
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filtration and increase their circulation time. It has been observed that a second dose of 
PEG-modified liposomes is rapidly cleared from the blood and when given twice in 
the same rat at several-day intervals, called the accelerated blood clearance (ABC) 
phenomenon815. Therefore, the pharmacokinetic behavior of the PEGylated aptamer-
doxorubicin conjugates should be monitored in future clinical studies.  
Besides targeting ABC transporters to overcome drug resistance in liver cancer stem 
cells, the other method used in the study is to disrupt the stemness of liver cancer cells 
via autophagy inhibition. In this study, 3-MA has been used as a pharmacological tool 
to inhibit autophagy via the inhibition of the Class III phosphoinositide 3-kinase (PI3K). 
Autophagy was reported to be play a protective role against apoptosis induced by 
chemotherapy in liver cancer cells, while 3-MA can elevate apoptosis816-818. Another 
study on liver cancer stem cells revealed that treatment of autophagy inhibition 
increased apoptosis to the CD133+ liver cancer stem cells cultured in the hypoxic and 
nutrient-deprived tumor microenvironment449. The autophagy inhibitor HCQ has been 
undergone 52 clinical trials against several types of cancer, nine of which have been 
completed until the end of May 2017, most of which are at phase I or II level. Results 
have showed that HCQ is tolerable in patients up to 1200 mg daily. The efficacy of 
HCQ in the treatment of cancer still needs to be tested in further trials. In our study, 
we have revealed that inhibition of autophagy by 3-MA or anti-ATG5 siRNA can 
increase doxorubicin-induced apoptosis (Chapter 5, Figure 5.13 and 5.15). Moreover, 
the combination treatment of autophagy inhibition and CD133 aptamer-doxorubicin 
conjugate is more potent than autophagy inhibition plus doxorubicin to induce 
apoptosis in both the bulk and stem cell population of liver cancer. Since more 
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autophagy inhibitors have been developed and shown better specificity and anti-cancer 
efficacy in pre-clinical studies compared to HCQ, such as SBI-0206965, spautin-1, 
SAR405, NSC185058, ROC325 and lys05819, they can be used in our future studies 
which may prove to be better at augmenting the efficacy of CD133 aptamer-
doxorubicin conjugates to eliminate both the bulk and cancer stem cell population of 
liver cancer. Moreover, the cancer stem cell-targeting EpCAM or CD133 aptamer can 
be used to deliver these autophagy inhibitors, or anti-autophagy siRNAs to the cancer 
stem cells thus offering better therapeutic index.  
6.2. Conclusion 
The general conclusions of this work are described below: 
1) Inhibition of MDR1 or ABCG2 with either pharmacological inhibitor or siRNA 
significantly increased the cellular accumulation of doxorubicin, leading to 
increased apoptosis in both the bulk tumor and the cancer stem cell populations 
of liver cancer compared to doxorubicin.  
2) Combined treatment of MDR1 inhibition and doxorubicin functionally 
impaired self-renewal of liver cancer stem cells.  
3) Combined treatment of ABCG2 inhibition functionally impaired self-renewal 
of the cancer stem cell population from liver cancer cells with high level of 
ABCG2 expression but not liver cancer cells with relatively low expression of 
ABCG2. 
4) An aptamer-guided drug delivery system has been used to deliver doxorubicin 
into CD133-expressing liver cancer cells, resulting in increased doxorubicin 
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accumulation, increased apoptosis in both the bulk and cancer stem cell 
population of liver cancer cells, and enhanced capacity to impair self-renewal 
of liver cancer stem cells compared to free doxorubicin. 
5) Treatment of doxorubicin induced autophagy in liver cancer cells while the 
addition of 3-MA can reverse such effect. Treatment of 3-MA alone did not 
affect autophagic activity of liver cancer cells after 48 hours incubation. 
6) Inhibition of autophagy augments the capacity of doxorubicin or CD133 
aptamer-doxorubicin conjugate to induce apoptosis in the both the bulk and 
cancer stem cell populations of liver cancer, resulted in the enhanced capacity 
of doxorubicin or CD133 aptamer-doxorubicin conjugate to impair the self-
renewal in liver cancer stem cells. 
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